

Quorum Health Corp
Form 10-Q
November 06, 2018

fSep2

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 001-37550

QUORUM HEALTH CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of

incorporation or organization)

47-4725208

(I.R.S. Employer Identification No.)

1573 Mallory Lane Brentwood, Tennessee 37027

(Address of principal executive offices) (Zip code)

(615) 221-1400

(Registrant's telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Edgar Filing: Quorum Health Corp - Form 10-Q

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	Accelerated filer
Non-accelerated filer	Smaller reporting company
Emerging growth company	

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 2, 2018, there were 31,527,641 shares outstanding of the registrant’s Common Stock.

QUORUM HEALTH CORPORATION

Quarterly Report on Form 10-Q

Table of Contents

	Page
PART I – FINANCIAL INFORMATION	
Item 1. <u>Financial Statements</u>	1
Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	50
Item 3. <u>Quantitative and Qualitative Disclosures about Market Risk</u>	79
Item 4. <u>Controls and Procedures</u>	79
PART II – OTHER INFORMATION	
Item 1. <u>Legal Proceedings</u>	81
Item 1A. <u>Risk Factors</u>	84
Item 6. <u>Exhibits</u>	85
<u>Signatures</u>	86

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

QUORUM HEALTH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(In Thousands, Except Earnings per Share and Shares)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Operating revenues		\$557,847		\$1,731,007
Provision for bad debts		58,545		173,919
Net operating revenues	\$460,507	499,302	\$1,419,959	1,557,088
Operating costs and expenses:				
Salaries and benefits	226,237	251,780	705,868	781,691
Supplies	48,949	58,657	160,732	186,591
Other operating expenses	143,716	145,357	440,910	466,394
Depreciation and amortization	16,612	20,735	52,015	63,441
Rent	11,661	12,377	35,551	36,631
Electronic health records incentives earned	(31)	(287)	(617)	(4,516)
Legal, professional and settlement costs	1,519	2,050	10,349	6,519
Impairment of long-lived assets and goodwill	32,438	5,261	72,198	21,461
Loss (gain) on sale of hospitals, net	805	79	8,927	(5,112)
Loss on closure of hospitals, net	1,111	—	18,195	—
Transaction costs related to the Spin-off	—	173	—	204
Total operating costs and expenses	483,017	496,182	1,504,128	1,553,304
Income (loss) from operations	(22,510)	3,120	(84,169)	3,784
Interest expense, net	32,450	32,216	95,307	90,204
Income (loss) before income taxes	(54,960)	(29,096)	(179,476)	(86,420)
Provision for (benefit from) income taxes	(1,074)	(542)	(1,162)	(86)
Net income (loss)	(53,886)	(28,554)	(178,314)	(86,334)
Less: Net income (loss) attributable to noncontrolling interests	54	637	1,200	1,048
Net income (loss) attributable to Quorum Health Corporation	\$(53,940)	\$(29,191)	\$(179,514)	\$(87,382)
Earnings (loss) per share attributable to Quorum Health Corporation stockholders:				
Basic and diluted	\$(1.85)	\$(1.03)	\$(6.21)	\$(3.11)
Weighted-average shares outstanding:				
Basic and diluted	29,215,823	28,245,833	28,891,363	28,068,085

See accompanying notes

1

QUORUM HEALTH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

COMPREHENSIVE INCOME (LOSS)

(In Thousands)

	Three Months		Nine Months Ended	
	Ended September		September 30,	
	30,		2018	2017
	2018	2017	2018	2017
Net income (loss)	\$(53,886)	\$(28,554)	\$(178,314)	\$(86,334)
Amortization and recognition of unrecognized pension cost components, net of income taxes	114	123	39	365
Comprehensive income (loss)	(53,772)	(28,431)	(178,275)	(85,969)
Less: Comprehensive income (loss) attributable to noncontrolling interests	54	637	1,200	1,048
Comprehensive income (loss) attributable to Quorum Health Corporation	\$(53,826)	\$(29,068)	\$(179,475)	\$(87,017)
See accompanying notes				

QUORUM HEALTH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Par Value per Share and Shares)

	September 30, 2018	December 31, 2017
ASSETS		
Current assets:		
Cash and cash equivalents	\$6,066	\$5,617
Patient accounts receivable, net of allowance for doubtful accounts of \$352,509 at December 31, 2017	318,284	343,145
Inventories	46,964	53,459
Prepaid expenses	21,225	21,167
Due from third-party payors	64,109	97,202
Current assets of hospitals held for sale	—	8,112
Other current assets	58,162	47,440
Total current assets	514,810	576,142
Property and equipment, at cost	1,284,695	1,405,184
Less: Accumulated depreciation and amortization	(718,309)	(729,905)
Total property and equipment, net	566,386	675,279
Goodwill	401,073	409,229
Intangible assets, net	49,866	64,850
Long-term assets of hospitals held for sale	—	7,734
Other long-term assets	80,994	95,607
Total assets	\$1,613,129	\$1,828,841
LIABILITIES AND EQUITY		
Current liabilities:		
Current maturities of long-term debt	\$1,544	\$1,855
Accounts payable	146,403	171,250
Accrued liabilities:		
Accrued salaries and benefits	87,287	77,803
Accrued interest	22,046	10,466
Due to third-party payors	43,934	47,705
Current liabilities of hospitals held for sale	—	2,577
Other current liabilities	47,750	43,687
Total current liabilities	348,964	355,343
Long-term debt	1,185,684	1,212,035
Deferred income tax liabilities, net	6,670	7,774
Other long-term liabilities	129,825	137,954
Total liabilities	1,671,143	1,713,106
Redeemable noncontrolling interests	2,279	2,325
Equity:		

Edgar Filing: Quorum Health Corp - Form 10-Q

Quorum Health Corporation stockholders' equity (deficit):		
Preferred stock, \$0.0001 par value per share, 100,000,000 shares authorized, none issued	—	—
Common stock, \$0.0001 par value per share, 300,000,000 shares authorized; 31,527,885 shares issued and outstanding at September 30, 2018, and 30,294,895 shares issued and outstanding at December 31, 2017	3	3
Additional paid-in capital	554,847	549,610
Accumulated other comprehensive income (loss)	(1,917)	(1,956)
Accumulated deficit	(627,730)	(448,216)
Total Quorum Health Corporation stockholders' equity (deficit)	(74,797)	99,441
Nonredeemable noncontrolling interests	14,504	13,969
Total equity (deficit)	(60,293)	113,410
Total liabilities and equity	\$1,613,129	\$1,828,841
See accompanying notes		

3

QUORUM HEALTH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF EQUITY (DEFICIT)

For the Nine Months Ended September 30, 2018

(In Thousands, Except Shares)

Quorum Health Corporation								
Stockholders' Equity								
	Redeemable Noncontrolling Interests	Common Shares	Stock Amount	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Nonredeemable Noncontrolling Interests	Total Equity (Deficit)
Balance at December 31, 2017	\$ 2,325	30,294,895	\$ 3	\$ 549,610	\$ (1,956)	\$ (448,216)	\$ 13,969	\$ 113,410
Comprehensive income (loss)	(715)	—	—	—	39	(179,514)	1,915	(177,560)
Stock-based compensation expense	—	1,565,656	—	7,986	—	—	—	7,986
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	—	(332,666)	—	(1,979)	—	—	—	(1,979)
Cash distributions to noncontrolling investors	(101)	—	—	—	—	—	(1,380)	(1,380)
Adjustments to redemption values of redeemable noncontrolling interests	770	—	—	(770)	—	—	—	(770)
Balance at September 30, 2018	\$ 2,279	31,527,885	\$ 3	\$ 554,847	\$ (1,917)	\$ (627,730)	\$ 14,504	\$ (60,293)

QUORUM HEALTH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF EQUITY

Edgar Filing: Quorum Health Corp - Form 10-Q

For the Nine Months Ended September 30, 2017

(In Thousands, Except Shares)

Quorum Health Corporation

Stockholders' Equity

	Redeemable Noncontrolling Interests	Common Stock Shares	Additional Paid-in Capital Amount	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Nonredeemable Noncontrolling Interests	Total Equity	
Balance at December 31, 2016	\$ 6,807	29,482,050	\$ 3	\$ 537,911	\$ (2,760)	\$ (334,026)	\$ 14,441	\$ 215,569
Comprehensive income (loss)	(1,158)	—	—	—	365	(87,382)	2,206	(84,811)
Stock-based compensation expense	—	985,302	—	7,702	—	—	—	7,702
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	—	(217,850)	—	(1,503)	—	—	—	(1,503)
Cash distributions to noncontrolling investors	(42)	—	—	—	—	—	(3,809)	(3,809)
Reclassification of noncontrolling interests	(363)	—	—	—	—	—	363	363
Redemption of shares from noncontrolling interests	(3,402)	—	—	2,235	—	—	(77)	2,158
Adjustments to redemption values of redeemable noncontrolling interests	(264)	—	—	264	—	—	—	264
Balance at September 30, 2017	\$ 1,578	30,249,502	\$ 3	\$ 546,609	\$ (2,395)	\$ (421,408)	\$ 13,124	\$ 135,933

See accompanying notes

QUORUM HEALTH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Cash flows from operating activities:				
Net income (loss)	\$(53,886)	\$(28,554)	\$(178,314)	\$(86,334)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:				
Depreciation and amortization	16,612	20,735	52,015	63,441
Non-cash interest expense, net	1,860	1,793	6,394	3,223
Provision for (benefit from) deferred income taxes	(1,129)	(642)	(1,104)	(387)
Stock-based compensation expense	2,766	2,374	7,986	7,702
Impairment of long-lived assets and goodwill	32,438	5,261	72,198	21,461
Loss (gain) on sale of hospitals, net	805	79	8,927	(5,112)
Non-cash portion of loss on hospital closures	—	—	6,394	—
Changes in reserves for self-insurance claims, net of payments	4,623	4,999	15,003	16,253
Changes in reserves for legal, professional and settlement costs, net of payments	—	—	—	(3,651)
Other non-cash expense (income), net	380	233	387	238
Changes in operating assets and liabilities, net of acquisitions and divestitures:				
Patient accounts receivable, net	9,206	9,156	30,280	(21,193)
Due from and due to third-party payors, net	8,344	(3,176)	29,322	12,231
Inventories, prepaid expenses and other current assets	(7,353)	9,756	(7,582)	2,024
Accounts payable and accrued liabilities	12,108	(12,002)	2,394	(10,710)
Long-term assets and liabilities, net	1,560	(268)	(1,365)	1,603
Net cash provided by (used in) operating activities	28,334	9,744	42,935	789
Cash flows from investing activities:				
Capital expenditures for property and equipment	(9,576)	(11,525)	(34,895)	(50,667)
Capital expenditures for software	(483)	(3,005)	(1,527)	(6,174)
Acquisitions, net of cash acquired	(63)	(33)	(121)	(1,920)
Proceeds from the sale of hospitals	—	9,084	39,170	29,240
Other investing activities, net	10	—	259	—
Net cash provided by (used in) investing activities	(10,112)	(5,479)	2,886	(29,521)
Cash flows from financing activities:				
Borrowings under revolving credit facilities	121,000	131,000	368,000	433,000
Repayments under revolving credit facilities	(135,000)	(136,000)	(368,000)	(388,000)
Borrowings of long-term debt	90	175	157	247
Repayments of long-term debt	(354)	(4,670)	(31,801)	(16,517)

Edgar Filing: Quorum Health Corp - Form 10-Q

Payments of debt issuance costs	—	(181)	(2,268)	(3,119)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(36)	(14)	(1,979)	(1,503)
Cash distributions to noncontrolling investors	(678)	—	(1,481)	(3,851)
Purchases of shares from noncontrolling investors	—	(1,244)	—	(1,244)
Net cash provided by (used in) financing activities	(14,978)	(10,934)	(37,372)	19,013
Net change in cash, cash equivalents and restricted cash	3,244	(6,669)	8,449	(9,719)
Cash, cash equivalents and restricted cash at beginning of period	10,822	22,405	5,617	25,455
Cash, cash equivalents and restricted cash at end of period	\$14,066	\$15,736	\$14,066	\$15,736
Supplemental cash flow information:				
Interest payments, net	\$18,702	\$13,105	\$77,413	\$79,677
Income tax payments, net of refunds	46	311	533	339
Non-cash purchases of property and equipment under capital lease obligations	—	—	—	54
See accompanying notes				

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – DESCRIPTION OF THE BUSINESS AND SPIN-OFF

Description of the Business

The principal business of Quorum Health Corporation, a Delaware corporation, and its subsidiaries (collectively, “QHC” or the “Company”) is to provide hospital and outpatient healthcare services in its markets across the United States. As of September 30, 2018, the Company owned or leased a diversified portfolio of 27 hospitals in rural and mid-sized markets, which are located in 14 states and have a total of 2,604 licensed beds. The Company provides outpatient healthcare services through its hospitals and affiliated facilities, including urgent care centers, diagnostic and imaging centers, physician clinics and surgery centers. The Company’s wholly-owned subsidiary, Quorum Health Resources, LLC (“QHR”), provides hospital management advisory and healthcare consulting services to non-affiliated hospitals located throughout the United States. Over 95% of the Company’s net operating revenues are attributable to its hospital operations business.

Description of the Spin-off

On April 29, 2016, Community Health Systems, Inc. (“CHS”, or “Parent” when referring to the carve-out period prior to April 29, 2016) completed the spin-off of 38 hospitals, including their affiliated facilities, and QHR to form Quorum Health Corporation through the distribution of 100% of the common stock of QHC, issued at a par value of \$0.0001 per share, to CHS stockholders of record as of the close of business on April 22, 2016 (the “Record Date”) and cash proceeds to CHS of \$1.2 billion (the “Spin-off”). Each CHS stockholder received a distribution of one share of QHC common stock for every four shares of CHS common stock held as of the Record Date plus cash in lieu of fractional shares. Quorum Health Corporation began trading on the New York Stock Exchange (“NYSE”) under the ticker symbol “QHC” on May 2, 2016.

In connection with the Spin-off, QHC issued \$400 million in aggregate principal amount of 11.625% Senior Notes due 2023 (the “Senior Notes”) on April 22, 2016, pursuant to an indenture (the “Indenture”) by and between the Company and Regions Bank, as Trustee. The Senior Notes were issued at a discount of \$6.9 million, or 1.734%. The gross offering proceeds of the Senior Notes were deposited into a segregated escrow account at the closing of the offering on April 22, 2016. On April 29, 2016, the Company entered into a credit agreement (the “Senior Credit Facility”) consisting of an \$880 million senior secured term loan facility (the “Term Loan Facility”), which was issued at a discount of \$17.6 million, or 98% of par value, and a \$100 million senior secured revolving credit facility (the “Revolving Credit Facility”). In addition, the Company entered into a \$125 million senior secured asset-based revolving credit facility (the “ABL Credit Facility”) on April 29, 2016. The net offering proceeds of the Senior Notes were released to QHC from the escrow account on April 29, 2016. The net offering proceeds of the Senior Notes, together with the net borrowings under the Term Loan Facility, were used to pay \$1.2 billion of the cash proceeds to CHS, as mentioned above, and to pay the Company’s fees and expenses related to the Spin-off. The cash proceeds paid to CHS were characterized as a one-time, tax-free cash distribution.

In connection with the Spin-off, QHC and CHS entered into a Separation and Distribution Agreement, a Tax Matters Agreement and an Employee Matters Agreement on April 29, 2016, which, collectively, governed or continue to govern the allocation of employees, assets and liabilities that were transferred to QHC from CHS, including but not limited to investments, working capital, property and equipment, employee benefits and deferred tax assets and liabilities. In addition, QHC and CHS entered into various transition services agreements and other ancillary agreements that govern certain relationships and activities of QHC and CHS for five years following the Spin-off. See

Note 16 — Related Party Transactions for additional information on the agreements that exist between QHC and CHS after the Spin-off.

In connection with the Spin-off, CHS contributed \$530.6 million of additional paid-in capital to QHC and made a \$13.5 million cash contribution to QHC, pursuant to the Separation and Distribution Agreement. This contribution consisted of \$20.0 million of cash contributed to fund a portion of QHC's initial working capital, reduced by \$6.5 million for the difference in estimated and actual financing transaction fees related to the Spin-off.

6

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

The following table provides a summary of the major transactions to effect the Spin-off of QHC as a newly formed, independent company (dollars in thousands):

	Long-Term Debt	Due to Parent, Net	Common Stock Shares	Amount	Additional Paid-in Capital	Parent's Equity
Balance at April 29, 2016 (prior to the Spin-off)	\$24,179	\$1,813,836	—	\$ —	\$—	\$3,137
Borrowings of long-term debt, net of debt issuance discounts	1,255,464	—	—	—	—	—
Payments of debt issuance costs	(29,146)	—	—	—	—	—
Cash proceeds paid to Parent	—	(1,217,336)	—	—	—	—
Transfer of liabilities from Parent	—	(22,292)	—	—	—	—
Net deferred income tax liability resulting from the Spin-off	—	(46,783)	—	—	—	—
Non-cash capital contribution from Parent	—	(527,425)	—	—	530,562	(3,137)
Distribution of common stock	—	—	27,719,645	3	(3)	—
Distribution of restricted stock awards	—	—	692,409	—	—	—
Balance at April 29, 2016 (after the Spin-off)	\$1,250,497	\$—	28,412,054	\$ 3	\$530,559	\$—

NOTE 2 - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The condensed consolidated financial statements and accompanying notes of the Company presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”). In the opinion of the Company’s management, the condensed consolidated financial information presented herein includes all adjustments necessary to present fairly the results of operations, financial position and cash flows of the Company for the interim periods presented. Results of operations for interim periods should not be considered indicative of the results of operations expected for the full year ending December 31, 2018. Certain information and disclosures have been condensed or omitted as presented herein and as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim period presentation. The Company’s management believes the financial statements and disclosures presented herein are adequate in order to make the information presented not misleading. The condensed consolidated financial statements should be read in conjunction with the consolidated and combined financial statements and accompanying notes thereto for the year ended December 31, 2017, contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2018 (the “2017 Annual Report on Form 10-K”).

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its subsidiaries in which it holds either a direct or indirect ownership of a majority voting interest. Investments in less-than-wholly-owned consolidated subsidiaries of QHC are presented separately in the equity component of the Company's consolidated balance sheets to distinguish between the interests of QHC and the interests of the noncontrolling investors. Revenues and expenses from these subsidiaries are included in the respective individual line items of the Company's consolidated statements of income, and net income is presented both in total and separately to distinguish the amounts attributable to the Company and the amounts attributable to the interests of the noncontrolling investors. Noncontrolling interests that are redeemable, or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company, are presented in mezzanine equity in the Company's consolidated balance sheets. Intercompany transactions and accounts of the Company are eliminated in consolidation.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Reclassifications and Immaterial Restatements

Certain revisions have been made to prior period balances as follows:

Beginning in the fourth quarter of 2017, the Company reclassified and separately presented in its consolidated statements of cash flows the amounts for gross borrowings and repayments of its revolving credit facilities. Both items are included in cash flows from financing activities. Previously, these amounts were netted in the Company's presentation of its consolidated statements of cash flow. This reclassification is considered immaterial and had no effect on the Company's consolidated results of operations or financial position.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company's consolidated financial statements and accompanying notes. Actual results could differ from those estimates under different assumptions or conditions.

Revenues and Accounts Receivable

Adoption of ASC Topic 606 "Revenue from Contracts with Customers"

On January 1, 2018, the Company adopted Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 606 ("ASC 606") using the modified retrospective method to all contracts existing on January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with the Company's historical accounting under ASC 605. The key impacts on the Company's consolidated financial statements include the following:

• Prior to the adoption of ASC 606, a significant portion of the Company's allowance for doubtful accounts related to amounts due from self-pay patients, as well as co-pays and deductibles owed to the Company by patients with insurance. Under ASC 606, the estimated allowance for these patient accounts is generally considered a direct reduction to net operating revenues rather than as a provision for bad debts.

• Prior to the adoption of ASC 606, the Company's presentation and disclosure of net revenue by payor included the portion of the revenue related to co-pays and deductibles as third-party revenues. Under ASC 606, the co-pays and deductibles portions of net revenue are classified as self-pay after insurance.

Revenue Recognition

The Company reports revenues from patient services at its hospitals and affiliated facilities at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients, governmental programs and third-party payors such as Medicare, Medicaid, health maintenance organizations, preferred provider organizations, private insurers and others, and include variable consideration for retroactive revenue adjustments due to settlements of audits, reviews and investigations. Generally, the Company bills the patient and third-party payors several days after the services are performed or the patient is discharged. Revenue is recognized as the performance obligations are satisfied. Billings and collections are outsourced to CHS under the transition services agreements that were entered into in connection with the Spin-off. See Note 16 — Related Party

Transactions for additional information on these agreements.

Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges for services anticipated to be provided. The Company believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Company's hospitals receiving inpatient acute care services. The Company measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Company does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Company has elected to apply the optional exemption provided in ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

at the end of the reporting period. The performance obligations for these contracts are generally completed when the patient is discharged, which generally occurs within days or weeks following the end of the reporting period.

The Company determines the transaction price based on standard billing rates for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and patient responsibility after insurance in accordance with the Company's policy, and/or implicit price concessions provided to uninsured patients and patient responsibility after insurance. The Company determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients.

The Company recognizes revenues related to its QHR business when either the performance obligation has been satisfied or over time as the hospital management advisory and healthcare consulting services are provided, and reports these revenues at the amount expected to be collected from the non-affiliated hospital clients of QHR.

Payor Sources

The primary sources of payment for patient healthcare services are third-party payors, including federal and state agencies administering the Medicare and Medicaid programs, other governmental agencies, managed care health plans, commercial insurance companies, workers' compensation carriers and employers. Self-pay revenues are the portion of patient service revenues derived from patients who do not have health insurance coverage and the patient responsibility portion of services that are not covered by health insurance plans. Non-patient revenues primarily include revenues from QHR's hospital management advisory and healthcare consulting services business, rental income and hospital cafeteria sales.

The following table provides a summary of net operating revenues by payor source (dollars in thousands):

	Three Months Ended September 30,			
	2018	2017		
	\$ Amount	% of Total	\$ Amount	% of Total
Medicare	\$123,788	26.9 %	\$156,547	31.4 %
Medicaid	97,803	21.2 %	92,563	18.5 %
Managed care and commercial plans	185,493	40.3 %	184,390	36.9 %
Self-pay and self-pay after insurance	33,647	7.3 %	42,385	8.5 %
Non-patient	19,776	4.3 %	23,417	4.7 %
Total net operating revenues	\$460,507	100.0 %	\$499,302	100.0 %

Nine Months Ended September 30,	
2018	2017
\$ Amount	\$ Amount

Edgar Filing: Quorum Health Corp - Form 10-Q

		% of Total		% of Total
Medicare	\$398,477	28.1 %	\$468,627	30.1 %
Medicaid	270,047	19.0 %	292,380	18.8 %
Managed care and commercial plans	560,445	39.5 %	583,073	37.4 %
Self-pay and self-pay after insurance	125,619	8.8 %	140,296	9.0 %
Non-patient	65,371	4.6 %	72,712	4.7 %
Total net operating revenues	\$1,419,959	100.0 %	\$1,557,088	100.0 %

Revenues from Medicare Advantage Plans that are included in Medicare revenues in the table above were \$32.0 million and \$47.0 million for the three months ended September 30, 2018 and 2017, respectively, and \$103.4 million and \$133.4 million for the nine months ended September 30, 2018 and 2017, respectively.

Contractual Adjustments and Discounts

Agreements with third-party payors typically provide for payments at amounts less than standard billing rates. A summary of the payment arrangements with major third-party payors follows:

• **Medicare:** Inpatient acute care services are generally paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Outpatient services are paid using prospectively determined rates according to ambulatory payment classifications and, for some services, fee schedules. Physician services are paid based upon the Medicare Physician Fee Schedule. **Medicaid:** Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.

Other: Payment agreements with certain commercial insurance carriers, health maintenance organizations and preferred provider organizations generally provide for payment using prospectively determined rates per discharge, discounts from standard billing rates and prospectively determined daily rates.

Government programs, including Medicare and Medicaid programs, which represent a large portion of the Company's operating revenues, are highly complex programs to administer and are subject to interpretation of federal and state-specific reimbursement rates, new legislation and final cost report settlements. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations. In some instances, these investigations have resulted in organizations entering into significant settlement agreements or findings of criminal and civil liability. Compliance with such laws and regulations may be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have on the Company.

Contractual adjustments, or differences in standard billing rates and the payments derived from contractual terms with governmental and non-governmental third-party payors, are recorded based on management's best estimates in the period in which services are performed and a payment methodology is established with the patient. Recorded estimates for past contractual adjustments are subject to change, in large part, due to ongoing contract negotiations and regulation changes, which are typical in the U.S. healthcare industry. Revisions to estimates are recorded as contractual adjustments in the periods in which they become known and may be subject to further revisions. In addition, the contracts the Company has with commercial insurance payors may provide for retroactive audit and review of claims. Subsequent changes in estimates for third-party payors that are determined to be the result of an adverse change in a payor's ability to pay are recorded as bad debt expense. Bad debt expense for the three and nine months ended September 30, 2018 was not material and is included in other operating expenses in the Company's consolidated statements of income. Billing and collections are outsourced to CHS under certain transition services agreements that were put in place by CHS in connection with the Spin-off. The Company's contractual adjustments are impacted by the timing and ability of CHS to monitor the classification and collection of the Company's patient accounts receivable. Self-pay and other payor discounts are incentives offered by the Company to uninsured or underinsured patients and other payors to reduce their costs of healthcare services.

Third-Party Program Reimbursements

Cost report settlements under reimbursement programs with Medicare, Medicaid and other managed care plans for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company's historical experience, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as new information becomes available, or

as years are settled or are no longer subject to such audits, reviews, and investigations. Previous program reimbursements and final cost report settlements are included in due from and due to third-party payors in the consolidated balance sheets. Net adjustments arising from a change in the transaction price for estimated cost report settlements favorably (unfavorably) impacted net operating revenues by \$(0.5) million and \$2.5 million during the three months ended September 30, 2018 and 2017, respectively, and \$(0.4) million and \$2.5 million during the nine months ended September 30, 2018 and 2017, respectively.

Currently, several states utilize supplemental payment programs, including disproportionate share programs, for the purpose of providing reimbursement to providers to offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of federal and state resources, including, in certain instances, taxes, fees or other program expenses (collectively, "provider taxes") levied on the providers. The receivables and payables associated with these programs are included in due from and due to third-party payors in the Company's consolidated balance sheets.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

The following table provides a summary of the components of amounts due from and due to third-party payors (in thousands):

	September 30, 2018	December 31, 2017
Amounts due from third-party payors:		
Previous program reimbursements and final cost report settlements	\$ 13,878	\$ 17,383
State supplemental payment programs	50,231	79,819
Total amounts due from third-party payors	\$ 64,109	\$ 97,202
Amounts due to third-party payors:		
Previous program reimbursements and final cost report settlements	\$ 32,830	\$ 33,163
State supplemental payment programs	11,104	14,542
Total amounts due to third-party payors	\$ 43,934	\$ 47,705

After a state supplemental payment program is approved and fully authorized by the appropriate state legislative or governmental agency, the Company recognizes revenue and related expenses based on the terms of the program in the period in which amounts are estimable and revenue collection is reasonably assured. The revenues earned by the Company under these programs are included in net operating revenues and the expenses associated with these programs are included in other operating expenses in the Company's consolidated statements of income.

The following table provides a summary of the portion of Medicaid reimbursements included in the Company's consolidated statements of income that are attributable to state supplemental payment programs (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Medicaid state supplemental payment program revenues	\$57,555	\$46,866	\$158,186	\$138,544
Provider taxes and other expenses	19,131	16,523	55,326	50,646
Reimbursements attributable to state supplemental payment programs, net of expenses	\$38,424	\$30,343	\$102,860	\$87,898

The California Department of Health Care Services administers the Hospital Quality Assurance Fee ("HQAF") program, imposing a fee on certain general and acute care California hospitals. Revenues generated from these fees provide funding for the non-federal supplemental payments to California hospitals that serve California's Medi-Cal and uninsured patients. Under the HQAF program, the Company recognized \$8.7 million of Medicaid revenues and \$0.1 million of provider taxes for the three months ended September 30, 2018 and \$24.4 million of Medicaid revenues and \$4.4 million of provider taxes for the nine months ended September 30, 2018. There were no corresponding amounts recognized in the three and nine months ended September 30, 2017. The revenues and fees for the full year 2017 were recognized in the fourth quarter of 2017 when CMS approved the program.

The Company recognized \$7.3 million of Medicaid revenues in the three and nine months ended September 30, 2018 related to the sale the Illinois property tax credits. Recognition of the benefit from the Illinois credits was previously recognized as a reduction in other operating expenses. For the three and nine months ended September 30, 2017, the Company recognized \$7.8 million from the sale the Illinois property tax credits as a direct reduction to other operating expenses. The Company determined that the Illinois property tax credits operate as a supplemental payment program for uncompensated charity care.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Self-Pay and Self-Pay After Insurance

Generally, patients who are covered by third-party payors are responsible for related co-pays and deductibles, which vary in amount. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from the Company's standard billing rates. The Company estimates the transaction price for patients with co-pays and deductibles and for uninsured patients based on historical collection experience and current market conditions. The initial estimate of the transaction price is determined by reducing the Company's standard charges by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price, if any, are generally recorded as an adjustment to patient service revenue in the period of the change.

Charity Care

In the ordinary course of business, the Company provides services to patients who are financially unable to pay for hospital care. The related charges for those patients who are financially unable to pay that otherwise do not qualify for reimbursement from a governmental program are classified as charity care. The Company determines amounts that qualify for charity care primarily based on the patient's household income relative to the poverty level guidelines established by the federal government. The Company's policy is to not pursue collections for such amounts; therefore, the related charges are recorded in operating revenues at standard billing rates and fully offset in contractual adjustments. The Company's gross amounts of charity care revenues were \$7.6 million and \$5.7 million for the three months ended September 30, 2018 and 2017, respectively, and \$26.9 million and \$25.6 million for the nine months ended September 30, 2018 and 2017, respectively.

Accounts Receivable

Substantially all of the Company's receivables are related to providing healthcare services to patients at its hospitals and affiliated outpatient facilities.

For self-pay and self-pay after insurance receivables, the Company estimates the implicit price concession by reserving a percentage of all self-pay and self-pay after insurance accounts receivable without regard to aging category. The estimate of the implicit price concession is based on a model that considers historical cash collections, expected recoveries and any anticipated changes in trends. The Company's ability to estimate the implicit price concessions is not significantly impacted by the aging of accounts receivable, as management believes that substantially all of the risk exists at the point in time such accounts are identified as self-pay. Significant changes in payor mix, CHS's business office operations, including the CHS shared services centers' efforts in collecting the Company's accounts receivables, economic conditions, or trends in federal and state governmental healthcare coverage, among others, could affect the Company's estimates of implicit price concessions. The Company also continually reviews its overall estimate of implicit price concessions by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net operating revenues and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, and the impact of recent divestitures.

Edgar Filing: Quorum Health Corp - Form 10-Q

Collections are impacted by the economic ability of patients to pay, the effectiveness of CHS' billing and collection efforts, including their current policies on collections, and the ability of the Company to further attempt collection efforts. Billings and collections are outsourced to CHS under the transition services agreements that were established with the Spin-off. See Note 16 — Related Party Transactions for additional information on these agreements.

The following table provides a summary of the changes in the allowance for doubtful accounts (in thousands):

	Nine Months Ended September 30, 2018
Balance at beginning of period	\$352,509
Provision for bad debts	—
Impact of adoption of ASC 606	(352,509)
Balance at end of period	\$—

The Company has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Company's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Company does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

The Company has applied the practical expedient provided by FASB ASC 340-40-25-4 and all incremental customer contract acquisition costs are expensed as incurred, as the amortization period of the asset that the Company otherwise would have recognized is one year or less in duration.

Concentration of Credit Risk

The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company's hospitals and affiliated outpatient facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company's markets and non-governmental third-party payors, Medicare represents a significant concentration of credit risk from payors. Accounts receivable, net of contractual adjustments, from Medicare were \$59.0 million and \$66.6 million, or 18.5% and 18.2% of total patient accounts receivable, net as of September 30, 2018 and December 31, 2017, respectively. Additionally, the Company believes Illinois Medicaid represents a significant concentration of credit risk to the Company, due to the fiscal problems in the state of Illinois that can affect the timing and extent of payments due to providers, which are administered by the state of Illinois under the Medicaid program. The Company's accounts receivable, net of contractual adjustments, from Illinois Medicaid were \$21.5 million and \$28.8 million, or 6.7% and 7.9% of total patient accounts receivable, net as of September 30, 2018 and December 31, 2017, respectively. The Company's state supplemental program receivables from Illinois Medicaid were \$1.3 million and \$22.9 million, or 2.1% and 23.5% of total due from third-party payors, as of September 30, 2018 and December 31, 2017, respectively. The Company also believes California Medicaid represents a significant concentration of credit risk to the Company. The Company's state supplemental program receivables from California Medicaid were \$34.2 million and \$48.4 million, or 53.3% and 49.8% of total due from third-party payors, as of September 30, 2018 and December 31, 2017, respectively.

The Company's revenues are particularly sensitive to regulatory and economic changes in certain states where the Company generates significant revenues. Accordingly, any changes in the current demographic, economic, competitive or regulatory conditions in certain states in which revenues are significant could have an adverse effect on the Company's results of operations, financial condition or cash flows. Changes to Medicaid and other government-managed payor programs in these states, including reductions in reimbursement rates or delays in reimbursement payments under state supplemental payment or other programs, could also have a similar adverse effect.

The following table provides a summary of the states in which the Company generates more than 5% of its total net patient revenues as determined in each period (dollars in thousands):

	Number of Hospitals at September 30, 2018	Nine Months Ended September 30,			
		2018	% of	2017	% of
		\$ Amount	Total	\$ Amount	Total
Illinois	8	\$554,909	41.0 %	\$559,068	37.7 %
Oregon	1	172,319	12.7 %	155,903	10.5 %
California	2	136,357	10.1 %	112,260	7.6 %
Kentucky	3	87,935	6.5 %	85,017	5.7 %

Other Operating Expenses

The following table provides a summary of the major components of other operating expenses (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2018	2017	2018	2017
Purchased services	\$37,955	\$40,716	\$116,537	\$130,155
Taxes and insurance	33,631	24,929	100,313	92,782
Medical specialist fees	26,078	27,254	79,459	84,605
Transition services agreements	14,101	15,468	43,284	47,736
Repairs and maintenance	8,962	10,166	27,659	31,368
Utilities	6,559	7,853	18,274	21,245
Other miscellaneous operating expenses	16,430	18,971	55,384	58,503
Total other operating expenses	\$143,716	\$145,357	\$440,910	\$466,394

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

The Company records costs associated with the transition services agreements and other ancillary agreements with CHS in accordance with the terms of these agreements. These costs, which primarily include the costs of providing information technology, patient billing and collections and payroll services, are included in “Transition services agreements” in the table above.

See Note 16 — Related Party Transactions and Note 17 — Commitments and Contingencies for additional information on the transition services agreements with CHS.

General and Administrative Costs

Substantially all of the Company’s operating costs and expenses are “cost of revenues” items. Operating expenses that could be classified as general and administrative by the Company are costs related to corporate office functions, including, but not limited to tax, treasury, audit, risk management, legal, investor relations and human resources. These costs primarily consist of salaries and benefits expenses associated with these corporate office functions. General and administrative costs of the Company were \$14.2 million and \$13.8 million during the three months ended September 30, 2018 and 2017, respectively, and \$49.1 million and \$43.9 million during the nine months ended September 30, 2018 and 2017, respectively. General and administrative costs of the Company include severance costs at the corporate office of \$1.6 million during the three months ended September 30, 2018 with no corresponding amount during the three months ended September 30, 2017, and \$6.2 million and \$0.6 million during the nine months ended September 30, 2018 and 2017, respectively.

Electronic Health Records Incentives Earned

Pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), the Company receives incentive payments under the Medicare and Medicaid programs for its eligible hospitals and physician clinics that demonstrate meaningful use of certified Electronic Health Records (“EHR”) technology. EHR incentive payments are subject to audit and potential recoupment if it is determined that the applicable meaningful use standards were not met. EHR incentive payments are also subject to retrospective adjustment because the cost report data upon which the incentive payments are based is further subject to audit.

The Company incurs both capital expenditures and operating expenses in connection with the implementation of EHR technology initiatives. The amounts and timing of these expenditures does not directly correlate with the timing of the Company’s receipt or recognition of EHR incentive payments as earned. The Company is nearing completion of its full implementation of certified EHR, and therefore, its EHR incentive payments are declining and will ultimately end. The Company recognized EHR incentives earned of less than \$0.1 million and \$0.3 million for the three months ended September 30, 2018 and 2017, respectively, and \$0.6 million and \$4.5 million for the nine months ended September 30, 2018 and 2017, respectively, which were recorded as a reduction to operating expenses in the Company’s consolidated statements of income.

Legal, Professional and Settlement Costs

Legal, professional and settlement costs in the Company’s consolidated statements of income primarily include legal costs and related settlements, if any, associated with arbitration costs, regulatory claims, government investigations

into reimbursement payments and other litigation matters.

Loss (Gain) on Sale of Hospitals, Net

Loss (gain) on sale of hospitals, net relates to the Company's divestiture of hospitals and outpatient facilities. It is calculated as the difference between the cash proceeds from the sale and the carrying values of the associated net assets sold at the date of sale, less certain incremental direct selling costs.

Loss on Closure of Hospitals, Net

Loss on closure of hospitals, net relates to costs incurred by the Company for closure of hospitals and outpatient facilities, and includes severance, loss on disposal of property and equipment, write-down of assets, legal costs and other costs incurred by the Company related to the closure.

Transaction Costs Related to the Spin-off

Transaction costs related to the Spin-off consists of QHC's portion of the costs to effect the Spin-off and the costs associated with forming a new company. These costs include audit fees, management advisory and consulting costs, investment advisory costs, legal expenses and other miscellaneous costs.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the provision for (benefit from) income taxes in the consolidated statements of income in the period that includes the enactment date. The Company assesses the likelihood that deferred tax assets will be recovered from future taxable income. To the extent the Company believes that recovery is not likely, a valuation allowance is established. To the extent the Company establishes a valuation allowance or increases this allowance, the related expense is included in the provision for (benefit from) income taxes in the consolidated statements of income. The Company classifies interest and penalties, if any, related to its tax positions as a component of provision for (benefit from) income taxes.

Cash and Cash Equivalents

Cash includes cash on hand and cash with banks. Cash equivalents are short-term, highly liquid investments with a maturity of three months or less from the date acquired that are subject to an insignificant risk of change in value.

Restricted Cash

Restricted cash consists of cash held in escrow accounts to secure the Company's indemnification obligations under purchase agreements related to the sale of hospitals. The Company expects these obligations will be settled more than twelve months into the future. As a result, the Company's restricted cash is recorded in other long-term assets in the consolidated balance sheet as of September 30, 2018.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Company's consolidated balance sheets to the combined total as reported in the Company's consolidated statements of cash flows (in thousands):

	September 30, 2018	December 31, 2017
Cash and cash equivalents	\$ 6,066	\$ 5,617
Restricted cash included in other long-term assets	8,000	—
Cash, cash equivalents and restricted cash	\$ 14,066	\$ 5,617

Inventories

Inventories, primarily consisting of medical supplies and drugs, are stated at the lower of cost or market on a first-in, first-out basis.

Other Current Assets

Other current assets consists of the current portion of the receivables from CHS related to professional and general liability and workers' compensation liability insurance reserves that were indemnified by CHS in connection with the Spin-off, non-patient accounts receivable primarily related to QHR, receivables related to EHR incentives and other miscellaneous current assets.

Property and Equipment

Purchases of property and equipment are recorded at cost. Property and equipment acquired in a business combination are recorded at estimated fair value. Routine maintenance and repairs are expensed as incurred. Expenditures that increase capacities or extend useful lives are capitalized. The Company capitalizes interest related to financing of major capital additions with the respective asset. Depreciation is recognized using the straight-line method over the estimated useful life of an asset. The Company depreciates land improvements over 3 to 20 years, buildings and improvements over 5 to 40 years, and equipment and fixtures over 3 to 18 years. The Company also leases certain facilities and equipment under capital lease obligations. These assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the asset. Property and equipment assets that are held for sale are not depreciated.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Goodwill

The Company's hospital operations and QHR's hospital management advisory and healthcare consulting services operations meet the criteria to be classified as reporting units for goodwill. Goodwill was initially determined for QHC's hospital operations reporting unit based on a relative fair value approach as of September 30, 2013 (CHS' goodwill impairment testing date). Additional goodwill was allocated on a similar basis for four hospitals acquired by CHS in 2014 and included in the group of hospitals spun-off to QHC. For the QHR reporting unit, goodwill was allocated based on the amount recorded by CHS at the time of its acquisition in 2007. All subsequent goodwill generated from hospital, physician practice or other ancillary business acquisitions is recorded at fair value at the time of acquisition.

Intangible Assets

The Company's intangible assets primarily consist of purchase and development costs of software for internal use and contract-based intangible assets, including physician income guarantee contracts, medical licenses, hospital management contracts, non-compete agreements and certificates of need. There are no expected residual values related to the Company's intangible assets. Capitalized software costs are generally amortized over three years, except for software costs for significant system conversions, which are amortized over 8 to 10 years. Capitalized software costs that are in the development stage are not amortized until the related projects are complete. Assets for physician income guarantee contracts, hospital management contracts, non-compete agreements and certificates of need are amortized over the life of the individual contracts. Intangible assets held for sale are not amortized.

Impairment of Long-Lived Assets and Goodwill

Whenever an event occurs or changes in circumstances indicate that the carrying values of certain long-lived assets may be impaired, the Company projects the undiscounted cash flows expected to be generated by these assets. If the projections indicate that the carrying values are not expected to be recovered, such amounts are reduced to their estimated fair value based on a quoted market price, if available, or an estimated fair value based on valuation techniques available in the circumstances.

Goodwill arising from business combinations is not amortized. Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit's carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit's goodwill with the carrying value of the reporting unit's goodwill. The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year. The fair value of the related reporting units is estimated using both a discounted cash flow model as well as a multiple model based on earnings before interest, taxes, depreciation and amortization. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company's best estimate of a market participant's weighted-average cost of capital. Both models are based on the Company's best estimate of future revenues and operating costs and are reconciled to the Company's consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management

decisions of the Company.

See Note 3 — Impairment of Long-Lived Assets and Goodwill for additional information related to impairment recorded in the consolidated statements of income.

Other Long-Term Assets

Other long-term assets consist of the long-term portion of the receivables from CHS related to professional and general liability and workers' compensation liability insurance reserves that were indemnified by CHS in connection with the Spin-off, as well as deferred compensation plan assets, deposits, investments in unconsolidated subsidiaries, restricted cash and other miscellaneous long-term assets.

Other Current Liabilities

Other current liabilities consist of the current portion of professional and general liability insurance reserves, including the portion indemnified by CHS in connection with the Spin-off, as well as property tax accruals, legal accruals, deferred revenue related to EHR incentives, physician income guarantee liabilities and other miscellaneous current liabilities.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Professional and General Liability Insurance and Workers' Compensation Liability Insurance Reserves

As part of the business of owning and operating hospitals, the Company is subject to legal actions alleging liability on its part. To mitigate a portion of these risks, the Company maintains insurance exceeding a self-insured retention level for these types of claims. The Company's self-insurance reserves reflect the current estimate of all outstanding losses, including incurred but not reported losses, based on actuarial calculations as of period end. The loss estimates included in the actuarial calculations may change in the future based on updated facts and circumstances. The Company's insurance expense includes the actuarially determined estimates of losses for the current year, including claims incurred but not reported, the change in the estimates of losses for prior years based upon actual claims development experience as compared to prior actuarial projections, the insurance premiums for losses in excess of the Company's self-insured retention levels, the administrative costs of the insurance programs, and interest expense related to the discounted portion of the liability. The Company's reserves for professional and general liability and workers' compensation liability claims are based on semi-annual actuarial calculations, which are discounted to present value and consider historical claims data, demographic factors, severity factors and other actuarial assumptions. The reserves for self-insured claims are discounted based on the Company's risk-free interest rate that corresponds to the period when the self-insured claims are incurred and projected to be paid.

See Note 17 — Commitments and Contingencies for information related to the portion of the Company's insurance reserves for professional and general liability and workers' compensation liability that are indemnified by CHS.

Self-Insured Employee Health Benefits

The Company is self-insured for substantially all of the medical benefits of its employees. The Company maintains a liability for its current estimate of incurred but not reported employee health claims based on historical claims data provided by third-party administrators. The undiscounted reserve for self-insured employee health benefits was \$7.3 million and \$8.8 million as of September 30, 2018 and December 31, 2017, respectively, and is included in accrued salaries and benefits in the Company's consolidated balance sheets. Expense each period is based on the actual claims received during the period plus the impact of any adjustment to the liability for incurred but not reported employee health claims.

Noncontrolling Interests and Redeemable Noncontrolling Interests

The Company's consolidated financial statements include all assets, liabilities, revenues and expenses of less than 100% owned entities that it controls. Certain of the Company's consolidated subsidiaries have noncontrolling physician ownership interests with redemption features that require the Company to deliver cash upon the occurrence of certain events outside of its control, such as the retirement, death, or disability of a physician-owner. The carrying amount of redeemable noncontrolling interests is recognized in the Company's consolidated balance sheets at the greater of: (1) the initial carrying amount of these investments, increased or decreased for the noncontrolling interests' share of cumulative net income (loss), net of cumulative amounts distributed to the noncontrolling interest partners, if any, or (2) the redemption value of the investments held by the noncontrolling interest partners.

Assets and Liabilities of Hospitals Held for Sale

The Company reports separately from other assets in the consolidated balance sheet those assets that meet the criteria for classification as held for sale. Generally, assets that meet the criteria include those for which the carrying amount will be settled principally through a sale transaction rather than through continuing use. The asset must be available for immediate sale in its present condition, subject to usual or customary terms, and the sale must be probable to occur in the next 12 months. Similarly, the liabilities of a disposal group are classified as held for sale upon meeting these criteria. Immediately following classification as held for sale, the Company remeasures these assets and liabilities and adjusts the value to the lesser of the carrying amount or fair value less costs to sell. Assets and liabilities classified as held for sale are no longer depreciated or amortized into expense. The carrying values of assets classified as held for sale are reported net of impairment charges.

Stock-Based Compensation

The Company issues restricted stock awards to key employees and directors under the Quorum Health Corporation 2016 Stock Award Plan (the “2016 Stock Award Plan”). The Company recognizes compensation expense over each of the restricted stock award’s requisite service periods based on the estimated grant date fair value of each restricted stock award. See Note 14 — Stock-Based Compensation for additional information related to stock-based compensation.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Benefit Plans

The Company maintains various benefit plans, including defined contribution plans, a defined benefit plan and a deferred compensation plan, for which certain of the Company's subsidiaries are the plan sponsors. The rights and obligations of these plans were transferred from CHS to the Company, pursuant to the Separation and Distribution Agreement. Benefits costs are recorded as salaries and benefits expenses in the consolidated statements of income. The cumulative liability for these benefit costs is recorded in other long-term liabilities in the consolidated balance sheets.

The Company recognizes the unfunded liability of its defined benefit plan in other long-term liabilities in the consolidated balance sheets. Unrecognized gains (losses) and prior service credits (costs) are recorded as changes in other comprehensive income (loss) in the consolidated statements of income. The measurement date of the plan's assets and liabilities coincides with the Company's year end. The Company's pension benefit obligation is measured using actuarial calculations that incorporate discount rates, rate of compensation increases and expected long-term returns on plan assets. The calculations additionally consider expectations related to the retirement age and mortality of plan participants. The Company records pension benefit costs related to all of its plans as salaries and benefits expenses in the consolidated statements of income.

Fair Value of Financial Instruments

The Company utilizes the U.S. GAAP fair value hierarchy to measure the fair value of its financial instruments. The fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity's own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

The inputs used to measure fair value are classified into the following fair value hierarchy:

Level 1 - Quoted market prices in active markets for identical assets and liabilities.

Level 2 - Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3 - Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies or similar techniques reflecting the Company's own assumptions.

Segment Reporting

The principal business of the Company is to provide healthcare services at its hospitals and affiliated outpatient facilities. The Company's only other line of business is the hospital management advisory and healthcare consulting services it provides through QHR. The Company has determined that its hospital operations business and QHR business meet the criteria for separate segment reporting. The Company's corporate functions are reported in the all other reportable segment. See Note 13 — Segments for additional information related to the Company's segment reporting.

New Accounting Pronouncements

In February 2018, the FASB issued ASU 2018-02, Income Statement — Reporting Comprehensive Income, which allows for reclassification from accumulated other comprehensive income to retained earnings of the stranded tax effects in accumulated other comprehensive income resulting from the enactment of the comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”) and corresponding accounting treatment recorded in the fourth quarter of 2017. The ASU is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this ASU is permitted, including adoption in any interim period for reporting periods for which financial statements have not yet been issued. The Company does not anticipate that the adoption of this standard will have a significant impact on its consolidated balance sheet.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles — Goodwill and Other: Simplifying the Test for Goodwill Impairment, which simplifies the accounting for goodwill impairment by eliminating step two from the goodwill impairment test. This ASU instead permits an entity to recognize goodwill impairment as the excess of a reporting unit’s carrying value over the estimated fair value of the reporting unit, to the extent this amount does not exceed the carrying amount of goodwill. The new guidance continues to allow an entity to perform a qualitative assessment of goodwill impairment indicators in lieu of a quantitative assessment in certain situations. The ASU is effective for annual and interim reporting periods beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact this guidance may have on its consolidated results of operations, financial position and cash flows.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows — Restricted Cash, which addressed classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires a reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. The ASU does not define restricted cash or restricted cash equivalents; however, the nature of the restrictions should be disclosed. The guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. This ASU is to be applied using a retrospective transition method for each period presented. The Company adopted ASU 2016-18 on January 1, 2018 and concurrently revised its presentation of cash and cash equivalents on the consolidated statement of cash flows. For periods prior to January 1, 2018, the presentation of cash and cash equivalents on the consolidated statement of cash flows has been revised to conform to the current presentation.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which amends the accounting for leases and requires the rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for interim periods and fiscal years beginning after December 15, 2018, with early adoption permitted. Under ASU 2016-02, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients. The Company's adoption process of ASU 2016-02 is ongoing, including identifying and validating the population of both known and embedded leases, implementing the Company's acquired lease software and quantifying the impact on its consolidated financial statements. The Company anticipates that the adoption of ASU 2016-02 will result in a material increase in both total assets and total liabilities reflected on its consolidated balance sheets upon the recognition of right-of-use assets and obligations for leases currently classified as operating leases. In addition, the Company is continuing to evaluate and address the impact that the adoption of this standard will have on the Company's policies, procedures, financial disclosures and control framework. The Company anticipates substantially completing its evaluation of the impact of the adoption of ASU 2016-02 by December 1, 2018.

NOTE 3 – IMPAIRMENT OF LONG-LIVED ASSETS AND GOODWILL

During the three months ended September 30, 2018, the Company evaluated the fair value of hospitals intended for divestiture. In connection with this evaluation, the Company recognized long-lived asset impairment of \$32.4 million during the three months ended September 30, 2018, which consisted of \$31.5 million of property and equipment and \$0.9 million of capitalized software costs.

During the three months ended March 31, 2018, the Company evaluated the fair value of hospitals intended for divestiture. In connection with this evaluation, the Company recognized long-lived asset impairment of \$39.8 million during the three months ended March 31, 2018, which consisted of \$34.7 million of property and equipment and \$5.1 million of capitalized software costs.

During the three months ended September 30, 2017, the Company evaluated the fair value of hospitals classified as held for sale and other hospitals intended for potential divestiture. In connection with this evaluation, the Company recognized long-lived asset and goodwill impairment of \$5.3 million during the three months ended September 30, 2017, which consisted of \$3.7 million of property and equipment, \$1.0 million of intangibles and \$0.6 million of

goodwill impairment.

During the three months ended June 30, 2017, the Company evaluated the fair value of hospitals classified as held for sale and other hospitals intended for potential divestiture. In connection with this evaluation, the Company recognized \$12.9 million of impairment to property and equipment during the three months ended June 30, 2017.

During the three months ended March 31, 2017, management made a decision to classify certain hospitals as held for sale. In connection with this decision, the Company evaluated the estimated relative fair value of the hospitals classified as held for sale in relation to the overall fair value of the hospital operations reporting unit utilizing a September 30, 2016 measurement date, which was the measurement date of the Company's most recent annual goodwill impairment analysis, and recognized long-lived asset and goodwill impairment of \$3.3 million during the three months ended March 31, 2017, which consisted of \$1.1 million of property and equipment, \$0.8 million of capitalized software costs and \$1.4 million of goodwill.

NOTE 4 –DIVESTITURES

McKenzie Regional Hospital

On September 30, 2018, the Company sold 45-bed McKenzie Regional Hospital and its affiliated facilities ("McKenzie"), located in McKenzie, Tennessee, for proceeds of \$1.7 million, which were received in October 2018. For the three months ended September 30, 2018 and 2017, the Company's operating results included pre-tax losses of \$4.2 million and \$1.3 million, respectively, related to McKenzie, and pre-tax losses of \$6.0 million and \$3.2 million for the nine months ended September 30, 2018 and 2017, respectively. In addition to the above, the Company recorded a \$0.7 million loss on the sale of McKenzie in the nine months ended September 30, 2018, which includes a write-off of allocated goodwill of \$0.4 million.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Clearview Regional Medical Center

On March 31, 2018, the Company sold 77-bed Clearview Regional Medical Center and its affiliated facilities (“Clearview”), located in Monroe, Georgia, for proceeds of \$37.4 million, of which \$8.0 million was placed in an escrow account subject to resolution of certain outstanding litigation initiated before the Spin-off and for which CHS agreed to indemnify the Company for the resulting liability. For the three months ended September 30, 2018 and 2017, the Company’s operating results included pre-tax losses of \$1.7 million and \$0.7 million, respectively, related to Clearview, and pre-tax losses of \$5.3 million and \$2.3 million for the nine months ended September 30, 2018 and 2017, respectively. In addition to the above, the Company recorded a \$7.9 million loss on the sale of Clearview in the nine months ended September 30, 2018, which includes a write-off of allocated goodwill of \$9.4 million.

Vista Medical Center West

On March 1, 2018, the Company sold 70-bed Vista Medical Center West and its affiliated facilities (“Vista West”), located in Waukegan, Illinois, for proceeds of \$1.2 million. For the three months ended September 30, 2018 and 2017, the Company’s operating results included pre-tax losses of \$1.3 million and \$0.2 million, respectively, related to Vista West, and pre-tax losses of \$2.1 million and \$1.5 million for the nine months ended September 30, 2018 and 2017, respectively. In addition to the above, the Company recorded a \$0.2 million loss on the sale of Vista West in the nine months ended September 30, 2018.

Affinity Medical Center

On January 5, 2018, the Company announced plans to close Affinity Medical Center (“Affinity”) located in Massillon, Ohio. Subsequent to January 5, 2018, the Company’s affiliates entered into an agreement with the City of Massillon related to the closure whereby all of the owned real property and a portion of the related tangible assets located at the hospital would be transferred to the City of Massillon in exchange for nominal consideration and the City of Massillon’s assumption of certain ongoing real property lease obligations and equipment lease obligations. Operations ceased on February 11, 2018 and the Company transferred the agreed-upon assets to the City of Massillon on May 16, 2018. For the three months ended September 30, 2018 and 2017, the Company’s operating results included pre-tax losses of \$2.2 million and \$2.3 million respectively, related to Affinity, and pre-tax losses of \$26.6 million and \$8.3 million for the nine months ended September 30, 2018 and 2017, respectively. Included in the pre-tax loss for the nine months ended September 30, 2018 was \$18.2 million of closure costs related to the closure of Affinity which includes \$8.1 million of severance and salary continuation costs, \$5.0 million in losses associated with the disposal of assets that have no future value to the Company and \$5.1 million of other costs and fees related to termination of contracts and other miscellaneous costs. The Company anticipates that in the remainder of 2018 it will incur costs, beyond those already incurred of approximately \$0.5 million to \$1.0 million related to the wind down and transfer of assets to other facilities. In addition, beyond 2018, the Company is obligated to maintain patient health records for approximately 19 years with an estimated annual cost of \$0.3 million.

NOTE 5 – PROPERTY AND EQUIPMENT

The following table provides a summary of the components of property and equipment (in thousands):

Edgar Filing: Quorum Health Corp - Form 10-Q

	September 30, 2018	December 31, 2017
Property and equipment, at cost:		
Land and improvements	\$51,983	\$70,731
Building and improvements	724,753	790,619
Equipment and fixtures	496,939	529,150
Construction in progress	11,020	14,684
Total property and equipment, at cost	1,284,695	1,405,184
Less: Accumulated depreciation and amortization	(718,309)	(729,905)
Total property and equipment, net	\$566,386	\$675,279

Depreciation expense was \$12.4 million and \$14.6 million for the three months ended September 30, 2018 and 2017, respectively, and \$37.6 million and \$45.2 million for the nine months ended September 30, 2018 and 2017, respectively. See Note 6 — Goodwill and Intangible Assets for information on amortization expense related to leasehold improvements and property and equipment held under capital lease obligations. The total amount of assets held under capital lease obligations, at cost, was \$29.2 million at both September 30, 2018 and December 31, 2017. The total amount of assets held under capital lease obligations, net of accumulated amortization was \$24.2 million and \$25.6 million at September 30, 2018 and December 31, 2017, respectively.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Purchases of property and equipment accrued in accounts payable were \$3.0 million and \$6.8 million as of September 30, 2018 and December 31, 2017, respectively.

NOTE 6 – GOODWILL AND INTANGIBLE ASSETS

Goodwill

The following table provides a summary of changes in goodwill (in thousands):

	Nine Months Ended September 30, 2018
Balance at beginning of period	\$ 409,229
Acquisitions	77
Divestitures	(9,826)
Reclasses from held for sale	1,593
Balance at end of period	\$ 401,073

Goodwill related to the Company's hospital operations reporting unit was \$367.7 million and \$375.9 million as of September 30, 2018 and December 31, 2017, respectively. Goodwill related to the Company's hospital management advisory and healthcare consulting services reporting unit was \$33.3 million at both September 30, 2018 and December 31, 2017.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Intangible Assets

The following table provides a summary of the components of intangible assets (in thousands):

	September 30, 2018	December 31, 2017
Finite-lived intangible assets:		
Capitalized software costs:		
Cost	\$ 144,571	\$ 159,449
Accumulated amortization	(109,322)	(111,661)
Capitalized software costs, net	35,249	47,788
Physician guarantee contracts:		
Cost	5,431	7,489
Accumulated amortization	(3,147)	(4,290)
Physician guarantee contracts, net	2,284	3,199
Other finite-lived intangible assets:		
Cost	43,221	43,376
Accumulated amortization	(36,013)	(34,668)
Other finite-lived intangible assets, net	7,208	8,708
Total finite-lived intangible assets		
Cost	193,223	210,314
Accumulated amortization	(148,482)	(150,618)
Total finite-lived intangible assets, net	\$ 44,741	\$ 59,696
Indefinite-lived intangible assets:		
Tradenames	\$ 4,000	\$ 4,000
Licenses and other indefinite-lived intangible assets	1,125	1,154
Total indefinite-lived intangible assets	\$ 5,125	\$ 5,154
Total intangible assets:		
Cost	\$ 198,348	\$ 215,468
Accumulated amortization	(148,482)	(150,618)
Total intangible assets, net	\$ 49,866	\$ 64,850

As of September 30, 2018, the Company had \$0.9 million of capitalized software costs that are currently in the development stage. Amortization of these costs will begin once the software projects are complete and ready for their intended use.

Amortization Expense

The following table provides a summary of the components of amortization expense (in thousands):

Edgar Filing: Quorum Health Corp - Form 10-Q

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Amortization of finite-lived intangible assets:				
Capitalized software costs	\$2,416	\$3,889	\$8,515	\$12,428
Physician guarantee contracts	497	416	1,942	1,572
Other finite-lived intangible assets	508	920	1,522	2,046
Total amortization expense related to finite-lived intangible assets	3,421	5,225	11,979	16,046
Amortization of leasehold improvements and property and equipment assets held under capital lease obligations	792	886	2,468	2,225
Total amortization expense	\$4,213	\$6,111	\$14,447	\$18,271

22

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

As of September 30, 2018, the weighted-average remaining amortization period of the Company's intangible assets subject to amortization, except for capitalized software costs and physician guarantee contracts, was approximately 3.8 years.

NOTE 7 – LONG-TERM DEBT

The following table provides a summary of the components of long-term debt (in thousands):

	September 30, 2018	December 31, 2017
Senior Credit Facility:		
Revolving Credit Facility, maturing 2021	\$—	\$—
Term Loan Facility, maturing 2022	800,696	831,158
ABL Credit Facility, maturing 2021	—	—
Senior Notes, maturing 2023	400,000	400,000
Unamortized debt issuance costs and discounts	(37,953)	(42,934)
Capital lease obligations	23,607	24,411
Other debt	878	1,255
Total debt	1,187,228	1,213,890
Less: Current maturities of long-term debt	(1,544)	(1,855)
Total long-term debt	\$1,185,684	\$1,212,035

Senior Credit Facility

In connection with the Spin-off, on April 29, 2016, the Company entered into a credit agreement (the “CS Agreement”), among the Company, the lenders party thereto and Credit Suisse AG, Cayman Islands Branch (“Credit Suisse”), as administrative agent and collateral agent. On April 11, 2017, the Company executed an agreement with its Senior Credit Facility lenders to amend certain provisions of its Senior Credit Facility (the “CS Amendment”), as described below. On March 14, 2018, the Company executed a second agreement with its Senior Credit Facility lenders to amend certain provisions of its Senior Credit Facility (the “CS Second Amendment”), as described below.

The CS Agreement initially provided for an \$880 million senior secured term loan facility (the “Term Loan Facility”) and a \$100 million senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Senior Credit Facility”). The Term Loan Facility was issued at a discount of \$17.6 million, or 98% of par value, and has a maturity date of April 29, 2022, subject to customary acceleration events and repayment, extension or refinancing. The Revolving Credit Facility has a maturity date of April 29, 2021, subject to certain customary acceleration events and repayment, extension or refinancing. The CS Amendment reduced the Revolving Credit Facility's capacity from \$100 million to \$87.5 million until December 31, 2017, at which time the capacity decreased to \$75.0 million through maturity. The CS Second Amendment further reduced the Revolving Credit Facility's capacity to \$62.5 million through maturity, effective with the execution of the amendment on March 14, 2018.

The CS Agreement contains customary covenants, including a maximum permitted Secured Net Leverage Ratio, as determined based on 12 month trailing Consolidated EBITDA, as defined in the CS Agreement. On April 11, 2017, the Company executed the CS Amendment with its Senior Credit Facility lenders to amend the calculation of the Secured Net Leverage Ratio beginning July 1, 2017 through maturity, among other provisions. In addition, the CS Amendment raised the minimum Secured Net Leverage Ratio required for the Company to remain in compliance for certain periods, and also changed the calculation of compliance for specified periods. The CS Second Amendment, which was executed on March 14, 2018, further amended the Secured Net Leverage Ratio for the period July 1, 2017 through maturity. As of September 30, 2018, the Company had a Secured Net Leverage Ratio of 4.15 to 1.00 implying additional borrowing capacity of \$167.0 million as of September 30, 2018.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

After giving effect to the CS Amendment and the CS Second Amendment, the maximum Secured Net Leverage Ratio permitted under the CS Agreement, as determined based on 12 month trailing Consolidated EBITDA and as defined in the CS Agreement follows:

Period	Maximum Secured Net Leverage Ratio
Period from January 1, 2017 to June 30, 2017	4.50 to 1.00
Period from July 1, 2017 to June 30, 2018	4.75 to 1.00
Period from July 1, 2018 to December 31, 2019	5.00 to 1.00
Period from January 1, 2020 and thereafter	4.50 to 1.00

In addition to amending the calculation of the Secured Net Leverage Ratio and the Maximum Secured Net Leverage Ratio, the CS Amendment and the CS Second Amendment also affected other terms of the CS Agreement as follows:

- Through April 29, 2022, the Company is required to use asset sales proceeds to make mandatory redemptions under the Term Loan Facility.
- Through December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments, as defined in the CS Agreement, only if the Secured Net Leverage Ratio, adjusted for the requested Incremental Term Loan borrowing, is below 3.35 to 1.00. After December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments for the greater of \$100 million or an amount which would produce a Secured Net Leverage Ratio of 3.35 to 1.00.
- Through December 31, 2018, the Company is allowed to incur Permitted Additional Debt, as defined in the CS Agreement, only if the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 4.50 to 1.00. After December 31, 2018, the Company may incur Permitted Additional Debt so long as the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 5.50 to 1.00.

Prior to the CS Amendment, interest under the Term Loan Facility accrued, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 1% plus 5.75%, or the alternate base rate plus 4.75%. Following the CS Amendment, interest under the Term Loan Facility accrues, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 1% plus 6.75%, or the alternate base rate plus 5.75%. The effective interest rate on the Term Loan Facility was 9.29% as of September 30, 2018. Interest under the Revolving Credit Facility accrues, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 0% plus 2.75%, or the alternate base rate plus 1.75%, and remains unchanged under the CS Amendment and the CS Second Amendment.

Borrowings from the Revolving Credit Facility are used for working capital and general corporate purposes. As of September 30, 2018, the Company had no borrowings outstanding under the Revolving Credit Facility and had \$13.7 million of letters of credit outstanding that were primarily related to the self-insured retention levels of professional and general liability and workers' compensation liability insurance as security for the payment of claims. As of September 30, 2018, the Company had borrowing capacity under its Revolving Credit Facility of \$48.8 million.

ABL Credit Facility

In connection with the Spin-off, on April 29, 2016, the Company entered into an ABL Credit Agreement (the “UBS Agreement,” and together with the CS Agreement, collectively, the “Credit Agreements”), among the Company, the lenders party thereto and UBS AG, Stamford Branch (“UBS”), as administrative agent and collateral agent. On April 11, 2017, we executed an amendment to the UBS Agreement with its lender party thereto, which aligned the provisions of the UBS Agreement with the CS Amendment. The UBS Agreement provides for a \$125 million senior secured asset-based revolving credit facility (the “ABL Credit Facility”). The available borrowings from the ABL Credit Facility, which are based on eligible patient accounts receivable, are used for working capital and general corporate purposes. As of September 30, 2018, the Company had no borrowings outstanding on the ABL Credit Facility and borrowing capacity of \$120.3 million.

The ABL Credit Facility has a maturity date of April 29, 2021, subject to customary acceleration events and repayment, extension or refinancing. Interest under the ABL Credit Facility accrues, at the option of the Company, at a base rate or LIBOR, subject to statutory reserves and a floor of 0%, except that all swingline borrowings will accrue interest based on the base rate, plus an applicable margin determined by the average excess availability under the ABL Credit Facility for the fiscal quarter immediately

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

preceding the date of determination. The applicable margin ranges from 1.75% to 2.25% for LIBOR advances and from 0.75% to 1.25% for base rate advances.

The ABL Credit Facility has a “Covenant Trigger Event” definition that requires the Company to maintain excess availability under the ABL Credit Facility equal to or greater than the greater of (i) \$12.5 million and (ii) 10% of the aggregate commitments under the ABL Credit Facility. If a Covenant Trigger Event occurs, then the Company is required to maintain a minimum Consolidated Fixed Charge Ratio of 1.10 to 1.00 until such time that a Covenant Trigger Event is no longer continuing. In addition, if excess availability under the ABL Credit Facility were to fall below the greater of (i) 12.5% of the aggregate commitments under the ABL Credit Facility and (ii) \$15.0 million, then a “Cash Dominion Event” would be triggered upon which the lenders could assume control of the Company’s cash.

Credit Agreement Covenants

In addition to the specific covenants described above, the Credit Agreements contain customary negative covenants which limit the Company’s ability to, among other things, incur additional indebtedness, create liens, make investments, transfer assets, merge or acquire assets, and make restricted payments, including dividends, distributions and specified payments on other indebtedness. They include customary events of default, including payment defaults, material breaches of representations and warranties, covenant defaults, default on other material indebtedness, customary Employee Retirement Income Security Act (“ERISA”) events of default, bankruptcy and insolvency, material judgments, invalidity of liens on collateral, change of control or cessation of business. The Credit Agreements also contain customary affirmative covenants and representations and warranties.

Senior Notes

On April 22, 2016, the Company issued \$400 million aggregate principal amount of 11.625% Senior Notes due 2023, pursuant to the Indenture. The Senior Notes were issued at a discount of \$6.9 million, or 1.734%, in a private placement and are senior unsecured obligations of the Company guaranteed on a senior basis by certain of the Company’s subsidiaries (the “Guarantors”). The Senior Notes mature on April 15, 2023 and bear interest at a rate of 11.625% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2016. Interest on the Senior Notes accrues from the date of original issuance and is calculated on the basis of a 360-day year comprised of twelve 30-day months. The effective interest rate on the Senior Notes was 12.49% as of September 30, 2018.

The Indenture contains covenants that, among other things, limit the ability of the Company and certain of its subsidiaries to incur or guarantee additional indebtedness, pay dividends or make other restricted payments, make certain investments, create or incur certain liens, sell assets and subsidiary stock, transfer all or substantially all of its assets or enter into merger or consolidation transactions.

On May 17, 2017, the Company exchanged the 11.625% Senior Notes due 2023 (the “Initial Notes”) in the aggregate principal amount of \$400 million, which were not registered under the Securities Act of 1933, as amended (the “Securities Act”), for a like principal amount of 11.625% Senior Notes due 2023 (the “Exchange Notes”), which have been registered under the Securities Act. The Initial Notes were substantially identical to the Exchange Notes, except that the Exchange Notes are registered under the Securities Act and are not subject to the transfer restrictions and

certain registration rights agreement provisions applicable to the Initial Notes.

25

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

On and after April 15, 2019, the Company is entitled, at its option, to redeem all or a portion of the Senior Notes upon not less than 30 nor more than 60 days' notice, at the following redemption prices, plus accrued and unpaid interest, if any, to the redemption date. The redemption prices are expressed as a percentage of the principal amount on the redemption date. Holders of record on the relevant record date have the right to receive interest due on the relevant interest payment date. In addition, prior to April 15, 2019, the Company may redeem some or all of the Senior Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, plus a "make whole" premium, as set forth in the Indenture. The Company is entitled to redeem up to 35% of the aggregate principal amount of the Senior Notes until April 15, 2019 with the net proceeds from certain equity offerings at the redemption price set forth in the Indenture.

The following table provides a summary of the redemption dates and prices related to the Senior Notes:

Period	Redemption Prices
Period from April 15, 2019 to April 14, 2020	108.719 %
Period from April 15, 2020 to April 14, 2021	105.813 %
Period from April 15, 2021 to April 14, 2022	102.906 %
Period from April 15, 2022 to April 14, 2023	100.000 %

Debt Issuance Costs and Discounts

The following table provides a summary of unamortized debt issuance costs and discounts (in thousands):

	September 30, 2018	December 31, 2017
Debt issuance costs	\$ 34,533	\$ 32,265
Debt discounts	24,536	24,536
Total debt issuance costs and discounts at origination	59,069	56,801
Less: Amortization of debt issuance costs and discounts	(21,116)	(13,867)
Total unamortized debt issuance costs and discounts	\$ 37,953	\$ 42,934

Capital Lease Obligations and Other Debt

The Company's debt arising from capital lease obligations primarily relates to its corporate office in Brentwood, Tennessee. As of September 30, 2018 and December 31, 2017, this capital lease obligation was \$17.4 million and \$17.9 million, respectively. The remainder of the Company's capital lease obligations relate to property and equipment at its hospitals and QHR. Other debt consists of physician loans and miscellaneous notes payable to banks.

Debt Maturities

The following table provides a summary of debt maturities for the next five years and thereafter (in thousands):

September
30, 2018

Remainder of 2018	\$403
2019	1,549
2020	1,621
2021	1,639
2022	802,096
Thereafter	417,873
Total debt, excluding unamortized debt issuance costs and discounts	\$1,225,181

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Interest Expense, Net

The following table provides a summary of the components of interest expense, net (in thousands):

	Three Months Ended September 30, 2018		Nine Months Ended September 30, 2018	
	2017		2017	
Senior Credit Facility:				
Revolving Credit Facility	\$63	\$98	\$205	\$429
Term Loan Facility	18,121	17,512	53,174	48,795
ABL Credit Facility	276	638	1,115	1,507
Senior Notes	11,626	11,631	34,865	34,886
Amortization of debt issuance costs and discounts	2,079	2,067	7,249	6,271
All other interest expense (income), net	285	270	(1,301)	(1,684)
Total interest expense, net	\$32,450	\$32,216	\$95,307	\$90,204

NOTE 8 – OTHER LONG-TERM ASSETS AND OTHER LONG-TERM LIABILITIES

The following table provides a summary of the components of other long-term assets (in thousands):

	September 30, 2018	December 31, 2017
Receivable for professional and general liability insurance reserves indemnified by CHS	\$ 31,903	\$ 44,377
Receivable for workers' compensation liability insurance reserves indemnified by CHS	11,734	14,545
Nonqualified Deferred Compensation Plan Assets	18,432	23,052
Restricted cash	8,000	—
Other miscellaneous long-term assets	10,925	13,633
Total other long-term assets	\$ 80,994	\$ 95,607

The following table provides a summary of the components of other long-term liabilities (in thousands):

	September 30, 2018	December 31, 2017
Professional and general liability insurance reserves	\$ 78,612	\$ 76,993
Workers' compensation liability insurance reserves	17,879	18,558
Benefit plan liabilities	28,639	36,103
Deferred rent	2,770	4,268

Edgar Filing: Quorum Health Corp - Form 10-Q

Other miscellaneous long-term liabilities	1,925	2,032
Total other long-term liabilities	\$ 129,825	\$ 137,954

See Note 17 — Commitments and Contingencies for additional information about the Company's insurance reserves.

NOTE 9 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying amounts of the Company's cash and cash equivalents, patient accounts receivable, amounts due from and due to third-party payors, restricted cash and accounts payable approximate their fair values due to the short-term maturity of these financial instruments.

27

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

The following table provides a summary of the carrying amounts and estimated fair values of the Company's long-term debt (in thousands):

	September 30, 2018		December 31, 2017	
	Carrying Amount	Estimated Fair Value	Carrying Amount	Estimated Fair Value
Revolving Credit Facility	\$—	\$—	\$—	\$—
Term Loan Facility	800,696	813,211	831,158	838,954
ABL Credit Facility	—	—	—	—
Senior Notes	400,000	401,088	400,000	393,396
Other debt	24,485	24,485	25,666	25,666
Total debt, excluding unamortized debt issuance costs and discounts	\$1,225,181	\$1,238,784	\$1,256,824	\$1,258,016

The Company considers its long-term debt instruments to be measured based on Level 2 inputs. Information about the valuation methodologies used in the determination of the fair values for the Company's long-term debt instruments follows:

• **Term Loan Facility.** The estimated fair value is based on publicly available trading activity and supported with information from the Company's lending institutions regarding relevant pricing for trading activity.

• **Senior Notes.** The estimated fair value is based on the closing market price for these notes.

• **All other debt.** The carrying values of the Company's other debt instruments, including the Revolving Credit Facility, ABL Credit Facility, capital lease obligations, physician loans and miscellaneous notes payable to banks, approximate their estimated fair values due to the nature of these obligations.

NOTE 10 – EQUITY

Preferred Stock

In connection with the Spin-off, the Company authorized 100,000,000 shares of preferred stock, par value of \$0.0001 per share. No shares have been issued as of September 30, 2018. The Board has the discretion, subject to limitations prescribed by Delaware law and by the Company's amended and restated certificate of incorporation, to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock, when and if issued.

Common Stock

In connection with the Spin-off, the Company authorized 300,000,000 shares of common stock, par value of \$0.0001 per share, and issued 28,412,054 shares of common stock on April 29, 2016 to CHS stockholders of record on the Record Date, or April 22, 2016. The common stock began trading on the NYSE on May 2, 2016 under the ticker symbol "QHC." As of September 30, 2018 and December 31, 2017, the Company had 31,527,885 shares and 30,294,895 shares, respectively, of common stock issued and outstanding.

Holders of the Company's common stock are entitled to one vote for each share held of record on all matters for which stockholders may vote. Holders of the Company's common stock do not have cumulative voting rights in the election of directors. There are no preemptive rights, conversion, redemption or sinking fund provisions applicable to the common stock. In the event of liquidation, dissolution or winding up, holders of common stock are entitled to share ratably in the assets available for distribution. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the Company's Credit Agreements and the Indenture impose restrictions on its ability to pay dividends.

Additional Paid-in Capital

In connection with the Spin-off, the Company issued common stock, as described above, to CHS stockholders. In addition, pursuant to the Separation and Distribution Agreement, CHS contributed capital in excess of par value of common stock of \$530.6 million, in lieu of a cash settlement payment, related to the remaining intercompany indebtedness with CHS and the Parent's equity attributable to CHS. See Note 1 — Description of the Business and Spin-off for a summary of the major transactions to effect the Spin-off.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Accumulated Deficit

Accumulated deficit of the Company represents the Company's cumulative net losses since the Spin-off date.

NOTE 11 – INCOME TAXES

The Company and its subsidiaries are subject to U.S. federal income tax and income tax of multiple state and local jurisdictions. The Company provides for income taxes based on the enacted tax laws and rates in jurisdictions in which it conducts its operations.

On December 22, 2017, the Tax Act was enacted, significantly decreasing the U.S. federal income tax rate from 35% to 21% for corporations effective January 1, 2018. As a result, the Company remeasured its deferred tax assets, liabilities and related valuation allowances as of the date of enactment. This remeasurement yielded a one-time benefit of approximately \$24.0 million due to the lower income tax rate in the fourth quarter of 2017. Given the substantial changes associated with the Tax Act, the estimated financial impacts for 2017 are provisional and subject to further interpretation and clarification of the Tax Act during 2018.

The Tax Act also provides for acceleration of depreciation for certain assets placed into service after September 27, 2017, as well as an increased limitation on the deductibility of executive compensation, a limitation on the deductibility of interest expense and new rules surrounding meals and entertainment expense and fines and penalties. The Company will continue to analyze additional information and guidance related to the Tax Act as supplemental legislation, regulatory federal or state guidance, or evolving technical interpretations become available. The Company will continue to refine the provisional amounts within the measurement period provided by Staff Accounting Bulletin No. 118. The Company expects to complete its analysis by the end of 2018.

The Company's effective tax rates were 2.0% and 1.9% for the three months ended September 30, 2018 and 2017, respectively, and 0.6% and 0.1% for the nine months ended September 30, 2018 and 2017, respectively. The increase in the Company's effective tax rate for the three and nine months ended September 30, 2018, when compared to the three and nine months ended September 30, 2017, was primarily due to the impairment or disposal of certain indefinite-lived assets and the change in expected realization of deferred tax assets under the new law established by the Tax Act.

The Company's deferred income tax liabilities, net were \$6.7 million as of September 30, 2018, compared to \$7.8 million as of December 31, 2017, a \$1.1 million decrease. This decrease was a result of an increase in deferred tax liabilities during the period due to tax deductible amortization on indefinite-lived intangibles including goodwill and the reclassification of refundable alternative minimum tax ("AMT") credit, which was offset by a decrease in deferred tax liabilities due to the impairment and disposal of certain indefinite-lived intangible assets during the period.

In the ordinary course of business, there is inherent uncertainty in quantifying the Company's income tax positions. The Company assesses its income tax positions and records income tax benefits for all tax years subject to examination based on management's evaluation of the facts, circumstances, and information available at the reporting date. The Company is not aware of any unrecognized income tax benefits; therefore, it has not recorded any such amounts for the three and nine months ended September 30, 2018 and 2017.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

NOTE 12 – EARNINGS PER SHARE

The following table provides a summary of the computation of basic and diluted earnings (loss) per share (in thousands, except earnings per share and shares):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Numerator:				
Net income (loss)	\$(53,886)	\$(28,554)	\$(178,314)	\$(86,334)
Less: Net income (loss) attributable to noncontrolling interests	54	637	1,200	1,048
Net income (loss) attributable to Quorum Health Corporation	\$(53,940)	\$(29,191)	\$(179,514)	\$(87,382)
Denominator:				
Weighted-average shares outstanding - basic and diluted	29,215,823	28,245,833	28,891,363	28,068,085
Earnings (loss) per share attributable to Quorum Health Corporation stockholders - basic and diluted				
	\$(1.85)	\$(1.03)	\$(6.21)	\$(3.11)

Due to the net loss attributable to Quorum Health Corporation in the three and nine months ended September 30, 2018 and 2017, no incremental shares are included in diluted earnings (loss) per share for these periods because the effect of the incremental shares would be anti-dilutive.

NOTE 13 – SEGMENTS

The Company operates two distinct operating segments, its hospital operations business and its hospital management advisory and healthcare consulting services business. The hospital operations segment includes the operations of the Company's owned and leased hospitals and their affiliated outpatient facilities. The hospital management advisory and healthcare consulting services segment includes the operations of QHR. Both segments meet the criteria as separate reportable segments. The financial information for the Company's corporate functions has been reported in the table below as part of the all other reportable segment.

The following tables provide a summary of financial information related to the Company's reportable segments (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Net operating revenues:				
Hospital operations	\$442,802	\$478,815	\$1,363,628	\$1,494,351
QHR operations	16,937	19,494	55,145	60,385

Edgar Filing: Quorum Health Corp - Form 10-Q

All other	768	993	1,186	2,352
Total net operating revenues	\$460,507	\$499,302	\$1,419,959	\$1,557,088

Adjusted EBITDA:

Hospital operations	\$39,137	\$39,227	\$109,455	\$118,229
QHR operations	4,715	5,391	13,518	15,848
All other	(9,710)	(12,350)	(34,088)	(41,237)
Total Adjusted EBITDA	\$34,142	\$32,268	\$88,885	\$92,840

September
30,
2018

December
31,
2017

Assets:

Hospital operations	\$1,481,792	\$1,687,576
QHR operations	58,082	61,752
All other	73,255	79,513
Total assets	\$1,613,129	\$1,828,841

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

The following table provides a reconciliation of Adjusted EBITDA to net income (loss), its most directly comparable U.S. GAAP financial measure (in thousands):

	Three Months		Nine Months Ended	
	Ended September		September 30,	
	30,		2018	2017
	2018	2017	2018	2017
Adjusted EBITDA	\$34,142	\$32,268	\$88,885	\$92,840
Interest expense, net	(32,450)	(32,216)	(95,307)	(90,204)
(Provision for) benefit from income taxes	1,074	542	1,162	86
Depreciation and amortization	(16,612)	(20,735)	(52,015)	(63,441)
Legal, professional and settlement costs	(1,519)	(2,050)	(10,349)	(6,519)
Impairment of long-lived assets and goodwill	(32,438)	(5,261)	(72,198)	(21,461)
Loss (gain) on sale of hospitals, net	(805)	(79)	(8,927)	5,112
Loss on closure of hospitals, net	(1,111)	—	(18,195)	—
Transition of transition services agreements	(2,445)	—	(3,682)	—
Transaction costs related to the Spin-off	—	(173)	—	(204)
Post-spin headcount reductions and executive severance	(1,722)	(850)	(7,688)	(2,543)
Net income (loss)	\$(53,886)	\$(28,554)	\$(178,314)	\$(86,334)

NOTE 14 – STOCK-BASED COMPENSATION

On April 1, 2016, the Company adopted the Quorum Health Corporation 2016 Stock Award Plan (“2016 Stock Award Plan”). The Company filed a Registration Statement on Form S-8 on April 29, 2016 to register 4,700,000 shares of QHC common stock that may be issued under the plan.

As defined in the Separation and Distribution Agreement pursuant to the Spin-off, QHC and CHS employees who held CHS restricted stock awards on the Record Date received QHC restricted stock awards for the number of whole shares, rounded down, of QHC common stock that they would have received as a shareholder of CHS as if the underlying CHS stock were unrestricted on the Record Date, except, that with respect to a portion of CHS restricted stock awards granted to any QHC employees on March 1, 2016 that were cancelled and forfeited on the Spin-off date. The QHC restricted stock awards received by QHC and CHS employees in connection with the Spin-off vest on the same terms as the CHS restricted stock awards to which they relate, through the continued service by such employees with their respective employer. CHS restricted stock awards were adjusted by increasing the number of shares of CHS stock subject to restricted stock awards by an amount of whole shares, rounded down, necessary to preserve the intrinsic value of such awards at the Spin-off date. QHC did not issue any stock options as part of the distribution of shares to holders of CHS stock options.

The following table provides a summary of the activity related to unvested QHC restricted stock awards held by QHC and CHS employees during the nine months ended September 30, 2018 that were distributed in the Spin-off (in shares):

QHC
Awards
Distributed
in Spin-off

Unvested restricted stock awards at December 31, 2017	266,880
Vested	(136,562)
Forfeited	(48,717)
Unvested restricted stock awards at September 30, 2018	81,601

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

The following table provides a summary of the activity related to unvested restricted stock awards during the nine months ended September 30, 2018 that were granted to QHC employees subsequent to the Spin-off:

	QHC Awards Granted Subsequent to Spin-off	
	Shares	Weighted- Average Grant Date Fair Value Per Share
Unvested restricted stock awards at December 31, 2017	1,779,488	\$ 9.58
Granted	1,616,707	6.10
Vested	(830,898)	9.81
Forfeited	(335,512)	9.01
Unvested restricted stock awards at September 30, 2018	2,229,785	7.06

During the nine months ended September 30, 2018, the Company granted 512,500 performance-based restricted stock awards to certain of its executive officers. If the performance-based objectives are attained in accordance with the targets set forth in the performance-based restricted stock award agreement, the restrictions on the restricted stock awards will lapse on the second anniversary of the grant date. In addition, the Company granted 939,167 time-based restricted stock awards in which the restrictions will lapse in equal installments on each of the first three anniversaries of the grant date. In addition, the Company granted 165,040 time-based restricted stock awards to its non-employee directors which will lapse on the first anniversary of the grant date.

The Company records stock-based compensation expense related to the vesting of QHC restricted stock awards issued to QHC employees on the Spin-off date, CHS restricted stock awards held by QHC employees on the Spin-off date, and restricted stock awards granted by QHC subsequent to the Spin-off. Stock-based compensation expense is included in salaries and benefits expenses in the consolidated statements of income.

The following table provides a summary of stock-based compensation expense (in thousands):

	Three Months Ended September 30, 2018		Nine Months Ended September 30, 2017	
Stock-based compensation resulting from the Spin-off	\$—	\$435	\$372	\$1,799
Stock-based compensation related to grants following the Spin-off	2,766	1,939	7,614	5,903
Total stock-based compensation expense	\$2,766	\$2,374	\$7,986	\$7,702

As of September 30, 2018, the Company had unrecognized stock-based compensation expense of \$10.6 million related to restricted stock awards.

NOTE 15 – EMPLOYEE BENEFIT PLANS

The Company maintains various benefit plans, including defined contribution plans, a defined benefit plan and a deferred compensation plan, of which certain of the Company’s subsidiaries are the plan sponsors. The rights and obligations of these plans were transferred from CHS in connection with the Spin-off, pursuant to the Separation and Distribution Agreement.

Defined Contribution Plans

The Quorum Health Retirement Savings Plan (the “Retirement Savings Plan”) is a defined contribution plan, which was established on January 1, 2016 by CHS in anticipation of the Spin-off. The assets and liabilities under this plan were transferred to QHC in connection with the Spin-off. The Retirement Savings Plan covers the majority of the employees at the Company’s subsidiaries. The Company has other minor defined contribution plans at certain of its hospitals that cover employees under the terms of these individual plans. Total expense (benefit) to the Company under all defined contribution plans was \$3.8 million and \$(4.9) million for the three months ended September 30, 2018 and 2017, respectively, and \$8.1 million and \$1.5 million for the nine months ended September 30, 2018 and 2017, respectively. The benefit in the three months ended September 30, 2017 related to a reduction in

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

discretionary employee benefits for the full year. The benefit costs associated with the Retirement Savings Plan are included in salaries and benefits expenses in the consolidated statements of income.

Deferred Compensation Plans

On August 18, 2016, the Compensation Committee of the Board adopted the Executive Nonqualified Excess Plan Adoption Agreement (the “Adoption Agreement”) and the Executive Nonqualified Excess Plan Document (the “Plan Document”), that together, the Adoption Agreement names as the QHCCS, LLC Nonqualified Deferred Compensation Plan (the “NQDCP”). The NQDCP is an unfunded, nonqualified deferred compensation plan that provides deferred compensation benefits for a select group of management, highly compensated employees and independent contractors of the Company’s wholly-owned subsidiary, QHCCS, LLC, a Delaware limited liability company (“QHCCS”), including the Company’s named executive officers. The NQDCP permits participants to defer a portion of their annual base salary, service bonus and performance-based compensation, as well as up to 100% of their incentive compensation in any calendar year. In addition to participant deferrals, QHCCS and/or its affiliates may make discretionary credits to participants’ accounts for any year. As of September 30, 2018, the assets and liabilities under this plan were \$18.4 million and \$19.8 million, respectively. As of December 31, 2017, the assets and liabilities under this plan were \$23.1 million and \$24.3 million, respectively. The assets and liabilities under this plan are included in other long-term assets and other long-term liabilities, respectively, in the consolidated balance sheets.

Supplemental Executive Retirement Plan

On April 1, 2016, the Board adopted the Quorum Health Corporation Supplemental Executive Retirement Plan (the “Original SERP”). Pursuant to the Employee Matters Agreement between the Company and CHS, the Company assumed the liabilities for all obligations under the Original SERP as of April 29, 2016, the Spin-off date, which related to QHC employees, as defined in the Employee Matters Agreement. In addition, as defined by the Employee Matters Agreement, no additional benefits were to accrue under the Original SERP following the Spin-off and no assets were transferred to the Company related to the Original SERP. The accrued benefit liability transferred to the Company for the Original SERP was \$6.0 million.

On May 24, 2016, the Board, upon recommendation of the Compensation Committee, approved the Company’s Amended and Restated Supplemental Executive Retirement Plan (the “Amended and Restated SERP”), in order to accrue additional benefits with respect to QHC Employees who otherwise qualify as “Participants” under the Amended and Restated SERP. The Amended and Restated SERP is a noncontributory non-qualified deferred compensation plan under Section 409A of the Internal Revenue Code. The benefit costs under the Amended and Restated SERP were \$0.3 million and \$0.5 million for the three months ended September 30, 2018 and 2017, respectively, and \$0.9 million and \$1.5 million for the nine months ended September 30, 2018 and 2017, respectively, and are included in salaries and benefits expenses in the consolidated statements of income. The long-term portion of the benefit liability for the Amended and Restated SERP was \$5.8 million and \$8.7 million as of September 30, 2018 and December 31, 2017, respectively. The current portion of the benefit liability as of September 30, 2018 was \$3.8 million. There was no current portion of the benefit liability as of December 31, 2017. The current portion of the benefit liability is included in accrued salaries and benefits and the long-term portion is included in other long-term liabilities in the consolidated balance sheets.

Director's Fees Deferral Plan

On September 16, 2016, the Board adopted the Quorum Health Corporation Director's Fees Deferral Plan (the "Director's Plan"). Pursuant to the Director's Plan, members of the Board may elect to defer and accumulate fees, including retainer fees and fees for attendance at Board meetings and Board committees. A director may elect that all or any specified portion of the director's fees to be earned during a calendar year be credited to a director's cash account and/or a director's stock unit account maintained on the individual director's behalf in lieu of payment. Payment of amounts credited to a director's cash account and stock unit account will be made upon a payment commencement event, as defined in the Director's Plan, in accordance with the payment method elected by the individual director, either in lump sum or in a number of annual installments, not to exceed 15 installments. Eligibility to participate in the Director's Plan extends to directors of the Board not employed by the Company or any of its subsidiaries. Pursuant to the Director's Plan, the Company registered and made available for issuance under the Director's Plan a maximum of 150,000 shares of QHC common stock.

Defined Benefit Pension Plan

QHC provides benefits to employees at one of its hospitals through a defined benefit plan (the "Pension Plan"). The Pension Plan provides benefits to covered individuals satisfying certain age and service requirements. Employer contributions to the Pension Plan are in accordance with the minimum funding requirements of ERISA. Benefit costs related to the Pension Plan were \$0.1 million for both the three months ended September 30, 2018 and 2017, and \$0.2 million and \$0.3 million for the nine months ended

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

September 30, 2018 and 2017, respectively. The Company recognizes the unfunded liability of the Pension Plan in other long-term liabilities in its consolidated balance sheets. Unrecognized gains (losses) and prior service credits (costs) are recognized as other comprehensive income (loss). The accrued benefit liability for the Pension Plan was \$0.8 million at both September 30, 2018 and December 31, 2017.

NOTE 16 – RELATED PARTY TRANSACTIONS

CHS was a related party to QHC prior to the Spin-off. The agreements between QHC and CHS as of and subsequent to the Spin-off are described below.

Agreements with CHS Related to the Spin-off

In connection with the Spin-off and effective as of April 29, 2016, the Company entered into certain agreements with CHS that allocated between the Company and CHS the various assets, employees, liabilities and obligations (including investments, property, employee benefits and tax-related assets and liabilities) that were previously part of CHS. In addition, these agreements govern certain relationships between, and activities of, the Company and CHS for a definitive period of time after the Spin-off, as specified by each individual agreement.

The agreements were as follows:

Separation and Distribution Agreement. This agreement governed the principal actions of both the Company and CHS that needed to be taken in connection with the Spin-off. It also sets forth other agreements that govern certain aspects of the Company's relationship with CHS following the Spin-off.

- **Tax Matters Agreement.** This agreement governs respective rights, responsibilities and obligations of the Company and CHS after the Spin-off with respect to tax liabilities and benefits, tax attributes, tax contests and other tax sharing regarding U.S. federal, state and local income taxes, other tax matters and related tax returns.

Employee Matters Agreement. This agreement governs certain compensation and employee benefit obligations with respect to the current and former employees and non-employee directors of both the Company and CHS. It also allocated liabilities and responsibilities relating to employment matters, employee compensation and benefit plans and programs as of the Spin-off date.

In addition to the agreements referenced above, the Company entered into certain transition services agreements and other ancillary agreements with CHS defining agreed upon services to be provided by CHS to certain or all QHC hospitals, as determined by each agreement, commencing on the Spin-off date. The agreements generally have terms of five years.

A summary of the major provisions of the transition services agreements follows:

Shared Services Centers Transition Services Agreement. This agreement defines services to be provided by CHS related to billing and collections utilizing CHS shared services centers. Services include, but are not limited to, billing and receivables management, statement processing, denials management, cash posting, patient customer service, and credit balance and other account research. In addition, it provides for patient pre-arrival services, including pre-registration, insurance verification, scheduling and charge estimates. Fees are based on a percentage of

cash collections each month.

Computer and Data Processing Transition Services Agreement. This agreement defines services to be provided by CHS for information technology infrastructure, support and maintenance. Services include, but are not limited to, operational support for various applications, oversight, maintenance and information technology support services, such as helpdesk, product support, network monitoring, data center operations, service ticket management and vendor relations. Fees are based on both a fixed charge for labor costs, as well as direct charges for all third-party vendor contracts entered into by CHS on QHC's behalf.

Receivables Collection Agreement ("PASI"). This agreement defines services to be provided by CHS' wholly-owned subsidiary, PASI, which currently serves as a third-party collection agency to QHC related to accounts receivable collections of both active and bad debt accounts of QHC hospitals, including both receivables that existed as of the Spin-off date and those that have occurred since the Spin-off date. Services include, but are not limited to, self-pay collections, insurance follow-up, collection letters and calls, payment arrangements, payment posting, dispute resolution and credit balance research. Fees are based on the type of service and are calculated based on a percentage of recoveries. Effective October 1, 2018, by mutual agreement of both companies, each of the parties' obligations under this transition services

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

agreement to the other were terminated. The Company replaced the services provided by CHS with external service providers and internal resources.

Billing and Collection Agreement (“PPSI”). This agreement defines services to be provided by CHS related to collections of accounts receivable generated by the Company’s affiliated outpatient healthcare facilities. Services include, but are not limited to, self-pay collections, insurance follow-up, collection letters and calls, payment arrangements, payment posting, dispute resolution and credit balance research. Fees are based on the type of service and are calculated based on a percentage of recoveries. Effective October 1, 2018, by mutual agreement of both companies, each of the parties’ obligations under this transition services agreement to the other were terminated. The Company replaced the services provided by CHS with external service providers and internal resources.

Employee Service Center Agreement. This agreement defines services to be provided by CHS related to payroll processing and human resources information systems support. Fees are based on a fixed charge per employee headcount per month.

Eligibility Screening Services Agreement. This agreement defines services to be provided by CHS for financial and program criteria screening related to Medicaid or other program eligibility for pure self-pay patients. Fees are based on a fixed charge for each hospital receiving services. Effective June 24, 2018, per mutual agreement of both companies, the employees responsible for screening patients for program eligibility were transferred to QHC, which terminated the obligations of both parties under this transition services agreement.

The total expenses recorded by the Company under the transition services agreements with CHS were \$14.1 million and \$15.5 million for the three months ended September 30, 2018 and 2017, respectively, and \$43.3 million and \$47.7 million for the nine months ended September 30, 2018 and 2017, respectively. The Company is disputing in arbitration, among other issues and actions, certain charges and lack of performance of various obligations under the transition services agreements with CHS.

See Note 17 — Commitments and Contingencies for additional information on the arbitration.

NOTE 17 - COMMITMENTS AND CONTINGENCIES

Legal Matters

The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental proceedings, including the matters described herein, will have a material adverse effect on the operating results, financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in these matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s consolidated results of operations or cash flows for any particular reporting period.

In connection with the Spin-off, CHS agreed to indemnify QHC for certain liabilities relating to outcomes or events occurring prior to the closing of the Spin-off, including (i) certain claims and proceedings known to be outstanding on or prior to the closing date of the Spin-off and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to the Company’s healthcare facilities prior to the closing date of the Spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by CHS, including professional and general liability and workers’ compensation

liability. In this regard, CHS will continue to be responsible for certain Health Management Associates, Inc. legal matters covered by its contingent value rights agreement that relate to the portion of CHS' business now held by QHC. Notwithstanding the foregoing, CHS is not indemnifying QHC in respect of any claims or proceedings arising out of, or related to, the business operations of QHR at any time or QHC's compliance with the Corporate Integrity Agreement ("CIA") with the United States Department of Health and Human Services Office of the Inspector General ("OIG"). Subsequent to the Spin-off, the OIG entered into an "Assumption of CIA Liability Letter" with the Company reiterating the applicability of the CIA to certain of the Company's hospitals, although the OIG declined to enter into a separate agreement with the Company.

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated amount of loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the amount of possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the amount of possible loss or range of loss. However, the Company is

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

unable to estimate an amount of possible loss or range of loss in some instances based on the significant uncertainties involved in, or the preliminary nature of, certain legal, regulatory and governmental matters.

Commercial Litigation and Other Lawsuits

• **Arbitration with Community Health Systems, Inc.** On August 4, 2017, the Company received a demand for arbitration from CHS seeking payment of certain amounts the Company has withheld pursuant to the Shared Services Centers Transition Services Agreement (the “SSC TSA”) and the Computer and Data Processing Transition Services Agreement (the “IT TSA”). The Company contends that the amounts are not payable to CHS and were not properly billed by CHS under the agreements. The matter is pending before the American Arbitration Association. CHS seeks payment of approximately \$12.1 million relating to these two transition services agreements. The Company is vigorously contesting the charges as not payable to CHS under the transition services agreements and has made counterclaims that include, among other things, termination of the SSC TSA, a ruling that the IT TSA is terminable at the Company’s option (as described below), and substantial damages the Company believes it has suffered as a result of the transition services agreements and other actions taken by CHS in connection with the Spin-off. Additionally, on March 19, 2018, the Company received notice from CHS that CHS was seeking to terminate, effective September 30, 2018, the SSC TSA and the IT TSA and to impose a September 30, 2018 deadline for completion of the transition services under the SSC TSA and IT TSA, as a result of alleged breaches by the Company of the agreements. The notice from CHS also provided an indication of CHS’s preference to terminate the Receivables Collection Agreement, the Eligibility Screening Services Agreement, and the Billing and Collection Agreement. The Company amended its counterclaims to include allegations that CHS’s attempt to terminate the SSC TSA and IT TSA and to impose a September 30, 2018 deadline for completing the transition of services under those contracts violated the terms of the contracts and was invalid and without effect. The validity and effectiveness of CHS’s attempt to terminate the SSC TSA and IT TSA and to impose a September 30, 2018 deadline was litigated during the course of arbitration proceedings held in late June 2018. After hearing testimony regarding the termination issues, the arbitration panel ruled that each of the SSC TSA and IT TSA will continue in effect according to their original terms through 2021, subject to any agreement by the parties to terminate the SSC TSA and the IT TSA at an earlier time. The panel ordered that, after the date of the ruling, the Company would prospectively pay the amounts invoiced under the TSAs as billed, but deferred ruling on the parties’ economic claims related to the TSAs. The arbitration reconvened October 1, 2018 with QHC presenting the Company’s counter-claims and defenses that certain amounts were not payable to CHS. The arbitration concluded October 9, 2018 and a decision is expected in mid-January 2019. The Company is unable to predict the outcome of this matter; however, it is reasonably possible that the Company may incur a loss in connection with this matter. Under some circumstances, losses incurred in connection with adverse outcomes in this matter could be material.

• **Zwick Partners LP and Aparna Rao, Individually and On Behalf of All Others Similarly Situated v. Quorum Health Corporation, Community Health Systems, Inc., Wayne T. Smith, W. Larry Cash, Thomas D. Miller and Michael J. Culotta.** On September 9, 2016, a shareholder filed a purported class action in the United States District Court for the Middle District of Tennessee against the Company and certain of its officers. The Amended Complaint, filed on September 13, 2017, purports to be brought on behalf of a class consisting of all persons (other than defendants) who purchased or otherwise acquired securities of the Company between May 2, 2016 and August 10, 2016 and alleges that the Company and certain of its officers violated federal securities laws, including Sections 10(b) and/or 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10b-5 promulgated thereunder, by making alleged false and/or misleading statements and failing to disclose certain information regarding aspects of the

Company's business, operations and compliance policies. On April 17, 2017, Plaintiff filed a Second Amended Complaint adding additional defendants, CHS, Wayne T. Smith and W. Larry Cash. On June 23, 2017, the Company filed a motion to dismiss, which Plaintiff opposed on August 22, 2017. On April 19, 2018, the Court denied the Company's motion to dismiss, and the Company filed its answer to the Second Amended Complaint on May 18, 2018. On July 13, 2018, Plaintiff filed its motion for class certification, which Defendants opposed on August 31, 2018. The motion for class certification is currently pending. On September 14, 2018, Plaintiff filed a Third Amended Complaint adding additional alleged misstatements. On October 12, 2018, Defendants moved to dismiss the new allegations, which motion is currently pending. The case is in discovery, and the Company is vigorously defending itself in this matter. The Company is unable to predict the outcome of this matter. However, it is reasonably possible that the Company may incur a loss in connection with this matter. The Company is unable to reasonably estimate the amount or range of such reasonably possible loss because discovery has only recently started and the case remains in its early stages. Under some circumstances, losses incurred in connection with adverse outcomes in this matter could be material.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

¶ United Tort Claimants v. Quorum Health Resources, LLC (U.S. Bankruptcy Court for the District of New Mexico); Douthitt - Dugger, et al. v. Quorum Health Resources, LLC (Bernalillo County, New Mexico District Court). Plaintiffs sued QHR and Gerald Champion Regional Medical Center in New Mexico state court and bankruptcy court arising from surgical procedures alleged to have been experimental and performed by an unqualified doctor. The parties have now agreed to a global settlement of the United Tort Claimants (“UTC”) claims for a confidential amount to be fully funded by Lexington Insurance Company (“Lexington”). The specific language of releases and related settlement documents is being negotiated and will be subject to bankruptcy court approval.

¶ Lexington Insurance Company v. Quorum Health Resources, LLC, et al. (Williamson County, Tennessee Chancery Court) Lexington has sued QHR in Williamson County, Tennessee seeking a judicial declaration that the UTC’s claims and the cost of defending QHR are not covered by Lexington. Lexington has now agreed not to seek reimbursement from QHR (1) for any part of the settlement with UTC (as described above); or (2) for the cost of defending QHR in the UTC litigation in New Mexico. The carrier has also agreed not to seek appellate review of prior court rulings in QHR’s favor on coverage issues. While QHR believes these agreements have been adequately confirmed with Lexington, further proceedings will be necessary in the Tennessee trial court to establish these agreements in a court order. QHR has asserted bad faith claims against Lexington and excess carrier Ironshore in the Tennessee state court action, which are expected to be set for trial in 2019. The Company has concluded that there is a remote likelihood of a material loss in these matters, and as a result, does not believe that either the UTC litigation in New Mexico nor the insurance coverage litigation in Tennessee state court will have a material adverse effect on the operating results, financial position or liquidity of the Company.

¶ R2 Investments, LDC v. Quorum Health Corporation, Community Health Systems, Inc., Wayne T. Smith, W. Larry Cash, Thomas D. Miller, Michael J. Culotta, John A. Clerico, James S. Ely, III, John A. Fry, William Norris Jennings, Julia B. North, H. Mitchell Watson, Jr. and H. James Williams. On October 25, 2017, a shareholder filed an action in the Circuit Court of Williamson County, Tennessee against the Company and certain of its officers and directors and CHS and certain of its officers and directors. The complaint alleges that the defendants violated the Tennessee Securities Act and common law by, among other things, making alleged false and/or misleading statements and failing to disclose certain information regarding aspects of the Company’s business, operations and financial condition. Plaintiff is seeking rescissionary, compensatory and punitive damages. The Company filed a motion to dismiss the action on January 16, 2018, which Plaintiff opposed on March 5, 2018. On May 11, 2018, the Court denied the Company’s motion to dismiss. The Company subsequently filed an answer to the complaint, and the case is now in discovery. The Company is vigorously defending itself in this matter. The Company is unable to predict the outcome of this matter. However, it is reasonably possible that the Company may incur a loss in connection with this matter. The Company is unable to reasonably estimate the amount or range of such reasonably possible loss because discovery has only recently started and the case remains in its early stages. Under some circumstances, losses incurred in connection with adverse outcomes in this matter could be material.

¶ Harvey Horwitz, Derivatively on Behalf of Quorum Health Corporation v. Thomas D. Miller, Michael J. Culotta, Barbara R. Paul, R. Lawrence Van Horn, William S. Hussey, James T. Breedlove, William M. Gracey, Joseph A. Hastings, and Adam Feinstein, and Quorum Health Corporation, as Nominal Defendant. On September 17, 2018, a purported shareholder filed a derivative action on behalf of the Company in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violation of Section 29(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and indemnification and contribution. Plaintiff seeks damages allegedly sustained by the Company, rescission of the Separation Agreement with CHS, corporate governance reforms, equitable and/or injunctive relief, restitution, and attorneys’ fees and costs. On October 26, 2018, the Court entered an order granting a stay of the case pending entry of an order on any motions for summary

judgment in the Rao v. Quorum Health Corporation case described above. Once the stay is lifted, the Company intends to move to transfer the action to Delaware consistent with the Company's by-laws. The Company is vigorously defending itself in this matter. The Company is unable to predict the outcome of this matter. However, it is reasonably possible that the Company may incur a loss in connection with this matter. The Company is unable to reasonably estimate the amount or range of such reasonably possible loss because the case remains in its early stages. Under some circumstances, losses incurred in connection with adverse outcomes in this matter could be material.

37

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Insurance Reserves

As part of the business of owning and operating hospitals, the Company is subject to potential professional and general liability and workers' compensation liability claims or other legal actions alleging liability on its part. The Company is also subject to similar liabilities related to its QHR business.

Prior to the Spin-off, CHS provided professional and general liability insurance and workers' compensation liability insurance to QHC and indemnified QHC from losses under these insurance arrangements related to the hospital operations business assumed by QHC in the Spin-off. The liabilities for claims prior to the Spin-off and related to QHC's hospital operations business were determined based on an actuarial study of QHC's operations and historical claims experience at its hospitals, including during the period of ownership by CHS. Corresponding receivables from CHS are established to reflect the indemnification by CHS for each of these liabilities for claims that related to events and circumstances that occurred prior to the Spin-off.

After the Spin-off, QHC entered into its own professional and general liability insurance and workers' compensation liability insurance arrangements to mitigate the risk for claims related to events occurring after the Spin-off date that exceed its self-insured retention levels. The Company maintains a self-insured retention level for professional and general liability claims of \$5 million per claim and maintains a \$0.5 million per claim, high deductible program for workers' compensation. Due to the differing nature of its business operations, the Company maintains separate insurance arrangements related to its subsidiary, QHR. The self-insured retention level for QHR is \$6 million for professional and general liability insurance.

The following table provides a summary of the Company's insurance reserves related to professional and general liability and workers' compensation liability, distinguished between those indemnified by CHS and those related to the Company's own risks (in thousands):

	September 30, 2018			
	Current Receivable	Long-Term Receivable	Current Liability	Long-Term Liability
Professional and general liability:				
Insurance reserves indemnified by CHS, Inc.	\$25,342	\$ 31,903	\$25,342	\$ 31,903
All other self-insurance reserves	—	—	4,189	46,709
Total insurance reserves for professional and general liability	25,342	31,903	29,531	78,612
Workers' compensation liability:				
Insurance reserves indemnified by CHS, Inc.	2,368	11,734	2,368	11,734
All other self-insurance reserves	—	—	2,093	6,145
Total insurance reserves for workers' compensation liability	2,368	11,734	4,461	17,879
Total self-insurance reserves	\$27,710	\$ 43,637	\$33,992	\$ 96,491
	December 31, 2017			
	Current Receivable	Long-Term Receivable	Current Liability	Long-Term Liability

Professional and general liability:				
Insurance reserves indemnified by CHS, Inc.	\$21,465	\$ 44,377	\$21,465	\$ 44,377
All other self-insurance reserves	—	—	2,883	32,616
Total insurance reserves for professional and general liability	21,465	44,377	24,348	76,993
Workers' compensation liability:				
Insurance reserves indemnified by CHS, Inc.	3,032	14,545	3,032	14,545
All other self-insurance reserves	—	—	3,120	4,013
Total insurance reserves for workers' compensation liability	3,032	14,545	6,152	18,558
Total self-insurance reserves	\$24,497	\$ 58,922	\$30,500	\$ 95,551

The receivables from CHS are included in other current assets and other long-term assets in the consolidated balance sheets. The liability for the current portion of professional and general liability claims is included in other current liabilities, while the current portion of the liability for workers' compensation claims is included in accrued salaries and benefits. The long-term portions of both claims liabilities are included in other long-term liabilities.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Construction and Capital Commitments

The Company is in the process of completing construction of a new patient tower and expanding surgical capacity at McKenzie – Willamette Medical Center, its hospital in Springfield, Oregon. During the three months ended September 30, 2018 and September 30, 2017, the Company incurred costs of \$3.6 million and \$6.5 million, respectively, and incurred costs of \$14.3 million and \$31.1 million during the nine months ended September 30, 2018 and 2017, respectively, related to this project. As of September 30, 2018, the Company has incurred a total of \$97.3 million of costs for this project, of which \$90.5 million has been placed into service as of September 30, 2018. The total estimated cost of this project, including equipment costs, is estimated to be approximately \$105.0 million. The project is expected to be substantially complete by the end of 2018.

NOTE 18 - SUBSEQUENT EVENTS

In October 2018, the Company utilized proceeds, including the receipt of \$8.0 million of restricted cash held in escrow, from divestitures to pay down \$9.9 million of principal on the Company's Term Loan Facility.

NOTE 19 - GUARANTOR AND NON-GUARANTOR SUPPLEMENTAL INFORMATION

The Senior Notes are senior unsecured obligations of the Company guaranteed on a senior basis by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries (the "Guarantors"). The Senior Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor's capital stock is sold, or when a sale of all of the subsidiary guarantor's assets used in operations occurs.

The condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 "Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered."

The accounting policies used in the preparation of this financial information are consistent with the accompanying condensed consolidated financial statements of the Company, except as follows:

• Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets.

• Investments in consolidated subsidiaries, as well as guarantor subsidiaries' investments in non-guarantor subsidiaries, are presented under the equity method of accounting with the related investments presented within the line items net investment in subsidiaries and other long-term liabilities in the supplemental condensed consolidating balance sheets.

• Income tax expense is allocated from the parent issuer to the income producing operations (other guarantors and non-guarantors) through stockholders' equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes.

The Company's intercompany activity consists primarily of daily cash transfers, the allocation of certain expenses and expenditures paid by the parent issuer on behalf of its subsidiaries, and the push down of investment in its subsidiaries. The parent issuer's investment in its subsidiaries reflects the activity since the Spin-off. Likewise, the parent issuer's equity in earnings of unconsolidated affiliates represents the Company's earnings since the Spin-off.

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Condensed Consolidating Statement of Income (Loss)

Three Months Ended September 30, 2018

(In Thousands)

	Parent	Other	Non-		
	Issuer	Guarantors	Guarantors	Eliminations	Consolidated
Net operating revenues	\$—	\$ 356,986	\$ 103,521	\$ —	\$ 460,507
Operating costs and expenses:					
Salaries and benefits	—	154,547	71,690	—	226,237
Supplies	—	35,237	13,712	—	48,949
Other operating expenses	—	115,994	27,722	—	143,716
Depreciation and amortization	—	12,431	4,181	—	16,612
Rent	—	6,580	5,081	—	11,661
Electronic health records incentives earned	—	14	(45)	—	(31)
Legal, professional and settlement costs	—	1,399	120	—	1,519
Impairment of long-lived assets and goodwill	—	32,438	—	—	32,438
Loss (gain) on sale of hospitals, net	—	805	—	—	805
Loss on closure of hospitals, net	—	1,111	—	—	1,111
Total operating costs and expenses	—	360,556	122,461	—	483,017
Income (loss) from operations	—	(3,570)	(18,940)	—	(22,510)
Interest expense (income), net	32,204	245	1	—	32,450
Equity in earnings of affiliates	22,932	(2,483)	—	(20,449)	—
Income (loss) before income taxes	(55,136)	(1,332)	(18,941)	20,449	(54,960)
Provision for (benefit from) income taxes	(1,196)	8	114	—	(1,074)
Net income (loss)	(53,940)	(1,340)	(19,055)	20,449	(53,886)
Less: Net income (loss) attributable to noncontrolling interests	—	—	54	—	54
Net income (loss) attributable to Quorum Health Corporation	\$(53,940)	\$(1,340)	\$(19,109)	\$ 20,449	\$(53,940)

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Condensed Consolidating Statement of Income (Loss)

Three Months Ended September 30, 2017

(In Thousands)

	Parent	Other	Non-		
	Issuer	Guarantors	Guarantors	Eliminations	Consolidated
Operating revenues	\$—	\$ 439,813	\$ 118,034	\$ —	\$ 557,847
Provision for bad debts	—	48,652	9,893	—	58,545
Net operating revenues	—	391,161	108,141	—	499,302
Operating costs and expenses:					
Salaries and benefits	—	176,085	75,695	—	251,780
Supplies	—	43,590	15,067	—	58,657
Other operating expenses	100	120,035	25,222	—	145,357
Depreciation and amortization	—	17,289	3,446	—	20,735
Rent	—	7,332	5,045	—	12,377
Electronic health records incentives earned	—	(377)	90	—	(287)
Legal, professional and settlement costs	—	2,050	—	—	2,050
Impairment of long-lived assets and goodwill	—	5,261	—	—	5,261
Loss (gain) on sale of hospitals, net	—	100	(21)	—	79
Transaction costs related to the Spin-off	—	134	39	—	173
Total operating costs and expenses	100	371,499	124,583	—	496,182
Income (loss) from operations	(100)	19,662	(16,442)	—	3,120
Interest expense (income), net	32,001	206	9	—	32,216
Equity in earnings of affiliates	(2,366)	3,184	—	(818)	—
Income (loss) before income taxes	(29,735)	16,272	(16,451)	818	(29,096)
Provision for (benefit from) income taxes	(544)	(266)	268	—	(542)
Net income (loss)	(29,191)	16,538	(16,719)	818	(28,554)
Less: Net income (loss) attributable to noncontrolling interests	—	—	637	—	637
Net income (loss) attributable to Quorum Health Corporation	\$(29,191)	\$ 16,538	\$(17,356)	\$ 818	\$(29,191)

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Condensed Consolidating Statement of Income (Loss)

Nine Months Ended September 30, 2018

(In Thousands)

	Parent	Other	Non-		
	Issuer	Guarantors	Guarantors	Eliminations	Consolidated
Net operating revenues	\$—	\$1,091,781	\$328,178	\$—	\$1,419,959
Operating costs and expenses:					
Salaries and benefits	—	484,728	221,140	—	705,868
Supplies	—	114,678	46,054	—	160,732
Other operating expenses	1,897	355,090	83,923	—	440,910
Depreciation and amortization	—	40,956	11,059	—	52,015
Rent	—	20,464	15,087	—	35,551
Electronic health records incentives earned	—	(416)	(201)	—	(617)
Legal, professional and settlement costs	—	10,229	120	—	10,349
Impairment of long-lived assets and goodwill	—	70,398	1,800	—	72,198
Loss (gain) on sale of hospitals, net	—	8,933	(6)	—	8,927
Loss on closure of hospitals, net	—	18,195	—	—	18,195
Total operating costs and expenses	1,897	1,123,255	378,976	—	1,504,128
Income (loss) from operations	(1,897)	(31,474)	(50,798)	—	(84,169)
Interest expense (income), net	96,612	(1,303)	(2)	—	95,307
Equity in earnings of affiliates	81,849	38,348	—	(120,197)	—
Income (loss) before income taxes	(180,358)	(68,519)	(50,796)	120,197	(179,476)
Provision for (benefit from) income taxes	(844)	(412)	94	—	(1,162)
Net income (loss)	(179,514)	(68,107)	(50,890)	120,197	(178,314)
Less: Net income (loss) attributable to noncontrolling interests	—	—	1,200	—	1,200
Net income (loss) attributable to Quorum Health Corporation	\$(179,514)	\$(68,107)	\$(52,090)	\$120,197	\$(179,514)

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Condensed Consolidating Statement of Income (Loss)

Nine Months Ended September 30, 2017

(In Thousands)

	Parent	Other	Non-		
	Issuer	Guarantors	Guarantors	Eliminations	Consolidated
Operating revenues	—	1,344,687	386,320	—	\$ 1,731,007
Provision for bad debts	—	146,261	27,658	—	173,919
Net operating revenues	—	1,198,426	358,662	—	1,557,088
Operating costs and expenses:					
Salaries and benefits	—	539,544	242,147	—	781,691
Supplies	—	134,866	51,725	—	186,591
Other operating expenses	2,992	373,979	89,423	—	466,394
Depreciation and amortization	—	53,408	10,033	—	63,441
Rent	—	21,494	15,137	—	36,631
Electronic health records incentives earned	—	(3,815)	(701)	—	(4,516)
Legal, professional and settlement costs	—	6,519	—	—	6,519
Impairment of long-lived assets and goodwill	—	21,461	—	—	21,461
Loss (gain) on sale of hospitals, net	—	100	(5,212)	—	(5,112)
Transaction costs related to the Spin-off	—	157	47	—	204
Total operating costs and expenses	2,992	1,147,713	402,599	—	1,553,304
Income (loss) from operations	(2,992)	50,713	(43,937)	—	3,784
Interest expense (income), net	91,934	(1,820)	90	—	90,204
Equity in earnings of affiliates	(7,457)	8,316	—	(859)	—
Income (loss) before income taxes	(87,469)	44,217	(44,027)	859	(86,420)
Provision for (benefit from) income taxes	(87)	(44)	45	—	(86)
Net income (loss)	(87,382)	44,261	(44,072)	859	(86,334)
Less: Net income (loss) attributable to noncontrolling interests	—	—	1,048	—	1,048
Net income (loss) attributable to Quorum Health Corporation	\$(87,382)	\$44,261	\$(45,120)	\$ 859	\$(87,382)

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended September 30, 2018

(In Thousands)

	Parent	Other	Non-		
	Issuer	Guarantors	Guarantors	Eliminations	Consolidated
Net income (loss)	\$ (53,940)	\$ (1,340)	\$ (19,055)	\$ 20,449	\$ (53,886)
Amortization and recognition of unrecognized pension cost components, net of income taxes	114	114	—	(114)	114
Comprehensive income (loss)	(53,826)	(1,226)	(19,055)	20,335	(53,772)
Less: Comprehensive income (loss) attributable to noncontrolling interests	—	—	54	—	54
Comprehensive income (loss) attributable to Quorum Health Corporation	\$ (53,826)	\$ (1,226)	\$ (19,109)	\$ 20,335	\$ (53,826)

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended September 30, 2017

(In Thousands)

	Parent	Other	Non-		
	Issuer	Guarantors	Guarantors	Eliminations	Consolidated
Net income (loss)	\$ (29,191)	\$ 16,538	\$ (16,719)	\$ 818	\$ (28,554)
Amortization and recognition of unrecognized pension cost components, net of income taxes	123	123	—	(123)	123
Comprehensive income (loss)	(29,068)	16,661	(16,719)	695	(28,431)
	—	—	637	—	637

Edgar Filing: Quorum Health Corp - Form 10-Q

Less: Comprehensive income (loss) attributable to
noncontrolling interests

Comprehensive income (loss) attributable to Quorum Health Corporation	\$(29,068)	\$ 16,661	\$(17,356)	\$ 695	\$ (29,068)
--	------------	-----------	-------------	--------	--------------

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Condensed Consolidating Statement of Comprehensive Income (Loss)

Nine Months Ended September 30, 2018

(In Thousands)

	Parent	Other	Non-		
	Issuer	Guarantors	Guarantors	Eliminations	Consolidated
Net income (loss)	\$(179,514)	\$(68,107)	\$(50,890)	\$ 120,197	\$(178,314)
Amortization and recognition of unrecognized pension cost components, net of income taxes	39	39	—	(39)	39
Comprehensive income (loss)	(179,475)	(68,068)	(50,890)	120,158	(178,275)
Less: Comprehensive income (loss) attributable to noncontrolling interests	—	—	1,200	—	1,200
Comprehensive income (loss) attributable to Quorum Health Corporation	\$(179,475)	\$(68,068)	\$(52,090)	\$ 120,158	\$(179,475)

Condensed Consolidating Statement of Comprehensive Income (Loss)

Nine Months Ended September 30, 2017

(In Thousands)

	Parent	Other	Non-		
	Issuer	Guarantors	Guarantors	Eliminations	Consolidated
Net income (loss)	\$(87,382)	\$ 44,261	\$(44,072)	\$ 859	\$(86,334)
Amortization and recognition of unrecognized pension cost components, net of income taxes	365	365	—	(365)	365
Comprehensive income (loss)	(87,017)	44,626	(44,072)	494	(85,969)
Less: Comprehensive income (loss) attributable to noncontrolling interests	—	—	1,048	—	1,048
	\$(87,017)	\$ 44,626	\$(45,120)	\$ 494	\$(87,017)

Comprehensive income (loss) attributable to Quorum
Health Corporation

45

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Condensed Consolidating Balance Sheet

September 30, 2018

(In Thousands)

	Parent Issuer	Other Guarantors	Non- Guarantors	Eliminations	Consolidated
ASSETS					
Current assets:					
Cash and cash equivalents	\$221	\$5,276	\$569	\$—	\$6,066
Patient accounts receivable, net of allowance for doubtful accounts	—	250,315	67,969	—	318,284
Inventories	—	36,967	9,997	—	46,964
Prepaid expenses	59	16,020	5,146	—	21,225
Due from third-party payors	—	56,581	7,528	—	64,109
Other current assets	248	41,587	16,327	—	58,162
Total current assets	528	406,746	107,536	—	514,810
Intercompany receivable	3	597,765	271,159	(868,927)	—
Property and equipment, net	—	428,481	137,905	—	566,386
Goodwill	—	235,418	165,655	—	401,073
Intangible assets, net	—	44,782	5,084	—	49,866
Other long-term assets	—	56,043	24,951	—	80,994
Net investment in subsidiaries	1,411,102	—	—	(1,411,102)	—
Total assets	\$1,411,633	\$1,769,235	\$712,290	\$(2,280,029)	\$1,613,129
LIABILITIES AND EQUITY					
Current liabilities:					
Current maturities of long-term debt	\$—	\$1,427	\$117	\$—	\$1,544
Accounts payable	80	126,489	19,834	—	146,403
Accrued liabilities:					
Accrued salaries and benefits	—	62,524	24,763	—	87,287
Accrued interest	22,046	—	—	—	22,046
Due to third-party payors	—	37,731	6,203	—	43,934
Other current liabilities	—	32,547	15,203	—	47,750
Total current liabilities	22,126	260,718	66,120	—	348,964
Long-term debt	1,162,743	22,736	205	—	1,185,684
Intercompany payable	294,891	271,163	302,874	(868,928)	—

Edgar Filing: Quorum Health Corp - Form 10-Q

Deferred income tax liabilities, net	6,670	—	—	—	6,670
Other long-term liabilities	—	224,768	31,683	(126,626)	129,825
Total liabilities	1,486,430	779,385	400,882	(995,554)	1,671,143
Redeemable noncontrolling interests	—	—	2,279	—	2,279
Equity:					
Quorum Health Corporation stockholders' equity (deficit):					
Preferred stock	—	—	—	—	—
Common stock	3	—	—	—	3
Additional paid-in capital	554,847	1,177,836	584,102	(1,761,938)	554,847
Accumulated other comprehensive income (loss)	(1,917)	(1,917)	—	1,917	(1,917)
Accumulated deficit	(627,730)	(186,069)	(289,477)	475,546	(627,730)
Total Quorum Health Corporation stockholders' equity (deficit)	(74,797)	989,850	294,625	(1,284,475)	(74,797)
Nonredeemable noncontrolling interests	—	—	14,504	—	14,504
Total equity	(74,797)	989,850	309,129	(1,284,475)	(60,293)
Total liabilities and equity	\$ 1,411,633	\$ 1,769,235	\$ 712,290	\$ (2,280,029)	\$ 1,613,129

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Condensed Consolidating Balance Sheet

December 31, 2017

(In Thousands)

	Parent	Other	Non-		
	Issuer	Guarantors	Guarantors	Eliminations	Consolidated
ASSETS					
Current assets:					
Cash and cash equivalents	\$ 1,051	\$ 4,222	\$ 344	\$ —	\$ 5,617
Patient accounts receivable, net of allowance for doubtful accounts	—	262,690	80,455	—	343,145
Inventories	—	43,276	10,183	—	53,459
Prepaid expenses	33	16,980	4,154	—	21,167
Due from third-party payors	—	93,323	3,879	—	97,202
Current assets of hospitals held for sale	—	8,112	—	—	8,112
Other current assets	—	32,867	14,573	—	47,440
Total current assets	1,084	461,470	113,588	—	576,142
Intercompany receivable	3	402,817	172,098	(574,918)	—
Property and equipment, net	—	543,073	132,206	—	675,279
Goodwill	—	243,618	165,611	—	409,229
Intangible assets, net	—	58,240	6,610	—	64,850
Long-term assets of hospitals held for sale	—	7,730	4	—	7,734
Other long-term assets	—	74,918	20,689	—	95,607
Net investment in subsidiaries	1,488,021	—	—	(1,488,021)	—
Total assets	\$ 1,489,108	\$ 1,791,866	\$ 610,806	\$ (2,062,939)	\$ 1,828,841
LIABILITIES AND EQUITY					
Current liabilities:					
Current maturities of long-term debt	\$ —	\$ 1,434	\$ 421	\$ —	\$ 1,855
Accounts payable	132	146,193	24,925	—	171,250
Accrued liabilities:					
Accrued salaries and benefits	—	56,522	21,281	—	77,803
Accrued interest	10,466	—	—	—	10,466
Due to third-party payors	—	46,381	1,324	—	47,705
Current liabilities of hospitals held for sale	—	2,577	—	—	2,577
Other current liabilities	516	30,664	12,507	—	43,687

Edgar Filing: Quorum Health Corp - Form 10-Q

Total current liabilities	11,114	283,771	60,458	—	355,343
Long-term debt	1,188,224	23,809	2	—	1,212,035
Intercompany payable	182,555	173,341	219,022	(574,918)	—
Deferred income tax liabilities, net	7,774	—	—	—	7,774
Other long-term liabilities	—	195,132	31,100	(88,278)	137,954
Total liabilities	1,389,667	676,053	310,582	(663,196)	1,713,106
Redeemable noncontrolling interests	—	—	2,325	—	2,325
Equity:					
Quorum Health Corporation stockholders' equity:					
Preferred stock	—	—	—	—	—
Common stock	3	—	—	—	3
Additional paid-in capital	549,610	1,291,581	471,767	(1,763,348)	549,610
Accumulated other comprehensive income (loss)	(1,956)	(1,956)	—	1,956	(1,956)
Accumulated deficit	(448,216)	(173,812)	(187,837)	361,649	(448,216)
Total Quorum Health Corporation stockholders' equity	99,441	1,115,813	283,930	(1,399,743)	99,441
Nonredeemable noncontrolling interests	—	—	13,969	—	13,969
Total equity	99,441	1,115,813	297,899	(1,399,743)	113,410
Total liabilities and equity	\$1,489,108	\$1,791,866	\$610,806	\$(2,062,939)	\$1,828,841

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Condensed Consolidating Statement of Cash Flows

Nine Months Ended September 30, 2018

(In Thousands)

	Parent Issuer	Other Guarantors	Non- Guarantors	Eliminations	Consolidated
Net cash provided by (used in) operating activities	\$(80,781)	\$ 124,538	\$ (822)	\$ —	\$ 42,935
Cash flows from investing activities:					
Capital expenditures for property and equipment	—	(21,193)	(13,702)	—	(34,895)
Capital expenditures for software	—	(1,400)	(127)	—	(1,527)
Acquisitions, net of cash acquired	—	(42)	(79)	—	(121)
Proceeds from the sale of hospitals	—	39,384	(214)	—	39,170
Other investing activities	—	190	69	—	259
Changes in intercompany balances with affiliates, net	—	(137,364)	—	137,364	—
Net cash provided by (used in) investing activities	—	(120,425)	(14,053)	137,364	2,886
Cash flows from financing activities:					
Borrowings under of revolving credit facilities	368,000	—	—	—	368,000
Repayments under revolving credit facilities	(368,000)	—	—	—	(368,000)
Borrowings of long-term debt	—	102	55	—	157
Repayments of long-term debt	(30,463)	(1,182)	(156)	—	(31,801)
Payments of debt issuance costs	(2,268)	—	—	—	(2,268)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	—	(1,979)	—	—	(1,979)
Cash distributions to noncontrolling investors	—	—	(1,481)	—	(1,481)
Changes in intercompany balances with affiliates, net	112,682	—	24,682	(137,364)	—
Net cash provided by (used in) financing activities	79,951	(3,059)	23,100	(137,364)	(37,372)
Net change in cash, cash equivalents and restricted cash	(830)	1,054	8,225	—	8,449
Cash, cash equivalents and restricted cash at beginning of period	1,051	4,222	344	—	5,617

Cash, cash equivalents and restricted cash at end of period	\$221	\$5,276	\$ 8,569	\$ —	\$ 14,066
---	-------	---------	----------	------	-----------

QUORUM HEALTH CORPORATION

UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

Condensed Consolidating Statement of Cash Flows

Nine Months Ended September 30, 2017

(In Thousands)

	Parent	Other	Non-		
	Issuer	Guarantors	Guarantors	Eliminations	Consolidated
Net cash provided by (used in) operating activities	\$(81,234)	\$ 88,802	\$ (6,779)	\$ —	\$ 789
Cash flows from investing activities:					
Capital expenditures for property and equipment	—	(18,057)	(32,610)	—	(50,667)
Capital expenditures for software	—	(5,412)	(762)	—	(6,174)
Acquisitions, net of cash acquired	—	(53)	(1,867)	—	(1,920)
Proceeds from sale of hospitals	—	9,348	19,892	—	29,240
Changes in intercompany balances with affiliates, net	—	(72,795)	—	72,795	—
Net cash provided by (used in) investing activities	—	(86,969)	(15,347)	72,795	(29,521)
Cash flows from financing activities:					
Borrowings under revolving credit facilities	433,000	—	—	—	433,000
Repayments under revolving credit facilities	(388,000)	—	—	—	(388,000)
Borrowings of long-term debt	—	247	—	—	247
Repayments of long-term debt	(15,032)	(1,219)	(266)	—	(16,517)
Payments of debt issuance costs	(3,119)	—	—	—	(3,119)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	—	(1,503)	—	—	(1,503)
Cash distributions to noncontrolling investors	—	—	(3,851)	—	(3,851)
Purchases of shares from noncontrolling investors	—	—	(1,244)	—	(1,244)
Changes in intercompany balances with affiliates, net	45,289	—	27,506	(72,795)	—
Net cash provided by (used in) financing activities	72,138	(2,475)	22,145	(72,795)	19,013
Net change in cash and cash equivalents	(9,096)	(642)	19	—	(9,719)
Cash and cash equivalents at beginning of period	21,609	3,498	348	—	25,455
Cash and cash equivalents at end of period	\$ 12,513	\$ 2,856	\$ 367	\$ —	\$ 15,736

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion of our financial condition, results of operations and cash flows, together with the unaudited condensed consolidated financial statements and the accompanying notes included in this Quarterly Report on Form 10-Q, as well as the audited consolidated and combined financial statements and accompanying notes, and additionally the sections entitled "Business" and "Risk Factors," included in our Annual Report on Form 10-K filed with the SEC on March 15, 2018 (the "2017 Annual Report on Form 10-K"). The financial information discussed below and included in our 2017 Annual Report on Form 10-K may not necessarily reflect what our results of operations, financial position and cash flows would have been had we been a stand-alone company for the entirety of the periods presented herein or what our results of operations, financial position and cash flows may be in the future. Except as otherwise indicated or unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to "we," "our," "us," "QHC" and the "Company" refer to the consolidated business operations of the hospitals and Quorum Health Resources, LLC ("QHR") that CHS spun off to Quorum Health Corporation on April 29, 2016 (the "Spin-off"). Additionally, all references to "CHS" and "Parent" refer to Community Health Systems, Inc. and its consolidated subsidiaries. References to our financial statements and financial outlook are on a consolidated basis unless otherwise noted.

Forward Looking Statements

Some of the matters discussed in this Quarterly Report on Form 10-Q include forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," "thinks," and similar expressions are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements.

These factors include, but are not limited to, the following:

- general economic and business conditions, both nationally and in the regions in which we operate;
- risks associated with our substantial indebtedness, leverage and debt service obligations, including our ability to comply with our debt covenants, including our senior credit facility, as amended;
- our ability to successfully complete divestitures and the timing thereof, our ability to complete any such divestitures on desired terms or at all, and our ability to realize the intended benefits from any such divestitures;
- changes in reimbursement methodologies and rates paid by federal or state healthcare programs, including Medicare and Medicaid, or commercial payors, and the timeliness of reimbursement payments, including delays in certain states in which we operate;
- the extent to which regulatory and economic changes occur in Illinois, where a material portion of our revenues are concentrated;
- demographic changes;
- the impact of changes made to the Affordable Care Act, the potential for repeal or additional changes to the Affordable Care Act, its implementation or its interpretation, as well as changes in other federal, state or local laws or regulations affecting the healthcare industry;
- increases in the amount and risk of collectability of patient accounts receivable, including lower collectability levels which may result from, among other things, self-pay growth and difficulties in collecting payments for which patients are responsible, including co-pays and deductibles;
- competition;
- changes in medical or other technology;
- any potential impairments in the carrying values of long-lived assets and goodwill or the shortening of the useful lives of long-lived assets;

- the costs associated with the transition of the transition services agreements (“TSAs”) with CHS, including the related arbitration proceeding, as well as the additional costs and risks associated with any operational problems, delays in collections from payors, and errors and control issues during the termination and transition process, and our ability to realize the intended benefits from transitioning the transition services agreements;
- an unfavorable outcome from the arbitration with CHS;
- the impact of certain outsourcing functions, and the ability of CHS, as provider of our billing and collection services pursuant to the TSAs, to timely and appropriately bill and collect;
- our ability to manage effectively our arrangements with third-party vendors for key non-clinical business functions and services;

50

our ability to achieve operating and financial targets and to control the costs of providing services if patient volumes are lower than expected;

our ability to achieve and realize the operational and financial benefits expected from our margin improvement program;

the effects related to outbreaks of infectious diseases;

our ability to attract and retain, at reasonable employment costs, qualified personnel, key management, physicians, nurses and other healthcare workers;

the impact of seasonal or severe weather conditions or earthquakes;

increases in wages as a result of inflation or competition for highly technical positions and rising medical supply and drug costs due to market pressure from pharmaceutical companies and new product releases;

our ongoing ability to demonstrate meaningful use of certified EHR technology, including meeting interoperability objectives, and avoid related penalties and recognize income for the related Medicare or Medicaid incentive payments, to the extent such payments have not expired;

the efforts of healthcare insurers, providers, large employer groups and others to contain healthcare costs, including the trend toward treatment of patients in less acute or specialty healthcare settings and the increased emphasis on value-based purchasing;

the failure to comply with governmental regulations;

our ability, where appropriate, to enter into, maintain and comply with provider arrangements with payors and the terms of these arrangements, which may be impacted by the increasing consolidation of health insurers and managed care companies and vertical integration efforts involving payors and healthcare providers;

the potential adverse impact of known and unknown government investigations, internal investigations, audits, and federal and state false claims act litigation and other legal proceedings, including the shareholder and creditor litigations against our company and certain of our officers and threats of litigation, as well as the significant costs and attention from management required to address such matters;

liabilities and other claims asserted against us, including self-insured malpractice claims;

the impact of cyber-attacks or security breaches, including, but not limited to, the compromise of our facilities and confidential patient data, potential harm to patients, remediation and other expenses, potential liability under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and consumer protection laws, federal and state governmental inquiries, and damage to our reputation;

our ability to utilize our income tax loss carryforwards and risks associated with the Tax Cuts and Jobs Act of 2017;

our ability to maintain certain accreditations at our existing facilities and any future facilities we may acquire;

the success and long-term viability of healthcare insurance exchanges and potential changes to the beneficiary enrollment process;

the extent to which states support or implement changes to Medicaid programs, utilize healthcare insurance exchanges or alter the provision of healthcare to state residents through regulation or otherwise;

the timing and amount of cash flows related to the California Hospital Quality Assurance Fee (“HQAF”) program, as well as the potential for retroactive adjustments for prior year payments;

the effects related to the continued implementation of the sequestration spending reductions and the potential for future deficit reduction legislation;

changes in U.S. generally accepted accounting principles, including the impacts of adopting newly issued accounting standards;

the availability and terms of capital to fund acquisitions, replacement facilities or other capital expenditures;

our ability to obtain adequate levels of professional and general liability and workers’ compensation liability insurance; and

the risk factors included in our other filings with the SEC and included in Part II, Item 1A of this Quarterly Report on Form 10-Q, if any.

Although we believe that these forward-looking statements are based upon reasonable assumptions, these assumptions are inherently subject to significant regulatory, economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond our control. Accordingly, we cannot give any

assurance that our expectations will in fact occur and caution that actual results may differ materially from those in the forward-looking statements. Given these

51

uncertainties, prospective investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are made as of the date of this filing. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Overview

As of September 30, 2018, we owned or leased a diversified portfolio of 27 hospitals in rural and mid-sized markets, which are located in 14 states and have a total of 2,604 licensed beds. Our hospitals provide a broad range of hospital and outpatient healthcare services, including general and acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic services, psychiatric and rehabilitation services. For our hospital operations business, we are paid for our services by governmental agencies, commercial insurers and directly by the patients we serve. We also operate QHR, a leading hospital management advisory and healthcare consulting services business. For our hospital management advisory and healthcare consulting services business, we are paid by the non-affiliated hospitals utilizing our services. Over 95% of our net operating revenues are attributable to our hospital operations business.

Business Strategy Summary

Our business strategy is focused on the following key objectives:

- improve our financial results and position by refining our portfolio to include high-quality, profitable hospitals and outpatient service facilities through the sale or closure of underperforming hospitals;
- strategically expand the breadth and capacity of the specialty care service lines and outpatient services we offer;
- enhance patient safety, quality of care and satisfaction at our healthcare facilities;
- improve the operating and financial performance of our hospital and clinical operations business; and
- grow our revenues through selective acquisitions.

We perform an ongoing strategic review of our hospitals based upon an analysis of financial performance, current competitive conditions, market demographic and economic trends and capital allocation requirements. As part of this strategy, we intend to divest or close underperforming hospitals and outpatient service facilities which, in turn, will allow us to reduce our corporate indebtedness and refine our hospital portfolio to become a sustainable group of hospitals and outpatient service facilities with higher operating margins. We are pursuing divestiture or closure opportunities that align with this strategy. Since the Spin-off, we have divested or closed 11 of the 38 hospitals we originally acquired from CHS. Our strategic review process is ongoing and we have targeted additional hospitals for divestiture with the intention of utilizing substantially all net proceeds to pay down our secured debt. We intend to divest or close these hospitals by the end of 2019. For a discussion of our recent divestiture and closure activities, see below section entitled "Recent Divestiture Activity."

Financial Overview

Our net operating revenues for the three months ended September 30, 2018 decreased \$38.8 million to \$460.5 million, compared to \$499.3 million for the three months ended September 30, 2017, a 7.8% decrease. The \$38.8 million decrease was primarily attributable to a \$64.0 million decrease in net operating revenues resulting from the hospitals sold or closed subsequent to the prior period, offset by \$8.7 million of HQAF program revenues recognized in the three months ended September 30, 2018 with no corresponding amount recorded in the three months ended September 30, 2017 and \$12.4 million due to an improved payor mix as well an increase in rate and acuity. In addition, we recognized revenues of \$7.3 million from the sale the Illinois property tax credits in the three months ended September 30, 2018. Recognition of the benefit from the Illinois property tax credits was previously recognized as a reduction in other operating expenses. For the three months ended September 30, 2017, the reduction to other

operating expenses was \$7.8 million. We believe the Illinois property tax credits operate as a supplemental payment program for uncompensated charity care. Income (loss) from operations for the three months ended September 30, 2018 was \$(22.5) million, compared to \$3.1 million for the three months ended September 30, 2017. Income (loss) from operations decreased primarily due to an increase in impairment charges of \$27.2 million. Our operating results for the three months ended September 30, 2018 reflect a 17.8% decrease in total admissions and a 16.2% decrease in total adjusted admissions compared to the same period in 2017. Same-facility admissions decreased 4.5% and adjusted admissions decreased 2.1% for the three months ended September 30, 2018 compared to the same period in 2017. The decrease in same-facility admissions and adjusted admissions was primarily a result of closing underperforming service lines and the termination of payor and physician contracts. The reduction in same-facility admissions was offset by an increase in our overall rate and acuity.

Our net operating revenues for the nine months ended September 30, 2018 decreased \$137.1 million to \$1,420.0 million, compared to \$1,557.1 million for the nine months ended September 30, 2017, a 8.8% decrease. The \$137.1 million decrease was primarily attributable to a \$197.3 million decrease in net operating revenues resulting from the hospitals sold or closed subsequent to the prior period, offset by a \$24.4 million increase related to the HQAF program with no corresponding amount recorded in the nine months ended September 30, 2017 and a \$34.7 million increase due to improved payor mix and an increase in rate and acuity. In

addition, we recognized revenues of \$7.3 million from the sale of the Illinois property tax credits in the nine months ended September 30, 2018. Recognition of the benefit from the Illinois property tax credits was previously recognized as a reduction in other operating expenses. For the nine months ended September 30, 2017, the reduction to other operating expenses was \$7.8 million. In addition, we had a \$2.3 million increase in revenues from the Medicare low volume hospital payment adjustments that related to the fourth quarter of 2017 as the program was not approved until the first quarter of 2018. Income (loss) from operations for the nine months ended September 30, 2018 was \$(84.2) million, compared to \$3.8 million for the nine months ended September 30, 2017. Income (loss) from operations decreased \$8.9 million related to the combined losses on the sales of Vista West, Clearview and McKenzie (each defined below), \$18.2 million related to the closure of Affinity (defined below), and \$72.2 million related to impairment of long-lived assets of hospitals intended for divestiture. Our operating results for the nine months ended September 30, 2018 reflect a 16.3% decrease in total admissions and a 15.9% decrease in total adjusted admissions compared to the same period in 2017. Same-facility admissions decreased 2.4% and adjusted admissions decreased 1.0% for the nine months ended September 30, 2018 compared to the same period in 2017. The decrease in same-facility admissions and adjusted admissions was primarily a result of closing underperforming service lines and the termination of payor and physician contracts. The reduction in same-facility admissions was offset by an increase in our overall rate and acuity.

Recent Divestiture Activity

On September 30, 2018, we sold 45-bed McKenzie Regional Hospital and its affiliated facilities (“McKenzie”), located in McKenzie, Tennessee, for proceeds of \$1.7 million, which were received in October 2018. For the three months ended September 30, 2018 and 2017, our operating results included pre-tax losses of \$3.2 million and \$1.3 million, respectively, related to McKenzie, and pre-tax losses of \$6.0 million and \$4.2 million for the nine months ended September 30, 2018 and 2017, respectively. In addition to the above, we recorded a \$0.7 million loss on the sale of McKenzie in the nine months ended September 30, 2018, which includes a write-off of allocated goodwill of \$0.4 million.

On March 31, 2018, we sold 77-bed Clearview Regional Medical Center and its affiliated facilities (“Clearview”), located in Monroe, Georgia, for proceeds of \$37.4 million, of which \$8.0 million was placed in an escrow account subject to resolution of certain outstanding litigation. This matter was resolved in October 2018 and we received the \$8.0 million of proceeds during October. For the three months ended September 30, 2018 and 2017, our operating results included pre-tax losses of \$1.7 million and \$0.7 million, respectively, related to Clearview, and pre-tax losses of \$5.3 million and \$2.3 million for the nine months ended September 30, 2018 and 2017, respectively. In addition to the above, we recorded a \$7.9 million loss on the sale of Clearview in the nine months ended September 30, 2018, which includes a write-off of allocated goodwill of \$9.4 million.

On March 1, 2018, we sold 70-bed Vista Medical Center West and its affiliated facilities (“Vista West”), located in Waukegan, Illinois, for proceeds of \$1.2 million. For the three months ended September 30, 2018 and 2017, our operating results included pre-tax losses of \$1.3 million and \$0.2 million, respectively, related to Vista West, and pre-tax losses of \$2.1 million and \$1.5 million for the nine months ended September 30, 2018 and 2017, respectively. In addition to the above, we recorded a \$0.2 million loss on the sale of Vista West in the nine months ended September 30, 2018.

On January 5, 2018, we announced plans to close Affinity Medical Center (“Affinity”) located in Massillon, Ohio. Subsequent to January 5, 2018, we entered into an agreement with the City of Massillon related to the closure whereby all of the owned real property and a portion of the related tangible assets located at the hospital would be transferred to the City of Massillon in exchange for nominal consideration and the City of Massillon’s assumption of certain ongoing real property lease obligations and equipment lease obligations. Operations ceased on February 11, 2018 and we transferred the agreed-upon assets to the City of Massillon on May 16, 2018. For the three months ended

September 30, 2018 and 2017, our operating results included pre-tax losses of \$2.2 million and \$2.3 million, respectively, related to Affinity, and pre-tax losses of \$26.6 million and \$8.3 million for the nine months ended September 30, 2018 and 2017, respectively. Included in the pre-tax losses for the nine months ended September 30, 2018 was \$18.2 million of closure costs related to the closure of Affinity which includes \$8.1 million of severance and salary continuation costs, \$5.0 million in losses associated with the disposal of assets that have no future value to us and \$5.1 million of other costs and fees related to termination of contracts and other miscellaneous costs. We anticipate that in the remainder of 2018 we will incur costs, beyond those already incurred of approximately \$0.5 million to \$1.0 million related to the wind down and transfer of assets to other facilities. In addition, beyond 2018, we are obligated to maintain patient health records for approximately 19 years with an estimated annual cost of \$0.3 million.

Update on TSAs and Arbitration with CHS

Since the Spin-off with CHS in April 2016, we have outsourced to CHS, through various TSAs, certain services including, among others, services related to patient eligibility screening, billing, accounts receivable collections and other revenue management services and support, as well as information technology, payroll processing and other human resources functions. On August 4, 2017, we received a demand for arbitration from CHS seeking payment of certain amounts withheld by us pursuant to the Shared Service Centers Transition Services Agreement (the "SSC TSA") and the Computer and Data Processing Transition Services Agreement (the "IT TSA"). We contend that the amounts are not payable to CHS and were not properly billed by CHS under the agreements. The matter is pending before the American Arbitration Association, and CHS seeks payment of approximately \$12.1 million relating to

these two TSAs. We are vigorously contesting the charges as not payable to CHS under the terms of the agreements and have made counterclaims that include, among other things, termination of the SSC TSA, a ruling that the IT TSA is terminable at our option (as described below), and substantial damages we believe we have suffered as a result of the TSAs and other actions taken by CHS in connection with the Spin-off. Additionally, on March 19, 2018, we received notice from CHS that CHS was seeking to terminate, effective September 30, 2018, the SSC TSA and the IT TSA and to impose a September 30, 2018 deadline for completion of the transition of services under the SSC TSA and the IT TSA. The notice from CHS also provided an indication of CHS's preference to terminate the Receivables Collection Agreement, the Eligibility Screening Services Agreement, and the Billing and Collection Agreement. We amended our counterclaims to include allegations that CHS's attempt to terminate the SSC TSA and the IT TSA, and to impose a September 30, 2018 deadline for completing the transition of services under those contracts violated the terms of the contracts, and was invalid and without effect.

The validity and effectiveness of CHS's attempt to terminate the SSC TSA and IT TSA and to impose a September 30, 2018 deadline was litigated during the course of arbitration proceedings held in late June 2018. After hearing testimony regarding the termination issues, the arbitration panel ruled that each of the SSC TSA and IT TSA will continue in effect according to their original terms through 2021, subject to any agreement by the parties to terminate the SSC TSA and the IT TSA at an earlier time. The panel ordered that, after the date of the ruling, we would pay the amounts invoiced under the TSAs as billed, but deferred ruling on the parties' economic claims related to the TSAs until additional arbitration proceedings in early October 2018. The arbitration reconvened October 1, 2018, with us presenting our claims that certain amounts are not payable to CHS and were not properly billed by CHS under the agreements, which constitute approximately \$12.1 million in dispute, and certain counterclaims against CHS. The arbitration concluded October 9, 2018 and a decision is expected in mid-January 2019. We continue to believe that termination of all the TSAs is in our best long-term interests, and are working to ensure that the transitions are undertaken in a manner that minimizes the associated risks inherent in such a termination. We completed transition of the Eligibility Screening Services TSA ("ESS TSA") during the second quarter of 2018. We completed transition of the Physician Practice Support Agreement ("PPSA"), which is related to the billing and collecting on accounts receivable for the physicians and owned clinics, and the Professional Account Services ("PASI") Receivables Collection Agreement, which is primarily related to collecting receivables on aged/bad debt accounts for both the physicians and hospitals, effective October 1, 2018. Terminating or transitioning the services provided by the transition services agreements with CHS could result in additional costs and a risk of operational problems, delays in collections from payors, potential errors and possible control issues during the termination and transition processes, any of which could adversely affect our business, results of operations, financial condition and cash flows. For additional information, see Item 1A. Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2018.

Healthcare Reform

The Affordable Care Act, as currently structured, mandates that substantially all U.S. citizens maintain health insurance coverage, while expanding access to coverage through a combination of private sector health insurance reforms and public program expansion. However, there is considerable uncertainty with regard to the future of the Affordable Care Act, as the presidential administration and certain members of Congress have expressed their intent to repeal or make significant changes to the law, its implementation and its interpretation. For example, in 2017, Congress eliminated the financial penalties associated with the individual mandate, effective January 1, 2019, which may result in fewer individuals electing to purchase health insurance. Further, in June 2018, the Department of Labor issued a final rule expanding availability of association health plans, which are not required to cover all of the essential health benefits mandated by the Affordable Care Act. This change may result in individuals purchasing less comprehensive coverage. In addition, several private health insurers have withdrawn from or limited their participation in the healthcare insurance exchanges, and the presidential administration has taken steps, including ending cost-sharing subsidies that were previously available to insurers, which may threaten the long-term viability of those marketplaces. Healthcare reform initiatives, including efforts to change, alter the implementation of, or repeal

the Affordable Care Act, may have an adverse effect on our business, results of operations, financial position, cash flow, capital resources and liquidity.

California 2017-2019 Hospital Quality Assurance Fee Program

The HQAF program provides funding for supplemental payments to hospitals that serve Medi-Cal and uninsured patients. Revenues generated from fees assessed on certain general and acute care California hospitals fund the non-federal supplemental payments to California's safety-net hospitals while drawing down federal matching funds that are issued as supplemental payments to hospitals for care of Medi-Cal patients. In November 2016, California voters approved a state constitutional amendment measure that extends indefinitely the statute that imposes fees on California hospitals seeking federal matching funds.

The fourth phase of the HQAF program expired on December 31, 2016. The California Department of Health Care Services ("DHCS") submitted the Phase V HQAF program package to CMS on March 30, 2017 for approval of the overall program structure and the fees or provider tax rates for the program period January 1, 2017 through June 30, 2019, and the fee-for-service inpatient and outpatient upper payments limits ("UPL") for each of the state fiscal years in the period January 1, 2017 through June 30, 2019. CMS issued formal approval of Phase V HQAF on December 15, 2017. The approvals included the inpatient and outpatient fee-for-service supplemental payments and the overall tax structure. The California Hospital Association will work with the DHCS to develop an

implementation schedule and update the draft model to reflect the CMS-approved amounts. However, CMS has not yet issued a decision on the managed care components of the Phase V HQAF program and, therefore, the payment amounts in the draft model are preliminary. Furthermore, the supplemental Medi-Cal managed care payments made through the new directed payment mechanism have been estimated using inpatient utilization data publicly reported to the California Office of Statewide Health Planning and Development for the fiscal year ending in 2015. However, in actuality, the directed payments will be made for inpatient and outpatient services provided to in-network patients during the current state fiscal year.

Of the total supplemental payments received by all hospitals, our portion represents 0.50%. We are estimating that our net impact over the 30-month period will be \$56.8 million. While uncertainties regarding the timing and amount of payments under the HQAF program exist, our estimates of cash collections at this time, net of any provider taxes, including those related to previous programs, are \$31.5 million for the full year 2018, \$22.3 million in 2019, \$12.7 million in 2020 and \$7.7 million in 2021.

Illinois 2018 Hospital Assessment Program Redesign

The Illinois Hospital Assessment program provides funding for supplemental payments to hospitals, particularly those that serve higher proportions of Medicaid and uninsured patients in Illinois. Revenues generated from fees assessed on certain general and acute care Illinois hospitals draw down federal matching funds that are issued as supplemental payments to hospitals for care of Medicaid patients. The program was redesigned to modernize payment methodologies and satisfy certain CMS requirements. The “new” program received CMS approval to begin effective July 1, 2018. Among other changes, the program includes updated base year data and requires a greater percentage of funds to hospitals to be delivered at the paid claims level rather than through lump sum payments.

According to the Illinois Health and Hospital Association, the total funding available to hospitals under the redesigned program will approximate the old program. However, funding allocations may vary with the updated base year data and other changes in payment methodology. The most recent models provided by the Illinois Health and Hospital Association show our hospital payments being reduced by approximately \$7.7 million annually.

Other Government Regulations

Our hospital operations business is highly regulated. We are required to comply with extensive, complicated and overlapping governmental laws and regulations at the federal, state and local levels. These laws and regulations govern every aspect of how our hospitals conduct their operations, including the service lines that must be offered for licensure as an acute care hospital, restrictions related to employing physicians, and requirements applicable to eligibility and payment structures under the Medicare and Medicaid programs. The failure to comply with these laws and regulations can result in severe penalties including criminal penalties, civil sanctions, and the loss of our ability to qualify for participation in the Medicare and Medicaid programs.

Rules, regulations and laws imposed on the U.S. healthcare industry are subject to ongoing and frequent changes with little or no notice and are often interpreted and applied differently by various regulatory agencies with authority to enforce such requirements. Each change or conflicting interpretation may require us to make changes at our hospitals and other healthcare facilities related to aspects such as space usage, equipment, technology, staffing and service lines. We may also be required to revise or implement operating policies and procedures that were previously believed to be compliant. The cost of compliance with governmental laws and regulations is a significant component of our overall operating costs. Furthermore, these costs have been rising in recent years due to new regulatory requirements and increasing enforcement provisions. Management anticipates that compliance costs will continue to grow in the foreseeable future. The U.S. healthcare industry has seen a number of ongoing investigations related to patient referrals, physician recruiting and employment practices, cost reporting and billing practices, medical necessity of

inpatient admissions, physician office leasing, laboratory and home healthcare services, physician ownership of hospitals and other healthcare providers, and joint ventures involving hospitals and physicians. Hospitals continue to be one of the primary focus areas of the Office of Inspector General (“OIG”), Department of Justice (“DOJ”) and other governmental fraud and abuse regulatory authorities and programs.

Basis of Presentation

Our financial statements as of and for the three and nine months ended September 30, 2017 include certain reclassifications to conform to the presentation as of and for the three and nine months ended September 30, 2018. These reclassifications had no net effect on our consolidated results of operations, financial position or cash flows reported in this Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2018. See Note 2 — Basis of Presentation and Significant Accounting Policies — Reclassifications and Immaterial Restatements in the accompanying consolidated financial statements.

Revenues

Adoption of ASC Topic 606 “Revenue from Contracts with Customers”

On January 1, 2018, we adopted ASC 606 using the modified retrospective method to all contracts existing on January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under Topic 605. The key impacts on our consolidated financial statements include the following:

• Prior to the adoption of ASC 606, a significant portion of our allowance for doubtful accounts related to amounts due from self-pay patients, as well as co-pays and deductibles owed to us by patients with insurance. Under ASC 606, the estimated allowance for these patient accounts are generally considered a direct reduction to net operating revenues rather than as previously reported as provision for bad debts.

• Prior to the adoption of ASC 606, our presentation and disclosure of net revenue by payor included the portion of the revenue related to co-pays and deductibles as third-party revenues. Under ASC 606, the co-pays and deductibles portions of net revenue are classified as self-pay after insurance.

Revenue Recognition

We generate revenues by providing healthcare services at our hospitals and affiliated outpatient service facilities to patients seeking medical treatment. Hospital revenues depend on, among other factors, inpatient occupancy and acuity levels, the volume of outpatient procedures and the charges and negotiated reimbursement rates for the healthcare services provided. Our primary sources of payment for patient healthcare services are third-party payors, including the Medicare and Medicaid programs, Medicare and Medicaid managed care programs, commercial insurance companies, other managed care programs, workers’ compensation carriers and employers. Self-pay revenues are the portion of our revenues generated from providing healthcare services to patients who do not have health insurance coverage as well as the patient responsibility portion of charges that are not covered for an individual by a health insurance program or plan. We generate revenues related to our QHR business when hospital management advisory and healthcare consulting services are provided. We generate other non-patient revenues primarily from rental income and hospital cafeteria sales.

Amounts we collect for medical treatment of patients covered by Medicare, Medicaid and non-governmental third-party payors are generally less than our standard billing rates. Our standard charges and reimbursement rates for routine inpatient services vary significantly depending on the type of medical procedure performed and the geographical location of the hospital. Differences in our standard billing rates and the amounts we expect to collect from third-party payors are classified as contractual adjustments. The reimbursements we ultimately receive as payments for services are determined for each patient instance of care, based on the contractual terms we negotiate with third-party payors or based on federal and state regulations related to governmental healthcare programs. Billings and collections are outsourced to CHS under TSAs that were put in place by CHS in connection with the Spin-off. Our contractual adjustments are impacted by the timing and ability of CHS to monitor the classification and collection of our patient accounts receivable. See Note 16 — Related Party Transactions in the accompanying consolidated financial statements for additional information on these agreements. Except for emergency department services, our policy is to determine the payment methodology with patients prior to when the services are performed. Self-pay and other payor discounts are incentives offered to uninsured or underinsured patients or other payors to reduce their costs of healthcare services.

Edgar Filing: Quorum Health Corp - Form 10-Q

The following table provides a summary of our net operating revenues for the three and nine months ended September 30, 2018 and 2017 by payor source (dollars in thousands):

	Three Months Ended September 30,			
	2018		2017	
	\$ Amount	% of Total	\$ Amount	% of Total
Medicare	\$123,788	26.9 %	\$156,547	31.4 %
Medicaid	97,803	21.2 %	92,563	18.5 %
Managed care and commercial	185,493	40.3 %	184,390	36.9 %
Self-pay and self-pay after insurance	33,647	7.3 %	42,385	8.5 %
Non-patient	19,776	4.3 %	23,417	4.7 %
Total net operating revenues	\$460,507	100.0 %	\$499,302	100.0 %

	Nine Months Ended September 30,			
	2018		2017	
	\$ Amount	% of Total	\$ Amount	% of Total
Medicare	\$398,477	28.1 %	\$468,627	30.1 %
Medicaid	270,047	19.0 %	292,380	18.8 %
Managed care and commercial	560,445	39.5 %	583,073	37.4 %
Self-pay and self-pay after insurance	125,619	8.8 %	140,296	9.0 %
Non-patient	65,371	4.6 %	72,712	4.7 %
Total net operating revenues	\$1,419,959	100.0 %	\$1,557,088	100.0 %

For the three months ended September 30, 2018 and 2017, Medicare revenues related to Medicare Advantage Plans were \$32.0 million and \$47.0 million, respectively, or 25.9% and 30.0%, respectively, as a percentage of total Medicare revenues. For the nine months ended September 30, 2018 and 2017, Medicare revenues related to Medicare Advantage Plans were \$103.4 million and \$133.4 million, respectively, or 25.9% and 28.5%, respectively, as a percentage of total Medicare revenues.

Charity Care

In the ordinary course of business, we provide services to patients who are financially unable to pay for hospital care. The related charges for those patients who are financially unable to pay that otherwise do not qualify for reimbursement from a governmental program are classified as charity care. We determine amounts that qualify for charity care primarily based on the patient's household income relative to the poverty level guidelines established by the federal government. Our policy is not to pursue collections for such amounts; therefore, the related charges are recorded in operating revenues at the standard billing rates and fully offset in contractual adjustments in the same period.

Critical Accounting Policies

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts and related disclosures. Actual results may differ from these estimates under different assumptions or conditions. Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions. The

critical accounting estimates and judgments presented below are not intended to be a comprehensive list of all our accounting policies that require estimates, but are limited to those that involve a higher degree of judgment and complexity. We believe the current assumptions and other considerations used to estimate amounts in our financial statements are appropriate. If actual results differ from these assumptions and considerations, the resulting impact could have a material adverse effect on our results of operations and financial condition.

Third-Party Reimbursements and State Supplemental Payment Programs

Our estimate of our patient revenues due from third-party payors is subject to complexities, including interpretations of governmental regulations and payor-specific contractual agreements that are frequently changing. The Medicare and Medicaid programs, which are the payor sources for a major portion of our patient revenues, are highly complex programs and subject to interpretation of federal and state-specific reimbursement rates, new or changing legislation and final cost report settlements. Contractual adjustments are recorded in the period services are performed and the patient's method of payment is verified. Estimates for contractual adjustments are subject to change, in large part, due to ongoing contract negotiations and regulatory changes, which is typical in the U.S. healthcare industry. Revisions to estimates for contractual adjustments are recorded in the periods in which they

become known and may be subject to further revisions. Hospital contractual adjustments calculations are reviewed on a monthly basis by management to ensure reasonableness and accuracy.

We use a third-party automated contractual adjustments system to calculate our contractual adjustments each month. Contractual adjustments are calculated utilizing historical paid claims data by payor source, which is uploaded into the system each month. The key assumptions used by the system to calculate the current period estimated contractual adjustments are derived on a payor-specific basis from the estimated contractual reimbursement percentage and historical paid claims data. The automated contractual adjustments system does not include patient account level information, as it estimates an average contractual adjustment for each payor source. Due to the complexities involved in the contractual adjustments estimates, actual reimbursement payments we receive from third-party payors could be different from the amounts we estimated and recorded. If the actual contractual reimbursement percentages by payor source differed by 1% from our estimated contractual reimbursement percentages, our net loss for the nine months ended September 30, 2018 would have changed by \$15.8 million. If we applied a 1% differential to our patient accounts receivable due from governmental, managed care and commercial third-party payors as of September 30, 2018, patient accounts receivable would have changed by \$15.9 million.

Cost report settlements under reimbursement programs with Medicare, Medicaid and other managed care plans are estimated and recorded in the period patient services are performed and any revisions to estimates of previous program reimbursements are recorded in subsequent periods until the final cost report settlements are determined. We account for cost report settlements in contractual adjustments in our consolidated statements of income and recognize these amounts as due from and due to third-party payors on our consolidated balance sheets. Contractual adjustments related to previous program reimbursements and final cost report settlements favorably (unfavorably) impacted net operating revenues by \$(0.5) million and \$2.5 million during the three months ended September 30, 2018 and 2017, respectively, and \$(0.4) million and \$2.5 million during the nine months ended September 30, 2018 and 2017, respectively.

Several states utilize supplemental payment programs, including disproportionate share programs, for the purpose of providing reimbursement to providers to offset a portion of the cost of providing care to Medicaid and indigent patients. The amounts due to us under such programs are included in due from third-party payors on our balance sheets. Some of these programs have participation costs, referred to as fees or provider taxes. We record these costs in due to third-party payors on our consolidated balance sheets. After a state supplemental program is approved and fully authorized, we recognize the reimbursement payments due to us from these programs in the periods amounts are estimable and revenue collection is reasonably assured. We record the revenues as favorable contractual adjustments in our net operating revenues and the related provider taxes as other operating expenses in our statements of income.

The following table shows the portion of our Medicaid reimbursements attributable to state supplemental payment programs for the three and nine months ended September 30, 2018 and 2017 (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30, 2018	September 30, 2017	September 30, 2018	September 30, 2017
Medicaid state supplemental payment program revenues	\$57,555	\$ 46,866	\$158,186	\$138,544
Provider taxes and other expenses	19,131	16,523	55,326	50,646
Reimbursements attributable to state supplemental payment programs, net of expenses	\$38,424	\$ 30,343	\$102,860	\$ 87,898

The California Department of Health Care Services administers the HQAF program, imposing a fee on certain general and acute care California hospitals. Revenues generated from these fees provide funding for the non-federal supplemental payments to California hospitals that serve California's Medi-Cal and uninsured patients. Under the HQAF program we recognized \$8.7 million of Medicaid revenues and \$0.1 million of provider taxes for the three months ended September 30, 2018 and \$24.4 million of Medicaid revenues and \$4.4 million of provider taxes for the nine months ended September 30, 2018. There were no corresponding amounts recognized in the three and nine months ended September 30, 2017. The revenues and fees for the full year 2017 were recognized in the fourth quarter of 2017 when CMS approved the current phase of the program.

In addition, we recognized \$7.3 million of Medicaid revenues in the three and nine months ended September 30, 2018 related to the sale the Illinois property tax credits. For the three and nine months ended September 30, 2017, the Company recognized \$7.8 million from the sale of the Illinois property tax credits as a direct reduction to other operating expenses.

The following table provides a summary of the components of amounts due from and due to third-party payors (in thousands):

	September 30, 2018	December 31, 2017
Amounts due from third-party payors:		
Previous program reimbursements and final cost report settlements	\$ 13,878	\$ 17,383
State supplemental payment programs	50,231	79,819
Total amounts due from third-party payors	\$ 64,109	\$ 97,202
Amounts due to third-party payors:		
Previous program reimbursements and final cost report settlements	\$ 32,830	\$ 33,163
State supplemental payment programs	11,104	14,542
Total amounts due to third-party payors	\$ 43,934	\$ 47,705

Accounts Receivable

Substantially all of our accounts receivable are related to providing healthcare services to patients at our hospitals and affiliated outpatient facilities. Collection of these accounts receivable is our primary source of cash and is critical to our operating performance. Our primary collection risks relate to uninsured patients and the patient financial responsibility portion of payments due from insured patients, generally co-pays and deductibles. Our policy is to verify the health insurance coverage of a patient prior to the procedure date for all medical treatment scheduled in advance. We do not verify insurance coverage in advance of treatment for walk-in and emergency room patients.

We adopted ASC 606 on January 1, 2018. Prior to the adoption of ASC 606, a significant portion of our allowance for doubtful accounts related to self-pay patients, as well as co-pays and deductibles owed to us by patients with insurance. Under ASC 606, the estimated allowance for these patients are generally considered a direct reduction to net operating revenues rather than as previously reported as provision for bad debts.

Collections are impacted by the economic ability of patients to pay and the effectiveness of CHS' billing and collection efforts, including their current policies on billings, accounts receivable payor classifications, collections, and our own efforts to further attempt collection. As previously stated, billings and collections are outsourced to CHS under the transition services agreements that were put in place with the Spin-off. See Note 16 — Related Party Transactions in the accompanying consolidated financial statements for additional information on these agreements. Significant changes in payor mix, centralized business office operations, including CHS' efforts in collecting our accounts receivables, economic conditions or trends in federal and state governmental healthcare coverage, among other things, could affect our collection levels.

Our policy is to write off gross accounts receivable if the balance is under \$10.00 or when such amounts are placed with outside collection agencies. We believe this policy accurately reflects our ongoing collection efforts and is consistent with practices within the U.S. healthcare industry. We had \$519.9 million and \$474.3 million of past due patient account balances at September 30, 2018 and December 31, 2017, respectively, being pursued by secondary collection agencies, excluding accounts being pursued by CHS's wholly-owned subsidiary, PASI, under the transition services agreement. Effective October 1, 2018, by mutual agreement of both companies, each of the parties' obligations under this transition services agreement to the other were terminated. We replaced the services provided by CHS either by utilizing external service providers and/or internal resources. We expect to collect less than 3%, net of estimated collection fees, of the amounts being pursued by these secondary collection agencies. As these amounts have been written-off, they are not included in accounts receivable in our consolidated balance sheets.

For self-pay receivables, the total amount of contractual adjustments, discounts and implicit price concessions that reduces these receivables to their net carrying value were \$552.0 million and \$545.8 million as of September 30, 2018 and December 31, 2017, respectively. If our actual collection percentage differed by 1% from our estimated collection percentage as a result of a change in recoveries, our net loss for the nine months ended September 30, 2018 would have changed \$6.1 million.

Days revenue outstanding related to patients accounts receivable, excluding amounts recorded as due to or due from third-party payors, was 64 days and 63 days as of September 30, 2018 and December 31, 2017, respectively.

Impairment of Long-Lived Assets and Goodwill

Whenever an event occurs or changes in circumstances indicate that the carrying values of certain long-lived assets may be impaired, we project the undiscounted cash flows expected to be generated by those assets. If the projections indicate that the carrying values are not expected to be recovered, the assets are reduced to their estimated fair value based on a quoted market price, if available, or an estimated value based on valuation techniques available in the circumstances.

Our hospital operations and hospital management advisory and healthcare consulting services operations meet the criteria to be classified as reporting units for goodwill. Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of a reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit's carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required. Step two is to compare the implied fair value of the reporting unit's goodwill with the carrying value of the reporting unit's goodwill. When an indicator of potential impairment is identified in interim periods, we evaluate goodwill for impairment at such date.

We perform our annual goodwill impairment evaluation in the fourth quarter of each year. For our annual evaluation, we estimate the fair value of each of our reporting units utilizing two modeling approaches, a discounted cash flow model and an earnings multiple model. The discounted cash flow model applies a discount rate to our cash flow forecasts that is based on our best estimate of a market participant's weighted-average cost of capital. The earnings multiple model applies a market supported multiple to EBITDA. Both models are based on our best estimate of future revenues and operating costs and expenses as of the testing date. Additionally, the results of both models are reconciled to our consolidated market capitalization, which considers the amount a potential buyer would be required to pay, in the form of a control premium, to gain sufficient ownership to set policies, direct operations and control management decisions of our company.

During the three months ended September 30, 2018, we evaluated the fair value of hospitals intended for divestiture. In connection with this evaluation, we recognized long-lived asset impairment of \$32.4 million during the three months ended September 30, 2018, which consisted of \$31.5 million of property and equipment and \$0.9 million of capitalized software costs. See Note 3 — Impairment of Long-Lived Assets and Goodwill in our accompanying consolidated financial statements.

During the three months ended March 31, 2018, we evaluated the fair value of hospitals intended for divestiture. In connection with this evaluation, we recognized long-lived asset impairment of \$39.8 million during the three months ended March 31, 2018, which consisted of \$34.7 million of property and equipment and \$5.1 million of capitalized software costs. See Note 3 — Impairment of Long-Lived Assets and Goodwill in our accompanying consolidated financial statements.

During the three months ended September 30, 2017, we evaluated the fair value of hospitals classified as held for sale and other hospitals intended for potential divestiture. In connection with this evaluation, we recognized long-lived asset and goodwill impairment of \$5.3 million during the three months ended September 30, 2017, which consisted of \$3.7 million of property and equipment, \$1.0 million of intangibles and \$0.6 million of goodwill impairment. See Note 3 — Impairment of Long-Lived Assets and Goodwill in our accompanying consolidated financial statements.

During the three months ended June 30, 2017, we evaluated the fair value of hospitals classified as held for sale and evaluated other hospitals intended for potential divestiture. In connection with this evaluation, we recognized \$12.9 million of impairment to property and equipment during the three months ended June 30, 2017. See Note 3 — Impairment of Long-Lived Assets and Goodwill in our accompanying consolidated financial statements.

During the three months ended March 31, 2017, management made a decision to classify certain hospitals as held for sale. In connection with this decision, we evaluated the estimated relative fair value of the hospitals classified as held for sale in relation to the overall fair value of the hospital operations reporting unit utilizing a September 30, 2016 measurement date, which was the measurement date of our most recent annual goodwill impairment analysis, and recognized \$3.3 million of impairment to long-lived assets and goodwill during the three months ended March 31, 2017, which consisted of \$1.1 million of property and equipment, \$0.8 million of capitalized software costs and \$1.4 million of goodwill. See Note 3 — Impairment of Long-Lived Assets and Goodwill in our accompanying consolidated

financial statements.

Professional and General Liability Insurance and Workers' Compensation Liability Insurance Reserves

As part of the business of owning and operating hospitals, we are subject to legal actions alleging liability on our part. To mitigate a portion of this risk, we maintain insurance exceeding a self-insured retention level for these types of claims. Our self-insurance reserves reflect the current estimate of all outstanding losses, including incurred but not reported losses, based on actuarial calculations as of period end. The loss estimates included in the actuarial calculations may change in the future due to updated facts and circumstances. Insurance expense in the statements of income includes the actuarially determined estimates for losses in the current year, including claims incurred but not reported, the changes in estimates for losses in prior years based on actual claims development experience as compared to prior actuarial projections, the insurance premiums for losses related to policies obtained to cover amounts in excess of our self-insured retention levels, the administrative costs of the insurance programs, and interest expense related to the discounted portions of these liabilities. Our reserves for professional and general liability and workers' compensation liability claims are based on semi-annual actuarial calculations, which are discounted to present value and consider historical claims data, demographic factors, severity factors and other actuarial assumptions. The liabilities for self-insured claims are discounted based on our risk-free interest rate that corresponds to the period when the self-insured claims are incurred and projected to be paid.

A portion of our reserves for workers' compensation and professional and general liability claims included on our balance sheets relates to reserved claims and incurred but not reported claims prior to the Spin-off. These claims were fully indemnified by

CHS under the terms of the Separation and Distribution Agreement. As a result, we have a corresponding receivable from CHS related to these claims on our consolidated balance sheets. See Note 17 — Commitments and Contingencies in our accompanying consolidated financial statements for a table that summarizes the receivables and liabilities associated with our workers' compensation liability and professional and general liability claims as of September 30, 2018 and December 31, 2017.

Income Taxes

The breadth of our operations and the complexity of tax regulations require assessments of uncertainties and judgments in estimating the amount of income taxes that we will ultimately pay. The amount of final income taxes ultimately paid by us is dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of disputes arising from federal and state tax audits in the normal course of business.

We calculate our provision for income taxes and account for income taxes using the asset and liability method. Under this method, deferred income taxes are recorded to represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred income taxes during the year. Deferred income taxes result from differences between the financial and tax basis of our assets and liabilities and are adjusted for changes in tax rates and the enactment of new or amended tax laws.

Under the asset and liability method, valuation allowances are recorded to reduce deferred income tax assets when it is more likely than not that a tax benefit will not be realized. We assess the realization of our deferred tax assets to determine whether an income tax valuation allowance is required. Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we determine whether it is more likely than not that all or a portion of the deferred tax assets will be realized. The main factors that we consider include:

- cumulative earnings or losses in recent years, adjusted for certain nonrecurring items;
- expected earnings or losses in future years;
- unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and earnings levels;
- the availability, or lack thereof, of taxable income in prior carryback periods that would limit realization of tax benefits; and
- the carryforward period associated with the deferred tax assets and liabilities.

In the ordinary course of business, there is inherent uncertainty in quantifying our income tax positions. We assess our income tax positions and record deferred income tax benefits for all tax years subject to examination based upon management's evaluation of the facts, circumstances and information available at the reporting date about the ability to realize the benefit of the deferred tax assets or tax positions. For those tax positions where it is more likely than not that a future tax benefit will be sustained, our policy is to record the largest amount of income tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that an income tax benefit will not be sustained in the future, we do not recognize a deferred tax benefit in our financial statements. We record interest and penalties, net of any applicable tax benefit, related to income taxes, if any, as a component of the provision for income taxes when applicable.

See Note 11 — Income Taxes in the accompanying consolidated financial statements for information on the projected impact of the new tax laws.

New Accounting Pronouncements

In February 2018, the FASB issued ASU 2018-02, Income Statement — Reporting Comprehensive Income, which allows for reclassification from accumulated other comprehensive income to retained earnings of the stranded tax effects in accumulated other comprehensive income resulting from the enactment of the comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”) and corresponding accounting treatment recorded in the fourth quarter of 2017. The ASU is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this ASU is permitted, including adoption in any interim period for reporting periods for which financial statements have not yet been issued. We do not anticipate that the adoption of this standard will have a significant impact on our consolidated balance sheet.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles — Goodwill and Other: Simplifying the Test for Goodwill Impairment, which simplifies the accounting for goodwill impairment by eliminating step two from the goodwill impairment test. This ASU instead permits an entity to recognize goodwill impairment as the excess of a reporting unit's carrying value over the estimated fair value of the reporting unit, to the extent this amount does not exceed the carrying amount of goodwill. The new guidance continues to allow an entity to perform a qualitative assessment of goodwill impairment indicators in lieu of a quantitative assessment in certain situations. The ASU is effective for annual and interim reporting periods beginning after December 15, 2019, with early

adoption permitted. We are currently evaluating the impact this guidance may have on our results of operations, financial position and cash flows.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows — Restricted Cash, which addressed classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires a reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. The ASU does not define restricted cash or restricted cash equivalents; however, the nature of the restrictions should be disclosed. The guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. This ASU is to be applied using a retrospective transition method for each period presented. We adopted ASU 2016-18 on January 1, 2018 and concurrently revised our presentation of cash and cash equivalents on the consolidated statement of cash flows. For periods prior to January 1, 2018, the presentation of cash and cash equivalents on the consolidated statement of cash flows has been revised to conform to the current presentation.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which amends the accounting for leases and requires the rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for interim periods and fiscal years beginning after December 15, 2018, with early adoption permitted. Under ASU 2016-02, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients. Our adoption process of ASU 2016-02 is ongoing, including identifying and validating the population of both known and embedded leases, implementing our acquired lease software and quantifying the impact on our consolidated financial statements. We anticipate that the adoption of ASU 2016-02 will result in a material increase in both total assets and total liabilities reflected on our consolidated balance sheets upon the recognition of right-of-use assets and obligations for leases currently classified as operating leases. In addition, we are continuing to evaluate and address the impact that the adoption of this standard will have on our policies, procedures, financial disclosures and control framework. We anticipate substantially completing our evaluation of the impact of the adoption of ASU 2016-02 by December 1, 2018.

Results of Operations

We have summarized our results of operations, including certain financial and operating data for the three and nine months ended September 30, 2018 and 2017 on a comparative basis below. The definitions of certain terms used throughout the remainder of “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” follows:

Same-facility. Same-facility financial and operating data, as presented in the comparative discussions herein, excludes hospitals that were sold or closed prior to and as of the end of the current reporting period. Our same-facility operating results for the three and nine months ended September 30, 2018 and 2017, which are reported herein, have been adjusted to exclude the operating results of Sandhills Regional Medical Center and its affiliated facilities (“Sandhills”), Barrow Regional Medical Center and its affiliated facilities (“Barrow”), Cherokee Medical Center and its affiliated facilities (“Cherokee”), Trinity Hospital of Augusta and its affiliated facilities (“Trinity”), Lock Haven Hospital and its affiliated facilities (“Lock Haven”), Sunbury Community Hospital and its affiliated facilities (“Sunbury”), L.V. Stabler Memorial Hospital and its affiliated facilities (“L.V. Stabler”), Affinity, Vista West, Clearview and McKenzie which we sold or closed on December 1, 2016, December 31, 2016, March 31, 2017, June 30, 2017, September 30, 2017, September 30, 2017, October 31, 2017, February 11, 2018, March 1, 2018, March 31, 2018 and September 30, 2018, respectively.

Divestitures Group. The divestitures group, as of September 30, 2018, includes all hospitals that had been sold or closed by us since the Spin-off through September 30, 2018. The divestitures group includes Sandhills, Barrow,

Edgar Filing: Quorum Health Corp - Form 10-Q

Cherokee, Trinity, Lock Haven, Sunbury, L.V. Stabler, Affinity, Vista West, Clearview and McKenzie. This group of hospitals has certain ongoing operations during the wind-down periods related to the assets and liabilities which were not part of the hospital sale, which typically includes accounts receivable and third-party receivables and payables.

Licensed Beds. Licensed beds are the number of beds for which the appropriate state agency licenses a hospital, regardless of whether the beds are actually available for patient use.

Admissions. Admissions represent the number of patients admitted for inpatient services.

Adjusted Admissions. Adjusted admissions is computed by multiplying admissions by gross patient revenues and then dividing that number by gross inpatient revenues.

Total Surgeries. Total surgeries represent the number of inpatient and outpatient surgeries.

Emergency Room Visits. Emergency room visits represent the number of patients registered and treated in our emergency rooms.

Medicare Case Mix Index. Medicare case mix index is a relative value assigned to a diagnosis-related group of patients that is used in determining the allocation of resources necessary to treat the patients in that group. Medicare case mix index is calculated as the average case mix index for all Medicare admissions during the period.

Hospital Operations Man-Hours per Adjusted Admission. Hospital operations man-hours per adjusted admission is calculated as total paid employed and contract labor hours, including both hospitals and affiliated outpatient facilities including clinics, divided by adjusted admissions. It is used by management as a measure of productivity.

Days Revenue Outstanding. Days revenue outstanding approximates the average collection period for patient accounts receivable. It is calculated by dividing net patient accounts receivable at the end of the period by average net operating revenues per day for the most recent three months. Net patient accounts receivable excludes the amounts reported as due from and due to third-party payors related to final cost report settlements and state supplemental payment programs.

EBITDA. EBITDA is a non-GAAP financial measure that consists of net income (loss) before interest, income taxes, depreciation and amortization.

Adjusted EBITDA. Adjusted EBITDA, also a non-GAAP financial measure, is EBITDA adjusted to add back the effect of certain legal, professional and settlement costs, impairment of long-lived assets and goodwill, net gain (loss) on sale of hospitals, net loss on closure of hospitals, transition of TSAs, transaction costs related to the Spin-off, severance costs for post-spin headcount reductions and executive severance and changes in estimate related to collectability of patient accounts receivable. We use Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by our management to assess the operating performance of our hospital operations business and to make decisions on the allocation of resources. Additionally, management utilizes Adjusted EBITDA in assessing our consolidated results of operations and in comparing our results of operations between periods.

Adjusted EBITDA, Adjusted for Divestitures. Adjusted EBITDA, Adjusted for Divestitures, also a non-GAAP financial measure, is further adjusted to exclude the effect of negative EBITDA of the divestitures group. We present Adjusted EBITDA, Adjusted for Divestitures because management believes this measure provides investors and other users of our financial statements with additional information about how management assesses our results of operations.

Three Months Ended September 30, 2018 Compared to Three Months Ended September 30, 2017

The following table provides a summary of our results of operations, both in dollars and as a percentage of net operating revenues (dollars in thousands):

	Three Months Ended September 30, 2018		2017			
	\$ Amount	% of Revenues	\$ Amount	% of Revenues		
Operating revenues			\$557,847			
Provision for bad debts			58,545			
Net operating revenues	\$460,507	100.0 %	499,302	100.0 %		
Operating costs and expenses:						
Salaries and benefits	226,237	49.1 %	251,780	50.4 %		
Supplies	48,949	10.6 %	58,657	11.7 %		
Other operating expenses	143,716	31.4 %	145,357	29.2 %		
Depreciation and amortization	16,612	3.6 %	20,735	4.2 %		
Rent	11,661	2.5 %	12,377	2.5 %		

Edgar Filing: Quorum Health Corp - Form 10-Q

Electronic health records incentives earned	(31)	—	%	(287)	(0.1)	%
Legal, professional and settlement costs	1,519	0.3	%	2,050	0.4	%
Impairment of long-lived assets and goodwill	32,438	7.0	%	5,261	1.1	%
Loss (gain) on sale of hospitals, net	805	0.2	%	79	—	%
Loss on closure of hospitals, net	1,111	0.2	%	—	—	%
Transaction costs related to the Spin-off	—	—	%	173	—	%
Total operating costs and expenses	483,017	104.9	%	496,182	99.4	%
Income (loss) from operations	(22,510)	(4.9)	%	3,120	0.6	%
Interest expense, net	32,450	7.0	%	32,216	6.4	%
Income (loss) before income taxes	(54,960)	(11.9)	%	(29,096)	(5.8)	%
Provision for (benefit from) income taxes	(1,074)	(0.2)	%	(542)	(0.1)	%
Net income (loss)	(53,886)	(11.7)	%	(28,554)	(5.7)	%
Less: Net income (loss) attributable to noncontrolling interests	54	—	%	637	0.1	%
Net income (loss) attributable to Quorum Health Corporation	\$(53,940)	(11.7)	%	\$(29,191)	(5.8)	%

63

Edgar Filing: Quorum Health Corp - Form 10-Q

The following table reconciles Adjusted EBITDA and Adjusted EBITDA, Adjusted for Divestitures to net income (loss), the most directly comparable U.S. GAAP financial measure (in thousands):

	Three Months Ended September 30,	
	2018	2017
Net income (loss)	\$(53,886)	\$(28,554)
Interest expense, net	32,450	32,216
Provision for (benefit from) income taxes	(1,074)	(542)
Depreciation and amortization	16,612	20,735
EBITDA	(5,898)	23,855
Legal, professional and settlement costs	1,519	2,050
Impairment of long-lived assets and goodwill	32,438	5,261
Loss (gain) on sale of hospitals, net	805	79
Loss on closure of hospitals, net	1,111	—
Transition of transition services agreements	2,445	—
Transaction costs related to the Spin-off	—	173
Post-spin headcount reductions and executive severance	1,722	850
Adjusted EBITDA	34,142	32,268
Negative EBITDA of divested hospitals	8,651	6,032
Adjusted EBITDA, Adjusted for Divestitures	\$42,793	\$38,300

Revenues

The following table provides information related to our net operating revenues (dollars in thousands, except per adjusted admission amounts):

	Three Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Consolidated:				
Net patient revenues	\$440,731	\$475,885	\$(35,154)	(7.4)%
Non-patient revenues	19,776	23,417	(3,641)	(15.5)%
Total net operating revenues	\$460,507	\$499,302	\$(38,795)	(7.8)%
Net patient revenues per adjusted admission	\$9,679	\$8,756	\$923	10.5 %
Net operating revenues per adjusted admission	\$10,113	\$9,187	\$926	10.1 %
Same-facility:				
Net patient revenues	\$444,034	\$415,546	\$28,488	6.9 %
Non-patient revenues	19,810	23,051	(3,241)	(14.1)%
Total net operating revenues	\$463,844	\$438,597	\$25,247	5.8 %
Net patient revenues per adjusted admission	\$9,866	\$9,037	\$829	9.2 %
Net operating revenues per adjusted admission	\$10,306	\$9,538	\$768	8.1 %

Edgar Filing: Quorum Health Corp - Form 10-Q

The following table provides information related to our net operating revenues by payor source (dollars in thousands):

	Three Months Ended September 30,						2018 vs 2017	
	2018		2017		\$	%	Variance	Change in %
	\$ Amount	% of Total	\$ Amount	% of Total				
Consolidated:								
Medicare	\$123,788	26.9 %	\$156,547	31.4 %	\$(32,759)	(4.5)	%	
Medicaid	97,803	21.2 %	92,563	18.5 %	5,240	2.7	%	
Managed care and commercial	185,493	40.3 %	184,390	36.9 %	1,103	3.4	%	
Self-pay and self-pay after insurance	33,647	7.3 %	42,385	8.5 %	(8,738)	(1.2)	%	
Non-patient	19,776	4.3 %	23,417	4.7 %	(3,641)	(0.4)	%	
Total net operating revenues	\$460,507	100.0%	\$499,302	100.0%	\$(38,795)			
Same-facility:								
Medicare	\$122,846	26.5 %	\$132,080	30.1 %	\$(9,234)	(3.6)	%	
Medicaid	98,074	21.1 %	82,997	18.9 %	15,077	2.2	%	
Managed care and commercial	184,860	39.9 %	161,506	36.8 %	23,354	3.1	%	
Self-pay and self-pay after insurance	38,254	8.2 %	38,963	8.9 %	(709)	(0.7)	%	
Non-patient	19,810	4.3 %	23,051	5.3 %	(3,241)	(1.0)	%	
Total net operating revenues	\$463,844	100.0%	\$438,597	100.0%	\$25,247			

The following table provides information related to certain drivers of our net operating revenues:

	Three Months Ended September 30,			
	2018	2017	%	
			Variance	Variance
Consolidated:				
Number of licensed beds at end of period	2,604	3,051	(447)	(14.7)%
Admissions	17,797	21,646	(3,849)	(17.8)%
Adjusted admissions	45,536	54,350	(8,814)	(16.2)%
Total surgeries	17,927	24,168	(6,241)	(25.8)%
Emergency room visits	135,231	163,986	(28,755)	(17.5)%
Medicare case mix index	1.42	1.43	(0.01)	(0.7)%
Same-facility:				
Number of licensed beds at end of period	2,604	2,630	(26)	(1.0)%
Admissions	17,666	18,499	(833)	(4.5)%
Adjusted admissions	45,001	45,984	(983)	(2.1)%
Total surgeries	17,727	18,706	(979)	(5.2)%
Emergency room visits	134,153	135,628	(1,475)	(1.1)%
Medicare case mix index	1.43	1.42	0.01	0.7%

Net operating revenues for the three months ended September 30, 2018 decreased \$38.8 million compared to the three months ended September 30, 2017, consisting of a \$35.2 million decrease in net patient revenues and a \$3.6 million decrease in non-patient revenues. Our decrease in net patient revenues consisted of a \$63.6 million decline related to the divestitures group and a \$28.4 million increase related to our same-facility hospitals. Same-facility net patient revenues include \$8.7 million of revenues from the California HQAF program recognized in the three months ended September 30, 2018 and \$7.3 million of revenues from the sale of the Illinois property tax credits, with no comparable

revenues recorded in the 2017 period. Excluding the California HQAF and Illinois property tax credits revenues of \$16.0 million, same-facility net patient revenues increased \$12.4 million due to an improved payor mix, as well as an increase in rate and acuity. On a consolidated basis, admissions and adjusted admissions declined 17.8% and 16.2%, respectively, when comparing third quarter of 2018 to the same period in 2017. On a same-facility basis, admissions and adjusted admissions decreased 4.5% and 2.1%, respectively, when comparing third quarter of 2018 to the same period in 2017. The decrease in admissions and adjusted admissions was primarily a result of closing underperforming service lines and the termination of payor and physician contracts. The reduction in admissions was offset by an increase in our overall rate and acuity.

Salaries and Benefits

The following table provides information related to our salaries and benefits expenses (dollars in thousands, except per adjusted admission amounts):

	Three Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Salaries and benefits	\$226,237	\$251,780	\$(25,543)	(10.1)%
Hospital operations salaries and benefits	\$208,664	\$230,168	\$(21,504)	(9.3)%
Hospital operations salaries and benefits per adjusted admission	\$4,582	\$4,235	\$347	8.2 %
Hospital operations man-hours per adjusted admission	110.4	106.7	3.7	3.5 %

Salaries and benefits decreased \$25.5 million for the three months ended September 30, 2018 compared to the three months ended September 30, 2017. Salaries and benefits declined \$31.8 million related to the divestitures group, offset by an increase in same-facility salaries and benefits of \$6.3 million. The same-facility increase included \$1.7 million related to executive severance with the remainder of the increase primarily related to merit increases at our facilities.

Supplies

The following table provides information related to our supplies expense (dollars in thousands, except per adjusted admissions amounts):

	Three Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Supplies	\$48,949	\$58,657	\$(9,708)	(16.6)%
Supplies per adjusted admission	\$1,075	\$1,079	\$(4)	(0.4)%

Supplies expense decreased \$9.7 million for the three months ended September 30, 2018 when compared to the three months ended September 30, 2017, which primarily included an \$8.5 million decline related to the divestitures group.

Other Operating Expenses

The following table provides information related to our other operating expenses (dollars in thousands):

	Three Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Purchased services	\$37,955	\$40,716	\$(2,761)	(6.8)%
Taxes and insurance	33,631	24,929	8,702	34.9 %
Medical specialist fees	26,078	27,254	(1,176)	(4.3)%
Transition services agreements	14,101	15,468	(1,367)	(8.8)%
Repairs and maintenance	8,962	10,166	(1,204)	(11.8)%
Utilities	6,559	7,853	(1,294)	(16.5)%
Other miscellaneous operating expenses	16,430	18,971	(2,541)	(13.4)%
Total other operating expenses	\$143,716	\$145,357	\$(1,641)	(1.1)%

Other operating expenses decreased \$1.6 million for the three months ended September 30, 2018 compared to the three months ended September 30, 2017. Other operating expenses declined \$20.8 million related to the divestitures group, offset by an increase in same-facility other operating expenses of \$19.1 million. The same-facility increase was primarily due to a \$7.8 million increase in taxes due to the recognition of the sale of the Illinois property tax credits as an offset to net patient revenues whereas in the three months ended September 30, 2017, the amount was recognized as a reduction in taxes, an increase of \$2.6 million in medical specialist fees due to the addition of new service lines and changes in hospital-based providers, and an increase of \$4.0 million in purchased services primarily related to software maintenance contracts and consulting services.

Depreciation and Amortization

Depreciation and amortization expense decreased \$4.1 million during the three months ended September 30, 2018 compared to the three months ended September 30, 2017. This decrease was primarily due to the overall reduction in our long-lived assets due to the divestiture of five hospitals subsequent to the third quarter of 2017.

Rent

Rent expense decreased \$0.7 million during the three months ended September 30, 2018 compared to the three months ended September 30, 2017. As a percentage of net operating revenues, rent expense was comparable for the respective periods.

Electronic Health Records Incentives Earned

Electronic health records incentives earned decreased \$0.3 million for the three months ended September 30, 2018 compared to the three months ended September 30, 2017 primarily due to the decrease in activity as we move closer toward full implementation of EHR. See Note 2 — Basis of Presentation and Significant Accounting Policies in the accompanying consolidated financial statements for additional information on EHR.

Legal, Professional and Settlement Costs

Legal, professional and settlement costs decreased \$0.5 million for the three months ended September 30, 2018 compared to the three months ended September 30, 2017. These costs included legal costs and related settlements, if any, related to arbitration costs, regulatory claims, government investigations into reimbursement payments and other litigation matters. See Note 17 — Commitments and Contingencies in the accompanying consolidated financial statements for additional information on these matters.

Impairment of Long-Lived Assets and Goodwill

For the three months ended September 30, 2018, we recognized \$32.4 million of impairment to long-lived assets of certain hospitals which we have identified as potential divestiture candidates and for which we have received letters of intent. For the three months ended September 30, 2017, we recognized \$5.3 million of impairment to long-lived assets and goodwill of certain hospitals which we identified as potential divestiture candidates and for which we had received letters of intent.

Loss (Gain) on Sale of Hospitals, Net

For the three months ended September 30, 2018, we recognized a \$0.8 million loss primarily on the sale of McKenzie. We recognized a \$0.1 million loss on the sale of hospitals, net in the three months ended September 30, 2017 primarily related to the sale of Lock Haven and Sunbury. See Note 4 — Divestitures in the accompanying consolidated financial statements for additional information on divestitures.

Loss on Closure of Hospitals, Net

For the three months ended September 30, 2018, we recognized a \$1.1 million loss on closure of hospitals, net related to the closure of Affinity. We ceased operations at this hospital on February 11, 2018, but will have certain continuing closures costs during the wind-down period. See Note 4 — Divestitures in the accompanying consolidated financial statements for additional information on divestitures.

Interest Expense, Net

The following table provides information related to interest expense, net (dollars in thousands):

	Three Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Senior Credit Facility:				
Revolving Credit Facility	\$63	\$98	\$ (35)	(35.7)%
Term Loan Facility	18,121	17,512	609	3.5 %
ABL Credit Facility	276	638	(362)	(56.7)%

Edgar Filing: Quorum Health Corp - Form 10-Q

Senior Notes	11,626	11,631	(5)	—	%
Amortization of debt issuance costs and discounts	2,079	2,067	12		0.6	%
All other interest expense (income), net	285	270	15		5.6	%
Total interest expense, net	\$32,450	\$32,216	\$ 234		0.7	%

Interest expense, net remained flat when comparing the three months ended September 30, 2018 to the three months ended September 30, 2017. See Liquidity and Capital Resources below and Note 7 — Long-Term Debt in the accompanying consolidated financial statements for additional information on our indebtedness.

Provision for (Benefit from) Income Taxes

The benefit from income taxes increased \$0.5 million for the three months ended September 30, 2018 compared to the three months ended September 30, 2017. Our effective tax rates were 2.0% and 1.9% for these respective periods. The increase in the effective tax rate for the three months ended September 30, 2018, compared to the three months ended September 30, 2017, was primarily due to the impairment and disposal of certain indefinite-lived intangible assets and the change in the expected realization of deferred tax assets under the new laws established by the Tax Act.

Net Income (Loss) Attributable to Noncontrolling Interests

Net income (loss) attributable to noncontrolling interests was \$0.1 million and \$0.6 million in the three months ended September 30, 2018 and 2017, respectively. As a percentage of net operating revenues, it was comparable for the respective periods.

Edgar Filing: Quorum Health Corp - Form 10-Q

Nine Months Ended September 30, 2018 Compared to Nine Months Ended September 30, 2017

The following table provides a summary of our results of operations, both in dollars and as a percentage of net operating revenues (dollars in thousands):

	Nine Months Ended September 30, 2018		2017	
	\$ Amount	% of Revenues	\$ Amount	% of Revenues
Operating revenues			\$1,731,007	
Provision for bad debts			173,919	
Net operating revenues	\$1,419,959	100.0 %	1,557,088	100.0 %
Operating costs and expenses:				
Salaries and benefits	705,868	49.7 %	781,691	50.2 %
Supplies	160,732	11.3 %	186,591	12.0 %
Other operating expenses	440,910	31.0 %	466,394	29.9 %
Depreciation and amortization	52,015	3.7 %	63,441	4.1 %
Rent	35,551	2.5 %	36,631	2.4 %
Electronic health records incentives earned	(617)	— %	(4,516)	(0.3)%
Legal, professional and settlement costs	10,349	0.7 %	6,519	0.4 %
Impairment of long-lived assets and goodwill	72,198	5.1 %	21,461	1.4 %
Loss (gain) on sale of hospitals, net	8,927	0.6 %	(5,112)	(0.3)%
Loss on closure of hospitals, net	18,195	1.3 %	—	— %
Transaction costs related to the Spin-off	—	— %	204	— %
Total operating costs and expenses	1,504,128	105.9 %	1,553,304	99.8 %
Income (loss) from operations	(84,169)	(5.9)%	3,784	0.2 %
Interest expense, net	95,307	6.7 %	90,204	5.8 %
Income (loss) before income taxes	(179,476)	(12.6)%	(86,420)	(5.6)%
Provision for (benefit from) income taxes	(1,162)	— %	(86)	(0.1)%
Net income (loss)	(178,314)	(12.6)%	(86,334)	(5.5)%
Less: Net income (loss) attributable to noncontrolling interests	1,200	— %	1,048	0.1 %
Net income (loss) attributable to Quorum Health Corporation	\$(179,514)	(12.6)%	\$(87,382)	(5.6)%

The following table reconciles Adjusted EBITDA and Adjusted EBITDA, Adjusted for Divestitures to net income (loss), the most directly comparable U.S. GAAP financial measure (in thousands):

	Nine Months Ended September 30,	
	2018	2017
Net income (loss)	\$(178,314)	\$(86,334)
Interest expense, net	95,307	90,204
Provision for (benefit from) income taxes	(1,162)	(86)
Depreciation and amortization	52,015	63,441
EBITDA	(32,154)	67,225
Legal, professional and settlement costs	10,349	6,519
Impairment of long-lived assets and goodwill	72,198	21,461
Loss (gain) on sale of hospitals, net	8,927	(5,112)
Loss on closure of hospitals, net	18,195	—

Edgar Filing: Quorum Health Corp - Form 10-Q

Transition of transition services agreements	3,682	—
Transaction costs related to the Spin-off	—	204
Post-spin headcount reductions and executive severance	7,688	2,543
Adjusted EBITDA	88,885	92,840
Negative EBITDA of divested hospitals	21,290	20,510
Adjusted EBITDA, Adjusted for Divestitures	\$ 110,175	\$ 113,350

68

Revenues

The following table provides information related to our net operating revenues (dollars in thousands, except per adjusted admission amounts):

	Nine Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Consolidated:				
Net patient revenues	\$1,354,588	\$1,484,375	\$(129,787)	(8.7)%
Non-patient revenues	65,371	72,713	(7,342)	(10.1)%
Total net operating revenues	\$1,419,959	\$1,557,088	\$(137,129)	(8.8)%
Net patient revenues per adjusted admission	\$9,656	\$8,897	\$759	8.5%
Net operating revenues per adjusted admission	\$10,122	\$9,333	\$789	8.5%
Same-facility:				
Net patient revenues	\$1,331,907	\$1,265,465	\$66,442	5.3%
Non-patient revenues	64,884	71,116	(6,232)	(8.8)%
Total net operating revenues	\$1,396,791	\$1,336,581	\$60,210	4.5%
Net patient revenues per adjusted admission	\$9,850	\$9,264	\$586	6.3%
Net operating revenues per adjusted admission	\$10,330	\$9,785	\$545	5.6%

The following table provides information related to our net operating revenues by payor source (dollars in thousands):

	Nine Months Ended September 30,					
	2018		2017		2018 vs 2017	
	\$ Amount	% of Total	\$ Amount	% of Total	\$ Variance	Change in %
Consolidated:						
Medicare	\$398,477	28.1%	\$468,627	30.1%	\$(70,150)	(2.0)%
Medicaid	270,047	19.0%	292,380	18.8%	(22,333)	0.2%
Managed care and commercial	560,445	39.5%	583,073	37.4%	(22,628)	2.1%
Self-pay and self-pay after insurance	125,619	8.8%	140,296	9.0%	(14,677)	(0.2)%
Non-patient	65,371	4.6%	72,712	4.7%	(7,341)	(0.1)%
Total net operating revenues	\$1,419,959	100.0%	\$1,557,088	100.0%	\$(137,129)	
Same-facility:						
Medicare	\$387,812	27.8%	\$381,590	28.5%	\$6,222	(0.7)%
Medicaid	265,055	19.0%	256,211	19.2%	8,844	(0.2)%
Managed care and commercial	549,900	39.5%	501,592	37.6%	48,308	1.9%
Self-pay and self-pay after insurance	129,140	9.2%	126,071	9.4%	3,069	(0.2)%
Non-patient	64,884	4.5%	71,117	5.3%	(6,233)	(0.8)%
Total net operating revenues	\$1,396,791	100.0%	\$1,336,581	100.0%	\$60,210	

Edgar Filing: Quorum Health Corp - Form 10-Q

The following table provides information related to certain drivers of our net operating revenues:

	Nine Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Consolidated:				
Number of licensed beds at end of period	2,604	3,051	(447)	(14.7)%
Admissions	56,546	67,572	(11,026)	(16.3)%
Adjusted admissions	140,282	166,841	(26,559)	(15.9)%
Total surgeries	57,628	77,070	(19,442)	(25.2)%
Emergency room visits	424,417	504,500	(80,083)	(15.9)%
Medicare case mix index	1.43	1.42	0.01	0.7 %
Same-facility:				
Number of licensed beds at end of period	2,604	2,630	(26)	(1.0)%
Admissions	54,781	56,142	(1,361)	(2.4)%
Adjusted admissions	135,218	136,597	(1,379)	(1.0)%
Total surgeries	54,750	56,318	(1,568)	(2.8)%
Emergency room visits	407,090	406,188	902	0.2 %
Medicare case mix index	1.43	1.40	0.03	2.1 %

Net operating revenues for the nine months ended September 30, 2018 decreased \$137.1 million compared to the nine months ended September 30, 2017, consisting of a \$129.8 million decrease in net patient revenues and a \$7.3 million decrease in non-patient revenues. Our decrease in net patient revenues consisted of a \$196.2 million decline related to the divestitures group and a \$66.4 million increase related to our same-facility hospitals. Same-facility net patient revenues include \$24.4 million of revenues from the California HQAF program recognized in the nine months ended September 30, 2018 and \$7.3 million of revenues from the sale of the Illinois property tax credits, with no comparable revenues in the 2017 period. Excluding the California HQAF and Illinois property tax credits revenues of \$31.7 million, same-facility net patient revenues increased \$34.7 million due to an improved payor mix and an increase in rate and acuity. On a consolidated basis, admissions and adjusted admissions declined 16.3% and 15.9%, respectively, when comparing the nine months ended September 30, 2018 to the same period in 2017. On a same-facility basis, admissions and adjusted admissions decreased 2.4% and 1.0%, respectively, when comparing the nine months ended September 30, 2018 to the same period in 2017. The decrease in admissions and adjusted admissions was primarily a result of closing underperforming service lines and the termination of payor and physician contracts. The reduction in admissions was offset by an increase in our overall rate and acuity.

Salaries and Benefits

The following table provides information related to our salaries and benefits expenses (dollars in thousands, except per adjusted admission amounts):

	Nine Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Salaries and benefits	\$705,868	\$781,691	\$(75,823)	(9.7)%
Hospital operations salaries and benefits	\$641,110	\$713,348	\$(72,238)	(10.1)%
Hospital operations salaries and benefits per adjusted admission	\$4,570	\$4,276	\$294	6.9 %
Hospital operations man-hours per adjusted admission	110.2	105.6	4.7	4.4 %

Salaries and benefits decreased \$75.8 million for the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017. Salaries and benefits declined \$102.8 million related to the divestitures group. This decline was offset by an increase in same-facility salaries and benefits of \$27.0 million, of which \$2.2 million related to increased costs at our physician clinics as a result of recruitment efforts, \$7.7 million related to severance for headcount reductions and the remainder primarily related to merit increases at our facilities.

70

Supplies

The following table provides information related to our supplies expense (dollars in thousands, except per adjusted admission amounts):

	Nine Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Supplies	\$160,732	\$186,591	\$(25,859)	(13.9)%
Supplies per adjusted admission	\$1,146	\$1,118	\$28	2.5 %

Supplies expense decreased \$25.9 million for the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017. Supplies expense declined \$29.1 million related to the divestitures group, which was offset by an increase in same-facility supplies expense of \$3.2 million primarily due to an increase in orthopedic surgery cases at several of our larger facilities, which resulted in an increase in implant costs.

Other Operating Expenses

The following table provides information related to our other operating expenses (dollars in thousands):

	Nine Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Purchased services	\$116,537	\$130,155	\$(13,618)	(10.5)%
Taxes and insurance	100,313	92,782	7,531	8.1 %
Medical specialist fees	79,459	84,605	(5,146)	(6.1)%
Transition services agreements	43,284	47,736	(4,452)	(9.3)%
Repairs and maintenance	27,659	31,368	(3,709)	(11.8)%
Utilities	18,274	21,245	(2,971)	(14.0)%
Other miscellaneous operating expenses	55,384	58,503	(3,119)	(5.3)%
Total other operating expenses	\$440,910	\$466,394	\$(25,484)	(5.5)%

Other operating expenses decreased \$25.5 million for the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017. Other operating expenses declined \$64.3 million related to the divestitures group offset by an increase in same-facility other operating expenses of \$38.8 million. The same-facility increase was primarily due to a \$4.4 million increase in provider taxes associated with the California HQAF program with no comparable expenses in the 2017 period, an increase of \$7.8 million in taxes due to the recognition of sale of the Illinois property tax credits as an offset to net patient revenues in the current period whereas the amount was recognized as a reduction in taxes in the 2017 period, an increase of \$6.5 million in medical specialist fees due to the addition of new service lines and changes in hospital-based providers, and an increase of \$9.1 million in purchased services primarily related to software maintenance contracts and consulting services.

Depreciation and Amortization

Depreciation and amortization expense decreased \$11.4 million during the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017. This decrease was primarily due to the overall reduction in our long-lived assets due to the divestiture of five hospitals subsequent to the third quarter of 2017.

Rent

Rent expense decreased \$1.1 million during the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017. As a percentage of net operating revenues, rent expense was comparable for these respective periods.

Electronic Health Records Incentives Earned

Electronic health records incentives earned decreased \$3.9 million for the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017 primarily due to the decrease in activity as we move closer toward full implementation of EHR. See Note 2 — Basis of Presentation and Significant Accounting Policies in the accompanying consolidated financial statements for additional information on EHR.

Legal, Professional and Settlement Costs

Legal, professional and settlement costs increased \$3.8 million for the nine months ended September 30, 2018, compared to the nine months ended September 30, 2017. These costs included legal costs related to arbitration costs, regulatory claims, government investigations into reimbursement payments and other litigation matters. See Note 17 — Commitments and Contingencies in the accompanying consolidated financial statements for additional information on these matters.

Impairment of Long-Lived Assets and Goodwill

For the nine months ended September 30, 2018, we recognized \$72.2 million of impairment to long-lived assets which related to hospitals we identified as potential divestiture candidates for which we have received letters of intent. For the nine months ended September 30, 2017, we recognized \$21.5 million of impairment to long-lived assets and goodwill which related to hospitals classified as held for sale during the first quarter of 2017 and hospitals we identified as potential divestiture candidates for which we had received letters of intent.

Loss (Gain) on Sale of Hospitals, Net

For the nine months ended September 30, 2018, we recognized an \$8.9 million loss on the sales of hospitals, net, which included a net loss of \$7.9 million related to the sale of Clearview. We recognized a \$5.1 million gain on the sale of hospitals, net in the nine months ended September 30, 2017 primarily related to the sale of Trinity. See Note 4 — Divestitures in the accompanying consolidated financial statements for additional information on divestitures.

Loss on Closure of Hospitals, Net

For the nine months ended September 30, 2018, we recognized an \$18.2 million loss on closure of hospitals, net related to the closure of Affinity. We ceased operations at this hospital on February 11, 2018 and have certain continuing closures costs during the wind-down period. See Note 4 — Divestitures in the accompanying consolidated financial statements for additional information on divestitures.

Interest Expense, Net

The following table provides information related to interest expense, net (dollars in thousands):

	Nine Months Ended September 30,			
	2018	2017	\$ Variance	% Variance
Senior Credit Facility:				
Revolving Credit Facility	\$205	\$429	\$ (224)	(52.2)%
Term Loan Facility	53,174	48,795	4,379	9.0 %
ABL Credit Facility	1,115	1,507	(392)	(26.0)%
Senior Notes	34,865	34,886	(21)	(0.1)%
Amortization of debt issuance costs and discounts	7,249	6,271	978	15.6 %
All other interest expense (income), net	(1,301)	(1,684)	383	(22.7)%
Total interest expense, net	\$95,307	\$90,204	\$ 5,103	5.7 %

Interest expense, net increased \$5.1 million for the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017 primarily due to increased interest rates on our Term Loan Facility and increased amortization of debt issuance costs and discounts after the CS Second Amendment. See Liquidity and Capital Resources below and Note 7 — Long-Term Debt in the accompanying consolidated financial statements for additional information on our indebtedness.

Provision for (Benefit from) Income Taxes

The benefit from income taxes was \$1.2 million and \$0.1 million for the nine months ended September 30, 2018 and September 30, 2017, respectively. Our effective tax rates were 0.6% and 0.1% for the respective periods. The increase in the effective tax rate for the nine months ended September 30, 2018, when compared to the nine months ended

September 30, 2017 was primarily due to the impairment and disposal of certain indefinite-lived intangible assets and the change in expected realization of deferred tax assets under the new laws established by the Tax Act.

Net Income (Loss) Attributable to Noncontrolling Interests

Net income (loss) attributable to noncontrolling interests was \$1.2 million and \$1.0 million in the nine months ended September 30, 2018 and 2017, respectively. As a percentage of net operating revenues, it was comparable for the respective periods.

Liquidity and Capital Resources

Financial Outlook

Our primary sources of liquidity are cash flows from operations, proceeds from divestitures and available borrowing capacity under our revolving credit facilities. We believe that these amounts will be adequate to service our existing debt and finance internal growth and fund capital expenditures over the next 12 months and into the foreseeable future. Borrowings under our revolving credit facilities are intended to be used for working capital, capital expenditures and general corporate purposes. Our cash flows are negatively impacted by the significant amount of interest expense associated with the high debt leverage put in place to effect the Spin-off. Interest payments were \$77.4 million and \$79.7 million for the nine months ended September 30, 2018 and 2017,

respectively. In addition, California, a state in which we operate, is historically slow on payments for its Medicaid supplemental payment programs. As of September 30, 2018, receivables outstanding under the California state supplemental program were \$34.2 million.

We perform an ongoing strategic review of our hospitals based upon an analysis of financial performance, current competitive conditions, market demographic and economic trends and capital allocation requirements. As part of this strategy, we engage in initiatives to divest or close nonstrategic or underperforming hospitals and outpatient service facilities which, in turn, will allow us to reduce our corporate indebtedness and refine our hospital portfolio to become a strategic and sustainable group of hospitals and outpatient service facilities with higher operating margins. To date, we have received combined proceeds of \$86.5 million, including \$8.0 million of cash in escrow, from the sale of three hospitals in 2018, five hospitals in 2017 and two hospitals in 2016, which have been used to pay down \$84.8 million on our Term Loan Facility. We have targeted additional hospitals that we intend to sell or close by the end of 2019.

Statements of Cash Flows

As of September 30, 2018, we have \$8.0 million of proceeds on the sale of Clearview, which occurred on March 31, 2018, recorded as restricted cash. This portion of the total proceeds of \$37.4 million was being held in an escrow account subject to resolution of certain outstanding litigation. This matter was resolved in October 2018 and we received the \$8.0 million of proceeds during October of 2018. At September 30, 2018, we did not expect this legal matter to reach final settlement within the next twelve months. As a result, we have classified the amount held in escrow in other long-term assets in our consolidated balance sheets as of this date.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in our consolidated balance sheets to our consolidated statements of cash flow (dollars in thousands):

	September 30,		December 31,	
	2018	2017	2017	2016
Cash and cash equivalents	\$6,066	\$15,736	\$5,617	\$25,455
Restricted cash included in other long-term assets	8,000	—	—	—
Cash, cash equivalents and restricted cash	\$14,066	\$15,736	\$5,617	\$25,455

Three Months Ended September 30, 2018 Compared to Three Months Ended September 30, 2017

The following table provides a summary of our cash flows (in thousands):

	Three Months Ended September 30,		
	2018	2017	\$ Variance
Net cash provided by (used in) operating activities	\$28,334	\$9,744	\$18,590
Net cash provided by (used in) investing activities	(10,112)	(5,479)	(4,633)
Net cash provided by (used in) financing activities	(14,978)	(10,934)	(4,044)
Net change in cash, cash equivalents and restricted cash	\$3,244	\$(6,669)	\$9,913

Net cash provided by operating activities was \$28.3 million for the three months ended September 30, 2018 compared to \$9.7 million for the three months ended September 30, 2017, an increase of \$18.6 million. In the 2018 period, our cash flow from operations was favorably impacted by \$3.8 million in HQAF payments received during the three months ended September 30, 2018. In the 2017 period, our cash flow from operations was favorably impacted by \$7.8 million of cash received related to the sale of the Illinois property tax credits and \$5.0 million of accrued interest on

our term loan facility. All other changes in operating assets and liabilities on a comparative basis for the three months ended September 30, 2018 and 2017 were considered to be part of our normal business operations.

Net cash used in investing activities was \$10.1 million for the three months ended September 30, 2018 compared to \$5.5 million for the three months ended September 30, 2017, a \$4.6 million increase. In the 2018 period, we sold McKenzie for proceeds of \$1.7 million but did not receive the cash until October 2018. In the 2017 period, we sold Sunbury and Lock Haven for combined proceeds of \$9.1 million. We had a decrease in capital expenditures for property and equipment of \$1.9 million and a decrease in capital expenditures for software of \$2.5 million, primarily due to reduced spending as a result of hospital divestitures.

Net cash used in financing activities was \$15.0 million for the three months ended September 30, 2018 compared to \$10.9 million for the three months ended September 30, 2017. We had a reduction in our net borrowings under revolving credit facilities of \$9.0 million in the 2018 period, when compared to the 2017 period. In the 2017 period, we paid down \$4.2 million on our Term Loan Facility utilizing proceeds from divestitures.

Edgar Filing: Quorum Health Corp - Form 10-Q

Nine Months Ended September 30, 2018 Compared to Nine Months Ended September 30, 2017

The following table provides a summary of our cash flows (in thousands):

	Nine Months Ended September 30,		
	2018	2017	\$ Variance
Net cash provided by (used in) operating activities	\$42,935	\$789	\$42,146
Net cash provided by (used in) investing activities	2,886	(29,521)	32,407
Net cash provided by (used in) financing activities	(37,372)	19,013	(56,385)
Net change in cash, cash equivalents and restricted cash	\$8,449	\$(9,719)	\$18,168

Net cash provided by operating activities was \$42.9 million for the nine months ended September 30, 2018 compared to \$0.8 million for the nine months ended September 30, 2017, an increase of \$42.1 million. In the 2018 period, our cash flow from operations was favorably impacted by \$12.2 million in HQAF payments received during the nine months ended September 30, 2018 and unfavorably impacted by \$11.8 million of cash outlay related to the Affinity closure. In the 2017 period, our cash flow from operations was favorably impacted by \$7.8 million of cash received related to the sale of the Illinois property tax credits. All other changes in operating assets and liabilities on a comparative basis for the nine months ended September 30, 2018 and 2017 were considered to be part of our normal business operations.

Net cash provided by investing activities was \$2.9 million for the nine months ended September 30, 2018 compared to net cash used in investing activities of \$29.5 million for the nine months ended September 30, 2017, a \$32.4 million increase. Our expenditures for property and equipment decreased \$15.8 million on a consolidated basis, which included a \$16.8 million reduction in spending on the patient tower and expanded surgical capacity project at our Springfield, Oregon hospital as we are nearing completion. Our expenditures for software decreased \$4.6 million. In addition, we had proceeds of \$39.2 million in the 2018 period from the sale of hospitals compared to \$29.2 million of proceeds from the sale of hospitals in the 2017 period. The 2018 proceeds do not include \$1.7 million from the sale of McKenzie as the cash was not received until October 2018 and \$8.0 million held in escrow related to the Clearview sale.

Of the \$37.4 million proceeds received on the sale of Clearview in the 2018 period, \$8.0 million was maintained in an escrow account, as previously discussed, and is reflected as restricted cash in our consolidated statement of cash flows. This restricted cash is recognized in other long-term assets on our consolidated balance sheets as of September 30, 2018.

Net cash used in financing activities was \$37.4 million for the nine months ended September 30, 2018 compared to net cash provided by financing activities of \$19.0 million for the nine months ended September 30, 2017, a \$56.4 million decrease. In the 2018 period, we paid \$30.5 million on our Term Loan Facility, paid \$2.3 million of debt issuance costs related to the CS Second Amendment, which was completed on March 14, 2018, and made cash distributions of \$1.5 million to noncontrolling investors. In the 2017 period, we had net borrowings on our credit facilities of \$45.0 million, paid down \$16.5 million on our Term Loan Facility, incurred \$3.1 million of debt issuance costs related to the CS Amendment and made cash distributions of \$3.9 million to noncontrolling investors. Our debt repayments in both the nine months ended September 30, 2018 and 2017, other than the Term Loan Facility payment, primarily related to our capital lease obligation on the corporate office.

Capital Expenditures

Capital expenditures for property, equipment and software were \$36.4 million and \$56.8 million for the nine months ended September 30, 2018 and 2017, respectively. In addition, we had \$3.0 million and \$6.8 million of capital expenditures related to property and equipment accrued in accounts payable at September 30, 2018 and December 31, 2017, respectively. Capital expenditures during each of the nine months ended September 30, 2018 and 2017 primarily related to the patient tower and expanded surgical capacity project at our Springfield, Oregon hospital, as described below, and to purchases of equipment and minor renovations at our hospitals and investments in information systems infrastructure.

We are in the process of completing construction on a new patient tower and expanding the surgical capacity at our hospital in Springfield, Oregon. During the three months ended September 30, 2018 and 2017, we incurred costs of \$3.6 million and \$6.5 million, respectively, and incurred costs of \$14.3 million and \$31.1 million during the nine months ended September 30, 2018 and 2017, respectively, related to this project. As of September 30, 2018, we have incurred a total of \$97.3 million of costs for this project. The total estimated cost for this project, including equipment costs, is estimated to be approximately \$105 million. The project is expected to be substantially complete by the end of 2018.

Capital Resources

Our net working capital was \$165.8 million and \$220.8 million as of September 30, 2018 and December 31, 2017, respectively, a \$55.0 million decrease. This decrease was primarily related to our divestiture activity and a reduction in amounts due from third-party payors as we received \$38.6 million in HQAF payments during the nine months ended September 30, 2018 which was used to pay down our Term Loan Facility.

Long-Term Debt

The following table provides a summary of activity related to our long-term debt (in thousands):

Nine Months Ended September 30, 2018

	Total Debt at Beginning of Period	Borrowings	Repayments	Debt Issuance Costs Payments	Amortization	Total Debt at End of Period
Senior Credit Facility:						
Revolving Credit Facility, maturing 2021	\$—	\$—	\$—	\$—	\$—	\$—
Term Loan Facility, maturing 2022	831,158	—	(30,462)	—	—	800,696
ABL Credit Facility, maturing 2021	—	368,000	(368,000)	—	—	—
Senior Notes, maturing 2023	400,000	—	—	—	—	400,000
Unamortized debt issuance costs and discounts	(42,934)	—	—	(2,268)	7,249	(37,953)
Capital lease obligations	24,411	—	(804)	—	—	23,607
Other debt	1,255	157	(534)	—	—	878
Total debt	1,213,890	368,157	(399,800)	(2,268)	7,249	1,187,228
Less: Current maturities of long-term debt	(1,855)					(1,544)
Total long-term debt	\$1,212,035	\$368,157	\$(399,800)	\$(2,268)	\$7,249	\$1,185,684

The following table provides a summary of our long-term debt, allocated between fixed and variable debt (dollars in thousands):

	September 30, 2018	
	\$ Amount	% of Total Debt
Fixed	\$424,485	34.6 %
Variable	800,696	65.4 %
Total debt, excluding unamortized debt issuance costs and discounts	\$1,225,181	100.0%

Senior Credit Facility

In connection with the Spin-off, on April 29, 2016, we entered into a credit agreement (the “CS Agreement”), among us, the lenders party thereto and Credit Suisse AG, Cayman Islands Branch, as administrative agent and collateral agent. On April 11, 2017, we executed an agreement with our Senior Credit Facility lenders to amend certain provisions of our Senior Credit Facility (the “CS Amendment”), as described below. On March 14, 2018, we executed a second agreement with our Senior Credit Facility lenders to amend certain provisions of our Senior Credit Facility (the “CS Second Amendment”), as described below.

The CS Agreement initially provided for an \$880 million senior secured term loan facility (the “Term Loan Facility”) and a \$100 million senior secured revolving credit facility (the “Revolving Credit Facility”) and, together with the Term Loan Facility, the “Senior Credit Facility”). The Term Loan Facility was issued at a discount of \$17.6 million, or 98% of par value, and has a maturity date of April 29, 2022, subject to customary acceleration events and repayment,

extension or refinancing. The Revolving Credit Facility has a maturity date of April 29, 2021, subject to certain customary acceleration events and repayment, extension or refinancing. The CS Amendment reduced the Revolving Credit Facility's borrowing capacity from \$100 million to \$87.5 million until December 31, 2017, at which time the borrowing capacity decreased to \$75.0 million. The CS Second Amendment further reduced the Revolving Credit Facility's capacity to \$62.5 million through maturity, effective with the execution of the amendment on March 14, 2018.

The CS Agreement contains customary covenants, including a maximum permitted Secured Net Leverage Ratio, as determined based on 12 month trailing Consolidated EBITDA, as defined in the CS Agreement. On April 11, 2017, we executed the CS Amendment with our Senior Credit Facility lenders to amend the calculation of the Secured Net Leverage Ratio beginning July 1, 2017 through maturity, among other provisions. The CS Second Amendment, which was executed on March 14, 2018, further amended the Secured Net Leverage Ratio for the period July 1, 2017 through maturity. As of September 30, 2018, we had a Secured Net Leverage Ratio of 4.15 to 1.00 implying additional borrowing capacity of \$167.0 million as of September 30, 2018.

After giving effect to the CS Amendment and the CS Second Amendment, the maximum Secured Net Leverage Ratio permitted under the CS Agreement, as determined based on 12 month trailing Consolidated EBITDA and as defined in the CS Agreement, follows:

Period	Maximum Secured Net Leverage Ratio
Period from January 1, 2017 to June 30, 2017	4.50 to 1.00
Period from July 1, 2017 to June 30, 2018	4.75 to 1.00
Period from July 1, 2018 to December 31, 2019	5.00 to 1.00
Period from January 1, 2020 and thereafter	4.50 to 1.00

In addition to amending the calculation of the Secured Net Leverage Ratio and the Maximum Secured Net Leverage Ratio, the CS Amendment and CS Second Amendment also affected other terms of the CS Agreement as follows:

• Through April 29, 2022, we are required to use asset sales proceeds to make mandatory redemptions under the Term Loan Facility.

• Through December 31, 2018, we may request to exercise Incremental Term Loan Commitments, as defined in the CS Agreement, only if the Secured Net Leverage Ratio, adjusted for the requested Incremental Term Loan borrowing, is below 3.35 to 1.00. After December 31, 2018, we may request to exercise Incremental Term Loan Commitments for the greater of \$100 million or an amount which would produce a Secured Net Leverage Ratio of 3.35 to 1.00.

• Through December 31, 2018, we are allowed to incur Permitted Additional Debt, as defined in the CS Agreement, as long as our Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 4.50 to 1.00. After December 31, 2018, we may incur Permitted Additional Debt, as long as our Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 5.50 to 1.00.

Prior to the CS Amendment, interest under the Term Loan Facility accrued, at our option, at adjusted LIBOR, subject to statutory reserves and a floor of 1% plus 5.75%, or the alternate base rate plus 4.75%. Following the CS Amendment, interest under the Term Loan Facility accrues, at our option, at adjusted LIBOR, subject to statutory reserves and a floor of 1% plus 6.75%, or the alternate base rate plus 5.75%. The effective interest rate on the Term Loan Facility was 9.29% as of September 30, 2018. Interest on outstanding borrowings under the Revolving Credit Facility accrues, at our option, at adjusted LIBOR, subject to statutory reserves and a floor of 0% plus 2.75%, or the alternate base rate plus 1.75%, and remains unchanged under the CS Amendment and the CS Second Amendment.

As of September 30, 2018, we had no borrowings outstanding on the Revolving Credit Facility and had \$13.7 million of letters of credit outstanding that were primarily related to the self-insured retention levels of professional and general liability and workers' compensation liability insurance as security for the payment of claims. As of September 30, 2018, we had a borrowing capacity under our Revolving Credit Facility of \$48.8 million.

ABL Credit Facility

In connection with the Spin-off on April 29, 2016, we entered into an ABL Credit Agreement (the "UBS Agreement," and together with the CS Agreement, collectively, the "Credit Agreements"), among us, the lenders party thereto and UBS AG, Stamford Branch ("UBS"), as administrative agent and collateral agent. On April 11, 2017, we executed an amendment to the UBS Agreement with its lender party thereto, which aligned the provisions of the UBS Agreement with the CS Amendment. The UBS Agreement provides for a \$125 million senior secured asset-based revolving credit facility (the "ABL Credit Facility"). The available borrowings from the ABL Credit Facility, which are based on eligible patient accounts receivable, are used for working capital and general corporate purposes. As of September 30, 2018, we had no borrowings outstanding on the ABL Credit Facility and borrowing capacity of \$120.3 million.

The ABL Credit Facility has a maturity date of April 29, 2021, subject to customary acceleration events and repayment, extension or refinancing. Interest on outstanding borrowings under the ABL Credit Facility accrues, at our option, at a base rate or LIBOR, subject to statutory reserves and a floor of 0%, except that all swingline borrowings will accrue interest based on the base rate, plus an applicable margin determined by the average excess availability under the ABL Credit Facility for the fiscal quarter immediately preceding the date of determination. The applicable margin ranges from 1.75% to 2.25% for LIBOR advances and from 0.75% to 1.25% for base rate advances.

The ABL Credit Facility has a “Covenant Trigger Event” definition that requires us to maintain excess availability under the ABL Credit Facility equal to or greater than the greater of (i) \$12.5 million and (ii) 10% of the aggregate commitments under the ABL Credit Facility. If a Covenant Trigger Event occurs, then we are required to maintain a minimum Consolidated Fixed Charge Ratio of 1.10 to 1.00 until such time that a Covenant Trigger Event is no longer continuing. In addition, if excess availability under the ABL

Credit Facility were to fall below the greater of (i) 12.5% of the aggregate commitments under the ABL Credit Facility and (ii) \$15.0 million, then a “Cash Dominion Event” would be triggered upon which the lenders could assume control of our cash.

Credit Agreement Covenants

In addition to the specific covenants described above, the Credit Agreements contain customary negative covenants, which limit our ability to, among other things, incur additional indebtedness, create liens, make investments, transfer assets and merge or acquire assets, and make restricted payments, including dividends, distributions, and specified payments on other indebtedness. They include customary events of default, including payment defaults, material breaches of representations and warranties, covenant defaults, default on other material indebtedness, customary Employee Retirement Income Security Act events of default, bankruptcy and insolvency, material judgments, invalidity of liens on collateral, change of control or cessation of business. The Credit Agreements also contain customary affirmative covenants and representations and warranties.

Senior Notes

On April 22, 2016, we issued \$400 million aggregate principal amount of 11.625% Senior Notes due 2023, pursuant to the Indenture. The Senior Notes were issued at a discount of \$6.9 million, or 1.734%, in a private placement and are senior unsecured obligations guaranteed on a senior basis by certain of our subsidiaries (the “Guarantors”). The Senior Notes mature on April 15, 2023 and bear interest at a rate of 11.625% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, which began on October 15, 2016. Interest on the Senior Notes accrues from the date of original issuance and is calculated on the basis of a 360-day year comprised of twelve 30-day months. The effective interest rate on the Senior Notes was 12.49% as of September 30, 2018.

The Indenture contains covenants that, among other things, limit our ability and certain of our subsidiaries’ ability to incur or guarantee additional indebtedness, pay dividends or make other restricted payments, make certain investments, create or incur certain liens, sell assets and subsidiary stock, transfer all or substantially all of our assets or enter into merger or consolidation transactions.

On May 17, 2017, we exchanged the 11.625% Senior Notes due 2023 (the “Initial Notes”) in the aggregate principal amount of \$400 million, which were not registered under the Securities Act of 1933, as amended (the “Securities Act”), for a like principal amount of 11.625% Senior Notes due 2023 (the “Exchange Notes”), which have been registered under the Securities Act. The Initial Notes were substantially identical to the Exchange Notes, except that the Exchange Notes are registered under the Securities Act and are not subject to the transfer restrictions and certain registration rights agreement provisions applicable to the Initial Notes.

On and after April 15, 2019, we are entitled, at our option, to redeem all or a portion of the Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices, plus accrued and unpaid interest, if any, to the redemption date. The redemption prices are expressed as a percentage of the principal amount on the redemption date. Holders of record on the relevant record date have the right to receive interest due on the relevant interest payment date. In addition, prior to April 15, 2019, we may redeem some or all of the Senior Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, plus a “make whole” premium, as set forth in the Indenture. We are entitled to redeem up to 35% of the aggregate principal amount of the Senior Notes until April 15, 2019 with the net proceeds from certain equity offerings at the redemption price set forth in the Indenture.

The following table provides a summary of the redemption dates and prices related to the Senior Notes:

Edgar Filing: Quorum Health Corp - Form 10-Q

Period	Redemption Prices	
Period from April 15, 2019 to April 14, 2020	108.719	%
Period from April 15, 2020 to April 14, 2021	105.813	%
Period from April 15, 2021 to April 14, 2022	102.906	%
Period from April 15, 2022 to April 14, 2023	100.000	%

Debt Issuance Costs and Discounts

The following table provides a summary of unamortized debt issuance costs and discounts (in thousands):

	September 30, 2018	December 31, 2017
Debt issuance costs	\$ 34,533	\$ 32,265
Debt discounts	24,536	24,536
Total debt issuance costs and discounts at origination	59,069	56,801
Less: Amortization of debt issuance costs and discounts	(21,116)	(13,867)
Total unamortized debt issuance costs and discounts	\$ 37,953	\$ 42,934

Capital Lease Obligations and Other Debt

Our debt from capital lease obligations primarily relates to our corporate office in Brentwood, Tennessee. As of September 30, 2018, this capital lease obligation was \$17.4 million. Other debt consists of physician loans and miscellaneous notes payable to banks.

Debt Maturities

The following table provides a summary of our debt maturities for the next five years and thereafter (in thousands):

	September 30, 2018
Remainder of 2018	\$403
2019	1,549
2020	1,621
2021	1,639
2022	802,096
Thereafter	417,873
Total debt, excluding unamortized debt issuance costs and discounts	\$1,225,181

Noncontrolling Interests and Redeemable Noncontrolling Interests

Our financial statements include all assets, liabilities, revenues and expenses of less than 100% owned entities that we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. Certain of our consolidated subsidiaries have noncontrolling physician ownership interests with redemption features that require us to deliver cash upon the occurrence of certain events outside our control, such as the retirement, death, or disability of a physician-owner. We record the carrying amount of redeemable noncontrolling interests at the greater of: (1) the initial carrying amount increased or decreased for the noncontrolling interests' share of cumulative net income (loss), net of cumulative amounts distributed, if any, or (2) the redemption value. As of September 30, 2018, we had redeemable noncontrolling interests of \$2.3 million and non-redeemable noncontrolling interests of \$14.5 million that are included in our consolidated balance sheets.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to market risk associated with changes in interest rates on our variable rate long-term debt. In connection with the Spin-off, on April 29, 2016, we entered into two credit agreements, the Senior Credit Facility and the ABL Credit Facility, that subject us to variable interest rates tied to LIBOR or a base rate. As of September 30, 2018, we had outstanding principal amount of debt, excluding unamortized debt issuance costs and discounts, of \$800.7 million which was subject to variable rates of interest. If the interest rates on our variable rate long-term debt outstanding as of September 30, 2018, after taking into consideration the 1% floor on our Term Loan Facility, was 100 basis points higher for the nine months ended September 30, 2018, the additional interest expense impacting net income (loss) would have been \$6.1 million, or \$0.21 per basic and diluted share. We do not currently have any derivative or hedging arrangements, or other known exposures, to changes in interest rates.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed with the objective of providing reasonable assurance that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer (principal executive officer) (“CEO”) and chief financial officer (principal financial officer) (“CFO”), as appropriate to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Management, with the participation of our CEO and our CFO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15-15(e) of the Exchange Act, as of September 30, 2018, the end of the period covered by this Quarterly Report on Form 10-Q. Based on their evaluation, as of the end of the period covered by this Quarterly Report on Form 10-Q, the Company’s CEO and CFO have concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective because of the material weakness in our internal control over financial reporting described below. Notwithstanding such material weakness in internal control over financial reporting, our CEO and CFO have concluded that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, present fairly, in all material respects, our results of operations, financial position and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.

As previously disclosed in our 2017 Annual Report on Form 10-K, we identified a deficiency as it related to the controls intended to properly document and review on a timely basis our analysis of self-pay patient accounts receivable at a more comprehensive and disaggregated level related to our adoption of ASU 2014-09 Revenue from Contracts with Customers. We concluded that the deficiency constitutes a material weakness in our internal control over financial reporting. There were no material errors in the financial results or balances identified as a result of the control deficiency, and there was no restatement of prior period financial statements and no change in previously released financial results were required as a result of this control deficiency.

We have implemented a remediation plan to address the control deficiency that led to the material weakness. The remediation plan is ongoing and currently includes the following:

- Evaluating the effectiveness of specific new procedures related to the disaggregated analysis of the estimated transaction price, as determined by reducing our standard billing charges by any contractual adjustments, discounts and implicit price concessions, related to our self-pay and self-pay after insurance revenue that conforms to the requirements under ASC 2014-09; and
- Evaluating the effectiveness of specific review procedures designed to enhance our controls over the preparation of the disaggregated estimated transaction price, as determined by reducing our standard billing charges by any contractual adjustments, discounts and implicit price concessions, related to our self-pay and self-pay after insurance revenue.

Management believes that the above measures will help to effectively remediate the control deficiency that gave rise to this material weakness. Our material weaknesses will not be considered remediated until new internal controls are operational for a period of time and are tested, and management concludes that these controls are operating effectively. We anticipate that this material weakness will be remediated by the end of 2018.

We can give no assurance that the measures we have taken will remediate this material weakness or that additional material weaknesses will not arise in the future. Management will continue to assess the effectiveness of its remediation efforts in this matter in

connection with its evaluations of internal control over financial reporting. We will continue to monitor the effectiveness of these and other processes, procedures, and controls and will make any further changes management determines to be appropriate.

Changes in Internal Control over Financial Reporting

Except as described above, there have been no changes in our internal control over financial reporting during the three months ended September 30, 2018 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

80

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are subject to lawsuits and other legal matters arising in the ordinary course of our business, including claims of damages for personal injuries, medical malpractice, breach of hospital management contracts, breach of other contracts, wrongful restriction of or interference with physicians' staffing privileges and other employment-related claims. In certain of these claims, plaintiffs request payment for damages, including punitive damages that may not be covered by our insurance policies.

Healthcare facilities are also subject to the regulation and oversight of various federal and state governmental agencies. The healthcare industry has seen numerous ongoing investigations related to compliance and billing practices and hospitals, in particular, continue to be the subject of governmental fraud and abuse programs and a primary enforcement target for the OIG and DOJ. From time to time, we detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement payment practices or financial relationships with physicians. We avail ourselves of various mechanisms to address potential overpayments arising out of these issues, including repayment of claims, rebilling of claims, and participation in voluntary disclosure protocols offered by CMS and the OIG. Participating in voluntary repayment of claims and voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action. Additionally, under the federal False Claims Act, private parties have the right to bring qui tam, or "whistleblower," suits against healthcare facilities that submit false claims for payments to, or improperly retain overpayments from, governmental payors. Some states have adopted similar state whistleblower and false claims provisions. Qui tam or "whistleblower" actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act's requirements for filing such suits. As a result, they could lead to proceedings without our knowledge. Certain of our healthcare facilities have received, and from time to time other healthcare facilities may receive, inquiries or subpoenas from fiscal intermediaries or federal and state agencies. Any proceedings against us may involve potentially substantial settlement amounts, as well as the possibility of civil, criminal, or administrative fines, penalties or other sanctions which could be material. Settlements of suits involving Medicare and Medicaid issues routinely require both monetary payments as well as corporate integrity agreements from the offending healthcare company. Depending on how the underlying conduct is interpreted by the inquiring or investigating federal or state agency, the resolution could have a material adverse effect on our results of operations, financial position and cash flows.

In connection with the Spin-off, CHS agreed to indemnify us for certain liabilities relating to outcomes or events occurring prior to the closing of the Spin-off, including (i) certain claims and proceedings known to be outstanding on or prior to the Spin-off and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to our healthcare facilities prior to the closing date of the Spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by CHS, including professional and general liability and workers' compensation liability. In this regard, CHS will continue to be responsible for certain Health Management Associates, Inc. legal matters covered by its contingent value rights agreement that relate to the portion of CHS's business now held by us. Notwithstanding the foregoing, CHS is not indemnifying us in respect of any claims or proceedings arising out of, or related to, the business operations of QHR at any time or our compliance with the Corporate Integrity Agreement ("CIA") between CHS and the OIG. Subsequent to the Spin-off, the OIG entered into an "Assumption of CIA Liability Letter" with us reiterating the applicability of the CIA to certain of our hospitals, although the OIG declined to enter into a separate agreement with us.

We do not control and cannot predict with certainty the progress or final outcome of discussions with government agencies, investigations and legal proceedings against us. Therefore, the final amounts paid to resolve such matters,

claims and obligations could be material and could materially differ from amounts currently recorded, if any. Any such changes in our estimates or any adverse judgments could materially adversely impact our future results of operations, financial position and cash flows.

We have included a discussion of legal proceedings below, some, or all, of which may not be required to be disclosed in this Part II, Item 1 under SEC rules due to the nature of our business; however, we believe that the discussion of these open legal matters may provide useful information to security holders or other readers of this Quarterly Report on Form 10-Q. The proceedings discussed below do not include claims and lawsuits covered by professional and general liability or employment practices insurance and risk retention programs, none of which claims or lawsuits would in any event be required to be disclosed in this Part II, Item 1 under SEC rules. The legal matters referenced below are also discussed in Note 17 – Commitments and Contingencies to the accompanying consolidated financial statements.

With respect to all legal, regulatory and governmental proceedings, we consider the likelihood of a negative outcome. If we determine the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, we record an accrual for the estimated amount of loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and we are able to determine an estimate of the amount of possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, we disclose the estimate of the amount of possible loss or range of loss. However, we are unable to estimate an amount of possible loss or range of loss in some instances based on the significant uncertainties involved in, or the preliminary nature of, certain legal, regulatory and governmental matters.

Commercial Litigation and Other Lawsuits

• **Arbitration with Community Health Systems, Inc.** On August 4, 2017, we received a demand for arbitration from CHS seeking payment of certain amounts that we have withheld pursuant to the Shared Services Centers Transition Services Agreement (the “SSC TSA”) and the Computer and Data Processing Transition Services Agreement (the “IT TSA”). We contend that the amounts are not payable to CHS and were not properly billed by CHS under the agreements. The matter is pending before the American Arbitration Association. CHS seeks payment of approximately \$12.1 million relating to these two transition services agreements. We are vigorously contesting the charges as not payable to CHS under the transition services agreements and have made counterclaims that include, among other things, termination of the SSC TSA, a ruling that the IT TSA is terminable at our option (as described below), and substantial damages we believe we have suffered as a result of the transition services agreements and other actions taken by CHS in connection with the Spin-off. Additionally, on March 19, 2018, we received notice from CHS that CHS was seeking to terminate, effective September 30, 2018, the SSC TSA and the IT TSA and to impose a September 30, 2018 deadline for completion of the transition services under the SSC TSA and IT TSA, as a result of alleged breaches by the Company of the agreements. The notice from CHS also provided an indication of CHS’s preference to terminate the Receivables Collection Agreement, the Eligibility Screening Services Agreement, and the Billing and Collection Agreement. We amended our counterclaims to include allegations that CHS’s attempt to terminate the SSC TSA and IT TSA and to impose a September 30, 2018 deadline for completing the transition of services under those contracts violated the terms of the contracts and was invalid and without effect. The validity and effectiveness of CHS’s attempt to terminate the SSC TSA and IT TSA and to impose a September 30, 2018 deadline was litigated during the course of arbitration proceedings held in late June 2018. After hearing testimony regarding the termination issues, the arbitration panel ruled that each of the SSC TSA and IT TSA will continue in effect according to their original terms through 2021, subject to any agreement by the parties to terminate the SSC TSA and the IT TSA at an earlier time. The panel ordered that, after the date of the ruling, we would prospectively pay the amounts invoiced under the TSAs as billed, but deferred ruling on the parties’ economic claims related to the TSAs. The arbitration reconvened October 1, 2018 with QHC presenting our counter-claims and defenses that certain amounts were not payable to CHS. The arbitration concluded October 9, 2018 and a decision is expected in mid-January 2019. We are unable to predict the outcome of this matter; however, it is reasonably possible that we may incur a loss in connection with this matter. Under some circumstances, losses incurred in connection with adverse outcomes in this matter could be material. See Item 1A. Risk Factors in our Quarterly Report Form 10-Q for the quarterly period ended March 31, 2018.

• **Zwick Partners LP and Aparna Rao, Individually and On Behalf of All Others Similarly Situated v. Quorum Health Corporation, Community Health Systems, Inc., Wayne T. Smith, W. Larry Cash, Thomas D. Miller and Michael J. Culotta.** On September 9, 2016, a shareholder filed a purported class action in the United States District Court for the Middle District of Tennessee against QHC and certain of our officers. The Amended Complaint, filed on September 13, 2017, purports to be brought on behalf of a class consisting of all persons (other than defendants) who purchased or otherwise acquired securities of QHC between May 2, 2016 and August 10, 2016 and alleges that we and certain of our officers violated federal securities laws, including Sections 10(b) and/or 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, by making alleged false and/or misleading statements and failing to disclose certain information regarding aspects of our business, operations and compliance policies. On April 17, 2017, Plaintiff filed a Second Amended Complaint adding additional defendants, CHS, Wayne T. Smith and W. Larry Cash. On June 23, 2017, we filed a motion to dismiss, which Plaintiff opposed on August 22, 2017. On April 19, 2018, the Court denied our motion to dismiss, and we filed our answer to the Second Amended Complaint on May 18, 2018. On July 13, 2018, Plaintiff filed its motion for class certification, which Defendants opposed on August 31, 2018. The motion for class certification is currently pending. On September 14, 2018, Plaintiff filed a Third Amended Complaint adding additional alleged misstatements. On October 12, 2018, Defendants moved to dismiss the new allegations, which motion is currently pending. The case is now in discovery, and we are vigorously defending ourselves in this matter. We are unable to predict the outcome of this matter. However, it is reasonably possible that we may incur a loss in connection with this matter. We are unable to reasonably estimate the amount or range of such reasonably possible

loss because discovery has only recently started and the case remains in its early stages. Under some circumstances, losses incurred in connection with adverse outcomes in this matter could be material.

•United Tort Claimants v. Quorum Health Resources, LLC (U.S. Bankruptcy Court for the District of New Mexico); Douthitt - Dugger, et al. v. Quorum Health Resources, LLC (Bernalillo County, New Mexico District Court). Plaintiffs sued QHR and Gerald Champion Regional Medical Center in New Mexico state court and bankruptcy court arising from surgical procedures alleged to have been experimental and performed by an unqualified doctor. The parties have now agreed to a global settlement of the United Tort Claimants (“UTC”) claims for a confidential amount to be fully funded by Lexington Insurance Company (“Lexington”). The specific language of releases and related settlement documents is being negotiated and will be subject to bankruptcy court approval.

82

Lexington Insurance Company v. Quorum Health Resources, LLC, et al. (Williamson County, Tennessee Chancery Court)) Lexington has sued QHR in Williamson County, Tennessee seeking a judicial declaration that the UTC's claims and the cost of defending QHR are not covered by Lexington. Lexington has now agreed not to seek reimbursement from QHR (1) for any part of the settlement with UTC (as described above); or (2) for the cost of defending QHR in the UTC litigation in New Mexico. The carrier has also agreed not to seek appellate review of prior court rulings in QHR's favor on coverage issues. While QHR believes these agreements have been adequately confirmed with Lexington, further proceedings will be necessary in the Tennessee trial court to establish these agreements in a court order. QHR has asserted bad faith claims against Lexington and excess carrier Ironshore in the Tennessee state court action, which are expected to be set for trial in 2019. We have concluded that there is a remote likelihood of a material loss in these matters, and as a result, do not believe that either the UTC litigation in New Mexico nor the insurance coverage litigation in Tennessee state court will have a material adverse effect on our operating results, financial position or liquidity.

R2 Investments, LDC v. Quorum Health Corporation, Community Health Systems, Inc., Wayne T. Smith, W. Larry Cash, Thomas D. Miller, Michael J. Culotta, John A. Clerico, James S. Ely, III, John A. Fry, William Norris Jennings, Julia B. North, H. Mitchell Watson, Jr. and H. James Williams. On October 25, 2017, a shareholder filed an action in the Circuit Court of Williamson County, Tennessee against us and certain of our officers and directors and CHS and certain of its officers and directors. The complaint alleges that the defendants violated the Tennessee Securities Act and common law by, among other things, making alleged false and/or misleading statements and failing to disclose certain information regarding aspects of our business, operations and financial condition. Plaintiff is seeking rescissory, compensatory, and punitive damages. We filed a motion to dismiss the action on January 16, 2018, which Plaintiff opposed on March 5, 2018. On May 11, 2018, the Court denied our motion to dismiss. We subsequently filed an answer to the complaint, and the case is now in discovery. We are vigorously defending ourselves in this matter. We are unable to predict the outcome of this matter. However, it is reasonably possible that we may incur a loss in connection with this matter. We are unable to reasonably estimate the amount or range of such reasonably possible loss because discovery has only recently started and the case remains in its early stages. Under some circumstances, losses incurred in connection with adverse outcomes in this matter could be material.

Harvey Horwitz, Derivatively on Behalf of Quorum Health Corporation v. Thomas D. Miller, Michael J. Culotta, Barbara R. Paul, R. Lawrence Van Horn, William S. Hussey, James T. Breedlove, William M. Gracey, Joseph A. Hastings, and Adam Feinstein, and Quorum Health Corporation, as Nominal Defendant. On September 17, 2018, a purported shareholder filed a derivative action on behalf of the Company in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violation of Section 29(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and indemnification and contribution. Plaintiff seeks damages allegedly sustained by the Company, rescission of the Separation Agreement with CHS, corporate governance reforms, equitable and/or injunctive relief, restitution, and attorneys' fees and costs. On October 26, 2018, the Court entered an order granting a stay of the case pending entry of an order on any motions for summary judgment in the Rao v. Quorum Health Corporation case described above. Once the stay is lifted, we intend to move to transfer the action to Delaware consistent with our by-laws. We are vigorously defending ourselves in this matter. We are unable to predict the outcome of this matter. However, it is reasonably possible that we may incur a loss in connection with this matter. We are unable to reasonably estimate the amount or range of such reasonably possible loss because the case remains in its early stages. Under some circumstances, losses incurred in connection with adverse outcomes in this matter could be material.

Corporate Integrity Agreement

On August 4, 2014, CHS became subject to the terms of a five-year CIA with the OIG arising from a civil settlement with the U.S. Department of Justice, other federal agencies and identified relators that concluded previously announced investigations and litigation related to short stay admissions through emergency departments at certain of their affiliated hospitals. The OIG has required us to be bound by the terms of the CHS CIA commencing on the Spin-off date and applying to us for the remainder of the five-year compliance term required of CHS, which terminates on August 4, 2019.

Edgar Filing: Quorum Health Corp - Form 10-Q

The compliance measures and reporting and auditing requirements contained in the CIA include:

- continuing the duties and activities of the Corporate Compliance Officer, Corporate Compliance Work Group, and Facility Compliance Officers and committees;
- maintaining a written Code of Conduct, which sets forth our commitment to full compliance with all statutes, regulations, and guidelines applicable to federal healthcare programs;
 - maintaining written policies and procedures addressing matters included in our Compliance Program, including adherence to medical necessity and admissions standards for inpatient hospital stays;
- continuing general compliance training;

83

- providing specific training for employees and affiliates handling our billing, case management and clinical documentation;
- engaging an independent third party to perform an annual review of our compliance with the CIA;
- continuing the Confidential Disclosure Program and hotline to enable employees or others to disclose issues or questions regarding possible inappropriate policies or behavior;
- continuing the screening program to ensure that we do not hire or engage employees or contractors who are ineligible persons for federal healthcare programs;
- reporting any material deficiency which resulted in an overpayment to us by a federal healthcare program; and
- submitting annual reports to the OIG which describe in detail the operations of the Corporate Compliance Program.

A material, uncorrected violation of the CIA could lead to our suspension or disbarment from participation in Medicare, Medicaid and other federal and state healthcare programs. In addition, we are subject to possible civil penalties if we fail to substantially comply with the terms of the CIA, including stipulated penalties ranging from \$1,000 to \$2,500 per day. We are also subject to a stipulated penalty of \$50,000 for each false certification by us or any individual or entity on behalf of us in connection with reports required under the CIA. The CIA increases the amount of information we are required to provide to the federal government regarding our healthcare practices and our compliance with federal regulations. We believe that we are currently operating our business in compliance with the CIA and are unaware of any historical actions on our part that could represent a violation under the terms of the CIA.

Item 1A. Risk Factors

There have been no material changes to the risk factors discussed in the 2017 Annual Report on Form 10-K and the risk factor discussed in the Quarterly Report on Form 10-Q filed on May 10, 2018.

Item 6. Exhibits

No.	Description
10.1†	<u>Employment Agreement by and between Quorum Health Corporation and Robert H. Fish (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on August 27, 2018) (File No. 001-37550).</u>
10.2†	<u>Offer Letter by and between QHCCS and Glenn A. Hargreaves (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the SEC on August 27, 2018) (File No. 001-37550).</u>
10.3†	<u>Form of Inducement Award Restricted Stock Award Agreement (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on September 28, 2018) (File No. 001-37550).</u>
10.4†	<u>Form of Inducement Award Performance-Based Restricted Stock Award Agreement (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the SEC on September 28, 2018) (File No. 001-37550).</u>
10.5†	<u>Restricted Stock Inducement Award Agreement, by and between Robert H. Fish and Quorum Health Corporation (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed with the SEC on September 28, 2018) (File No. 001-37550).</u>
10.6†	<u>Performance-Based Restricted Stock Inducement Award Agreement, by and between Robert H. Fish and Quorum Health Corporation (incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed with the SEC on September 28, 2018) (File No. 001-37550).</u>
31.1*	<u>Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
31.2*	<u>Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
32.1**	<u>Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
32.2**	<u>Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101.INS*	XBRL Instance Document.
101.SCH*	XBRL Taxonomy Extension Schema.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase.
101.LAB*	XBRL Taxonomy Extension Label Linkbase.

101.PRE* XBRL Taxonomy Extension Presentation Linkbase.

* Filed herewith.

** Furnished herewith.

† Indicates a management contract or compensation plan or arrangement.

85

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

QUORUM HEALTH CORPORATION

(Registrant)

By: /s/ Robert H. Fish
Robert H. Fish
President and Chief Executive Officer
(principal executive officer)

By: /s/ Alfred Lumsdaine
Alfred Lumsdaine
Executive Vice President and
Chief Financial Officer
(principal financial officer)

By: /s/ Glenn A. Hargreaves
Glenn A. Hargreaves
Senior Vice President and
Chief Accounting Officer (principal accounting officer)

Date: November 6, 2018